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Abstract
Before 1990, options were limited for couples who were at risk for transmitting a genetic disease or a structural chromosomal
abnormality to their children. Couples traditionally underwent invasive procedures such as amniocentesis and chorionic villus sampling, after which termination was offered if the fetus was found to be affected. Many couples chose not to have children at all.
Since then, technological advances have allowed preimplantation genetic testing (PGT) to be offered to these couples. Couples who
choose PGT undergo in-vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI), where the oocyte is injected by a single
sperm and is then implanted into the mother a few days later. However, in PGT, a few cells are removed and genetically analyzed
before implantation to determine whether the embryo has a specific genetic defect or aneuploidy. The purpose of this paper is
to determine whether PGT causes adverse clinical outcomes by critically analyzing PGT research studies. Current research does
not seem to show any major adverse clinical outcomes after PGT especially in cases of singleton pregnancies. It is important to
continue to examine the effects of an embryo biopsy in terms of neonatal and obstetric outcomes, as well as future development.
Introduction
Preimplantation genetic testing (PGT) has become an
integral part of assisted reproductive technology (ART)
and over a third of ART Centers in the United States are
utilizing PGT technology (Kuliev, Rechitsky, 2017). There
are three kinds of PGT.The first, PGT-M, analyzes the embryo for monogenic diseases. This is generally used when
one or both parents carry a mutation, such as those
linked to Huntington’s disease or cystic fibrosis. Testing is
performed to ensure the single-gene trait has not been
passed to the embryo. It is often used after a previous
child has been diagnosed with a specific genetic condition.
PGT-M may also be used for sex selection, such as when
a parent is a carrier of an x-linked disorder (Pastore, et.
al. 2019). The second, PGT-A, and third, PGT-SR, are not
standard procedures and were developed to improve the
success rate of IVF. PGT-A is used to look for embryonic aneuploidy and PGT-SR is used to look for chromosomal structural rearrangements such as inversions
or translocations. PGT-A and PGT-SR are usually only
recommended in cases of previous failed rounds of IVF,
severe male infertility, recurrent pregnancy loss, in cases
where one or both parents have a balanced chromosome
structural rearrangement, or for patients at high risk for
embryo aneuploidy, such as those of advanced maternal
age.While all forms of PGT come with many ethical questions, in general PGT-M is considered more acceptable,
especially when it is used to prevent severe genetic diseases with few treatment options. Genetic counseling is
recommended before any form of PGT to ensure that
the couple understands the risks and limitations of the
procedure (Eskew, Jungheim, 2017).
There are multiple methods of performing PGT. Polar
body biopsy (PBB) is a common method for genetically analyzing an embryo. Polar bodies are formed during
meiosis of an oocyte and are not required for fertilization or embryo development. Therefore, they can be removed safely and screened without harming the embryo.

Additionally, PBB avoids errors due to the presence of
mosaicism that other methods of PGT incur. Mosaicism is
when different cells have different genotypes within one
organism and is not present at the zygote stage. PBB is
considered a less invasive procedure and is a good option
for patients who view more invasive procedures as unethical. However, PBB can only provide maternal genetic
information. Because PBB does not include paternal genetic information and cannot be used to determine gender, this method can only work in certain cases (Schenk,
et. al. 2018).
PGT can also be done through a blastomere biopsy
during the cleavage stage. This is done three days after
fertilization, when the embryo is between six to eight
cells. A blastomere biopsy is an invasive procedure where
cell-to-cell adhesions are loosened and one or two blastomeres are aspirated. The blastomeres are then genetically analyzed for either aneuploidy or specific genetic
mutations (Kalma, et. al. 2018). A blastomere biopsy allows both maternal and paternal genetic information to
be analyzed, which makes determining the gender of the
embryo possible. However, given that this is an invasive
procedure, this method may affect the growth and development of the embryo.While there is evidence that a day
three embryo can tolerate and overcome the possible
resultant damage, it is likely that embryos that would otherwise progress to implantation will be lost at this stage
of embryo development.Additionally, a blastomere biopsy
may not always be reliable since it is affected by both the
technical and biological problems associated with single
cell analysis. Specifically, mosaicism, which is at the highest level at this stage of development, can lead to false
positive and false negative errors. In order to compensate, two blastomeres can be removed. While this may
increase the accuracy of the genetic testing, around 25%
of the embryonic mass is removed, which may impact
clinical outcomes (Cimadomo, et. al. 2016).
A third method of PGT is a blastocyst biopsy. It is
5
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usually done five to six days after fertilization, when the
embryo is about one hundred cells. During a blastocyst
biopsy, five to six cells of the trophectoderm are removed
and analyzed. This method allows more cells to be tested, compared to the only one or two cells that can be
removed during a blastomere biopsy, and allows for improved accuracy of the genetic testing. Additionally, this
procedure removes a smaller proportion of embryo cell
mass when compared to the day three biopsy and only
removes cells from the trophectoderm, not the inner
cell mass. However, blastocyst biopsies have limitations
as well. Only 50% of IVF embryos develop to the blastocyst stage and waiting for a day five biopsy may result in
no transfer at all. Additionally, following a day five biopsy,
embryos typically need to be cryopreserved and then
thawed which precludes the transfer of a fresh embryo.
While there are many methods of performing PGT, each
method has its own benefits and limitations (Wang, et. al.
2018). Once the cells are removed, they are genetically
analyzed by either polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), array-comparative
genomic hybridization, and more recently, next-generation sequencing, in order to determine if there are any
genetic defects (Heijligers, et. al. 2018).
Because PGT is an invasive procedure, researchers have
wondered if it increases the risk of adverse clinical outcomes. It is especially important to monitor the safety of
PGT since the majority of the PGT couples, specifically
couples undergoing PGT-M, have no fertility issues and have
the alternative of a natural conception with or without invasive prenatal testing. This review is aimed at determining
whether PGT increases the risk of adverse obstetric and
neonatal clinical outcomes as well as future development.
Methods
The research discussed in this paper was collected using
EBSCO, ProQuest, PubMed and Google Scholar with access provided by the Touro College Library. All articles
included are original, peer reviewed research papers that
were analyzed to ensure accurate data.
Discussion
Neonatal Outcomes
Malformation/ Perinatal Death
A study was aimed at evaluating the safety of PGT and
focused on the rate of congenital malformations as well
as other adverse perinatal outcomes. In this study, embryos for PGT analysis were produced by intracytoplasmic
sperm injection (ICSI) and subjected to blastomere biopsy. Parents filled out a questionnaire regarding their pregnancy and the health of their child. Medical information,
6

such as age of both parents at embryo transfer, gravidity, parity, number of previous in vitro fertilization (IVF)/
PGT cycles, whether the embryo(s) was fresh or frozen/
thawed, how many blastomeres had been removed, and
how many embryos were transferred, was also obtained
from their doctor. The largest proportion of couples in
this study opted for PGT-M, in order to avoid passing an
autosomal dominant disease to the child. In this study,
more girls than boys were born after PGT with a ratio
of 1.2. This may be due to sex-selection, where a female
embryo is transferred to reduce the risk of inheriting an
X-linked condition. Major congenital malformations were
found in nine of the 364 live births (2.5%). Four of these
children had multiple congenital anomalies and five children (1.4%) had minor malformations. Three pregnancies
were terminated because of diagnoses of exencephaly,
trisomy 18, and trisomy 21. The major malformation rate
when including pregnancy terminations due to congenital malformations was 3.3%. A report by the European
Surveillance of Congenital Anomalies stated a prevalence
of 261.45 major and minor birth anomalies per 10,000
births (2.6%) between 2008 and 2012, which is similar
to the rate in this study. According to these results, the
risk of major malformations in children born after PGT
does not seem to be increased when compared to the
general population. The study also found that perinatal
deaths were reported in 3 out of 364 PGT pregnancies
studied.Two of the pregnancies were of a twin and a triplet. Additionally, at 37 weeks gestational age, a singleton
was stillborn, after an uncomplicated pregnancy. With a
perinatal mortality rate of 0.8%, no evidence for a potential increased risk in fetal or neonatal death was found
after PGT (Heijligers, et. al. 2018).
Similar results were found in a study that looked at the
health of 49 children conceived after PGT compared to
66 naturally conceived (NC) controls. Control children
were matched for age, sex, ethnicity, maternal educational
level and socioeconomic status. A majority of PGT subjects had undergone PGT-A, however the study did not
distinguish between subjects who had undergone PGTM, PGT-A, or PGT-SR. However, all PGT subjects were
born after an embryo biopsy at the eight to ten cell stage.
Pediatricians that assessed the children were blinded to
the conception status of the children, strengthening the
results of this study. The study found that two children
born after PGT had congenital anomalies, one with a
minor ear deformity and the other with mild hypospadias
(Banerjee, et. al. 2008).
Another study examined whether PGT blastomere biopsies impacted the health of infants up to two months of
age by comparing the data of 995 children born after PGT
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and 1507 children born after IVF and ICSI. Twenty-three
PGT children (2.3%) and 40 ICSI children (2.7%) presented major malformations. Major genital malformations
were recorded in seven PGT children and 9 ICSI children.
Four stillborns conceived after PGT and seven stillborns
conceived after ICSI presented major malformations. The
total major malformation rate, including stillborn and live
born, was comparable in the PGT group (2.6%) and the
ICSI group (3%). These results do not indicate that the
added cleavage-stage biopsy procedure increases the risk
of major birth defects compared to the ICSI procedure
(Desmyttere, et. al. 2012).
In another study, data from the PGT pregnancies of 158
singletons, 42 pairs of twins, and 1 set of triplets was compared to data obtained from 242 children born after IVF/
ICSI and 733 randomly selected NC children born during
the same time period. The mothers in all groups were
matched for age, preconception body mass index, and parity. Data collected included parental demographic information, type of biopsy performed (polar body and/ or blastomere biopsy), number of embryos transferred, whether
the embryo(s) were fresh or frozen/ thawed, gestational
age and mode of delivery. At two to four months, parents
also filled out a questionnaire regarding any malformations
that had not been diagnosed at birth. In both single and
multiple pregnancies, the type of embryo biopsy had no
significant influence the neonatal outcome. Four of the
PGT children (1.7%) presented congenital malformations.
One intrauterine fetal death occurred at 33 weeks with a
subsequent diagnosis of thrombophilia.The congenital malformation rate for PGT pregnancies is similar to the rates
found in other studies (Eldar-Geva, et. al. 2014).Additionally,
in another Israeli study completed around the same time
of 213,288 NC births, the rate of congenital malformations
was 1.9% which is similar to the rate of malformation after
PGT in this study (Farhi, et. al. 2013).
Another study looked at the health of 581 children
born after a blastomere biopsy. Questionnaires were sent
to both physicians and parents at conception and delivery and children were examined at two months of age,
usually by a clinical geneticist. The researchers followed
484 pregnancies, with three terminations for major malformations seen on prenatal ultrasounds. Of these, 385
were singleton pregnancies, 92 were twin pregnancies
and four were triplet pregnancies leading to a total of
581 PGT children. There were no differences in any of
the studied properties between biopsies done for PGT-M
or PGT-A and the results were therefore combined. As
seen in many other studies, sex distribution of live born
children was uneven with 54% girls for 46% boys and is
due to sex selection for X-linked diseases. Of the 581

children in the PGT cohort, eighteen were stillborn and
nine died neonatally. Of these 27 perinatal deaths, four
were in singleton pregnancies and 23 in multiple pregnancies. The rate of perinatal deaths in singletons is comparable to the ICSI cohort, however the ICSI multiple birth
cohort had a higher perinatal death rate. Major malformations were seen in 17 PGT fetuses which led three to
be terminated. This led to a malformation rate in born
and unborn children of 2.9%. Of the fourteen children
with malformations, two were stillborn and both were
from a multiple pregnancy. This leaves one inherited and
eleven sporadic mutations in the 563 PGT children born
alive with a rate of 2.13%. The major malformation rate
in the ICSI cohort was 3.13%. The main finding of this
study is that a day three embryo biopsy does not seem
to increase the risk of major malformations. When these
results are compared with the data collected from IVF/
ICSI children born within the same timeframe, the rate of
malformations is comparable. (Liebaers, et. al. 2010)
Gestational Age/ Birth Weight
Studies also looked at the gestational age and birthweight
of children conceived through PGT. In the study by
Heijligers et al. (2018), eighty percent of the PGT children
were born full term. Eight children, all from twin pregnancies (2.2%), were born very premature (<32 weeks).
The study distinguished very premature children from
premature children to show that the very premature
children were all from twin pregnancies. Less than 15% of
the PGT children had a low birth weight and were either
twins or triplets. Only one singleton had a very low birth
weight. The child was born at 35 weeks through caesarian section because of HELLP syndrome in the mother. A
z-score of + 0.17 was calculated for the singletons which
indicates a comparable birth weight between this cohort
and the rest of the Dutch population. In concordance
with other studies on PGT there is an evident increase in
prematurity and low and very low birth weight in multiples when compared to singletons.This strongly supports
the current Dutch single embryo transfer policy. Overall,
data from this study on pregnancy duration and birth
weight in the Dutch PGT population, especially in the singletons, seems similar to the published data on naturally
conceived children.
In the study performed by Eldar-Geva et. al. (2014),
the difference in mean birth weight for singleton pregnancies between the three groups was statistically significant. Singleton NC children had a significantly higher
birth weight than those born after ICSI (P=.006) but not
compared to the PGT singletons. Low birth weight was
also more frequent in the ICSI group than in the PGT and
7
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NC singletons. Also, significantly more ICSI twins (58%)
presented with low birth weight compared to 41.0% of
PGT twins and 44.2% of NC twins. Very low birth weight
(<1,500 g) was rare in all groups. There was also a statistically significant difference among the groups when
examining intrauterine growth for singleton pregnancies
(P=.001). Intrauterine growth restriction was more frequent in ICSI pregnancies (9.5%) than in NC (5.5%) or
PGT pregnancies (5.1%). Children born large for their
gestational age was more frequent in the PGT group
(16.5%) than the NC group (8.8%). The mean gestational
age, rates of preterm birth and intrauterine growth restriction for twin and triplet pregnancies were similar for
the three groups.
These results show that there are no increased risks of
intrauterine growth restriction or low birth weight in singleton or twin pregnancies after PGT compared to NC.
However, ICSI pregnancies did show an increased risk for
both of these complications. These results remained true
even after controlling for factors such as maternal age,
parity, BMI, number of embryos transferred and whether
the embryo was cryopreserved, which can affect pregnancy outcomes. The increased likelihood of adverse
outcomes in ICSI pregnancies may be due to the fertility
status of the parents. Infertile women are more prone
to adverse outcomes even when conceiving naturally, indicating that infertility itself is what increases the risk of
adverse outcomes such as low birth weight and preterm
delivery (Basso, Baird, 2003). This may explain the similarity of the results in birth weight and intrauterine growth
from PGT and NC pregnancies, since the majority of PGT
couples usually do not struggle with fertility.
The difference in pregnancy duration for singleton
pregnancies between the three cohorts was also statistically significant. NC pregnancies were longer, than both
the PGT and the ICSI pregnancies. However, for the PGT
group, these findings had no clinical significance because
the frequency of preterm deliveries, both <37 (7.4%) and
<34 weeks (1.3%) was comparable with NC pregnancies
(5.7% and 2.0%, respectively). However, 11.4% of the ICSI
cohort were born prematurely. PGT and ICSI pregnancies
may have been shorter for different reasons.Women who
undergo PGT are at high risk for autosomal recessive,
X-linked, or dominant genetic disease and therefore have
a higher incidence of previous pregnancy terminations for
affected fetuses. Complications associated with induced
abortions include premature delivery of future children
and cervical incompetence. Additionally, some of the PGT
women in the study had autosomal dominant diseases
such as myotonic dystrophy, achondroplasia, neurofibromatosis and tuberous sclerosis and because of this chose
8

to have a cesarean delivery at 37 to 38 weeks. In fact,
the PGT cesarean delivery rate was more than double in
PGT pregnancies. Additionally, some of the families had
critically ill children which may have placed an emotional
and physical burden on the family and pregnant mother
(Eldar-Geva, et. al. 2014). The preterm birth rate for the
IVF/ ICSI group is unsurprising. As discussed above many
studies have found that preterm birth is associated with
children conceived through IVF/ ICSI because of the parents underlying fertility issues (Wisborg, et. al. 2010).
Another study looked at the health of 49 PGT children
and 66 NC children. The PGT cohort had a significantly lower gestational age at birth (P = 0.0001) and more
preterm births than the NC group. The PGT group was
also more likely to have a lower birth weight and a higher
number of births with a birth weight of less than 2500
grams. Interestingly, this finding is consistent with other
studies of assisted reproduction outcomes such as IVF/
ICSI. In most cases PGT conception is closest to natural conception and not assisted reproduction conception, with regard to the reproductive health of parents.
Parents who opt to undergo the most common form of
PGT, PGT-M, usually do not have fertility issues but are
concerned with passing a genetic disease to their children. However, in this study, the majority of PGT patients
had undergone PGT-A in which parents bear closer risk
and resemblance to couples undergoing other assisted
reproductive conception. PGT-A is usually used after
failed IVF cycles or because of other fertility issues, such
as advanced maternal age. It is therefore unsurprising that
the age of the PGT mothers was significantly higher than
the NC mothers, (P = 0.0001) as was the rate of preterm
birth and low birth weight in the PGT group, which is
commonly seen in other assisted reproduction outcome
studies (Banrjee, et. al. 2008).
The study performed by Desmyttere et. al. (2012),
found that the average birthweight for PGT singletons
and PGT multiples with a very low birth weight (<1500 g)
was comparable with the ICSI children. However, significantly more ICSI multiples presented a low birthweight
(<2500 g), more specifically 268 (17.8%) ICSI compared
to 161 (16.2%) PGT babies. Again, this may be due to the
fertility status of the parents, since the ratio of infertile
couples was higher in the ICSI cohort than in the PGT
cohort. Measurements of height and head circumference showed no significant differences between the two
groups. Mean gestational age at birth for PGT singletons,
twins and triplets showed no difference compared to the
ICSI group. Additionally, the number of PGT singletons
and multiples born prematurely (<37 weeks) showed
no differences compared with their ICSI counterparts
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(all P-values > 0.05). Twenty-one ICSI and four PGT singletons versus 67 ICSI and 31 PGT multiples were born
very prematurely (<32 weeks) which is not significant
(P = 0.056 and P = 0.43 for singletons and multiples).
Admission after delivery to the neonatal intensive care
unit was comparable for both the PGT and ICSI groups
for singletons and multiples. These results show that singletons and multiples born after a PGT embryo biopsy
had similar neonatal outcomes in terms of auxological
data, gestational age and neonatal hospital admission, to
the control group of singletons and multiples with no
embryo biopsy. Additionally, in this study, PGT multiples
appear to be at a lower risk for low birthweight when
compared to IVF/ ICSI multiples.
The study by Liebaers et al. (2010) found that in the
PGT cohort, 11.5% of singletons and 65.7% of multiples
were born premature. In the ICSI cohort, 8.4% of singletons and 57.9% of multiples were born premature. Low
birthweight was observed in 7.4% of PGT singletons and
very low birth weight in 3 (0.8%) PGT children. Multiple
PGT births of a low birth weight (62.5%) were significantly lower than ICSI multiple births (49.4%). Very low
birth weight was observed in 19 of the PGT multiples.
These results suggest that a three day PGT biopsy does
not seem to add significant health risks for singleton PGT
children since when these results were compared to the
data collected from IVF/ ICSI children born within the
same years, gestational ages and birthweights were similar.
However, PGT multiples appeared to be at an increased
risk of low birthweight, preterm birth, and perinatal death
compared to ICSI multiples. Multiple pregnancies should
be avoided when possible and may potentially solve problems especially regarding perinatal death.
A similar study looked at whether women who conceived after PGT and their children have greater risks of
adverse pregnancy and birth outcomes compared with
children conceived spontaneously or after IVF with or
without intracytoplasmic sperm injection (ICSI). The study
looked at factors such as pre-eclampsia, preterm primary rupture of membranes, placenta previa, abruption of
placenta, preterm birth, low birth weight, major malformations, and neonatal admission. It was found that compared to women conceiving spontaneously, women who
had undergone PGT or IVF/ ICSI were older, more often
uniparous, had a higher BMI and smoked less often during
pregnancy. The children conceived after IVF/ ICSI had a
lower birth weight, shorter gestational age, longer neonatal
hospital admission and an increased risk of preterm birth
and malformations. Children born after PGT had a comparable risk of the same complications, however, the results
were just short of statistical significance for many of the

outcomes. Nonetheless, PGT children were found to have
a significant increased risk of preterm birth, shorter gestation, and longer neonatal hospital admission. The study
also looked at the difference in outcomes between PGTM, PGT-A and PGT-SR. When compared to NC children,
PGT-SR and PGT-A children did not have an increased risk
of adverse neonatal outcomes. When compared to IVF/
ICSI children, PGT-SR and PGT-A children had comparable
neonatal outcomes and were found to have a higher mean
birth weight. However, compared to NC children, children
born after PGT-M had a significantly lower birth weight,
shorter gestation and increased risk for longer neonatal
hospital admission. These results show an increased risk
of neonatal complications in PGT pregnancies when compared to spontaneous pregnancies. However, the risk of
adverse outcomes was generally comparable to IVF/ ICSI
pregnancies, indicating that the actual embryo biopsy does
not add additional risks. Additionally, when separating
PGT-SR and PGT-A pregnancies from PGT-M pregnancies,
adverse neonatal outcomes were only found in children
conceived through PGT due to a parental monogenetic
disorder (PGT-M) and not in children born after PGT-SR
and PGT-A. These results make it likely that the risk of adverse outcomes is not related to PGT itself, but to the underlying condition of the parents.These factors can include
the known genetic disorder, associated comorbidities or
any medications taken during pregnancy. (Bay, et. al. 2016)
A study compared the growth data at birth and two
years for 70 singletons born after PGT, ICSI or natural
conception. Children were matched for gender, language,
birth order and maternal education level. At birth, height
and head circumference data were comparable for the
PGT, IVF/ ICSI and NC cohorts.While the PGT singletons
tended to have a lower birthweight and gestational age
compared with the NC children, these differences did not
reach statistical significance. When comparing children
born after a biopsy of one or two blastomeres, weight,
height and head circumference measurements were
comparable for the two groups. Additionally, admission
to a neonatal ward was comparable in the three conception groups and PGT children did not experience more
hospital stays for medical reasons than the ICSI and NC
groups. PGT children were also reported to have undergone more complementary examinations (with normal
results) compared with NC and ICSI babies. However,
this is probably due to precautionary measures for ‘specially conceived’ children (Desmyttere, et. al. 2009).
Obstetric Outcomes
In the study performed by Eldar-Geva et. al. (2014), the incidence of pregnancy complications such as hypertension
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and diabetes were similar in the PGT, IVF/ ICSI and NC
groups. Of the PGT mothers 1% had hypertension and
2% had gestational diabetes. Of the ICSI and NC mothers, 1% had hypertension and 6% had diabetes, and 3%
had hypertension and 4% had diabetes, respectively.
Additionally, the differences in mode of delivery for singleton pregnancies was statistically significant. The cesarean delivery rates were 28.5% in the PGT group, 31.6% in
the ICSI group, and 11.0% in the NC group (P<.005). As
discussed earlier, the cesarean rate for the PGT cohort
was more than double the rate of the NC group in this
study and was probably due to the fact that women with
autosomal dominant diseases in the PGT cohort opted
to have a cesarean delivery at 37 to 38 weeks.
In the study performed by Desmyttere et. al. (2009),
increased rates of cesarean births were found when PGT
mothers were compared to IVF/ ICSI mothers. Results
also showed that when compared to NC mothers, PGT
mothers experienced more pregnancy complications
such as gestational diabetes, thyroid pathology, pregnancy-induced hypertension, placental pathology and premature contractions. However, there were no differences
regarding pregnancy complications when comparing PGT
and IVF/ ICSI mothers.
In the study performed by Bay et. al. (2016) the IVF/
ICSI cohort showed an increased risk of placental disorders, including placenta previa, pre-eclampsia, placental
abruption, preterm primary rupture of membranes, and
induction of labor or cesarean section. The women who
gave birth after PGT had a comparable risk for most of
the same complications when compared to the NC cohort, although for most of the outcomes the results were
just short of statistical significance. However, the PGT
cohort did show a significant increased risk of placenta
previa and cesarean section. Because the risk of adverse
outcomes was generally comparable to IVF/ ICSI pregnancies in many of these studies, it seems like the actual
embryo biopsy does not add additional risks.
When the study separated PGT-M subjects from PGT-A
and PGT-SR subjects interesting results emerged. PGT-SR
and PGT-A children did not have an increased risk of any
adverse obstetric outcomes, except for a higher risk of
placenta previa when compared to NC controls. When
compared to IVF/ ICSI children, PGT-SR and PGT-A children had comparable obstetric outcomes. However,
compared to NC children, children born after PGT-M
had a significantly increased risk for preterm primary
rupture of membranes, cesarean section and placenta
previa. Again, these results make it likely that the risk of
adverse outcomes is not related to PGT itself, but to the
underlying condition of the parents. However, there was
10

a consistent increased risk of placenta previa after both
PGT and IVF/ICSI, which suggests that parental factors do
not explain all the adverse outcomes.
Follow up Study
Growth
A study assessed whether PGT causes adverse outcomes
by comparing findings at birth and at 2 years of age for
singletons born after PGT, IVF/ ICSI, and NC. The study
also investigated whether the body size of children born
after biopsy of one blastomere was different from that of
children born after biopsy of two blastomeres. Subjects
in all groups were matched for gender, maternal educational level, mother tongue and birth order. A strength to
this study is that all children were examined by the same
pediatrician in a standardized way. At a two year follow
up, weight, height, head circumference, and waist and arm
measurements were comparable for the three cohorts.
These results show that PGT singletons do not appear
to be at a higher risk of growth retardation compared
with IVF/ ICSI and NC singletons. In PGT children, the
mean BMI was statistically significantly lower compared
with NC children. Growth parameters of the PGT children born after biopsy of one blastomere were comparable to children born after a biopsy of two blastomeres.
(Desmyttere, et. al. 2009)
The study performed by Banerjee et. al. (2008) found similar results. When assessed at the mean age of 18 months,
growth parameters for all PGT children were within the
normal range including the children who had been born
preterm and/ or with a low birthweight. Furthermore,
Desmyttere et. al. (2009) found that in their follow up study
that rates of chronic disease and chronic use of medication
were similar between PGT and NC children.
Socio-emotional and Language Development
A study was performed to assess the socio-emotional
and language development of children at age two born
after PGT, IVF/ ICSI, and NC, as well as parental wellbeing. A small number of children (n= 10) that were born
before between 33-36 weeks gestations were included
in the study and were equally distributed among the cohorts. Most of these children had a normal birth weight
(<2500 g), and none of them had a very low birth weight
or obtained an Apgar score of less than nine after ten
minutes. Twins were excluded from the study because
developmental outcome is affected by prematurity and
low birth weight, which are known to be more common in twins and triplets. NC and ICSI controls were
matched for gender, maternal education level, native language, and birth order. All members of the PGT cohort
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had a blastomere biopsy at the eight-cell stage. Parents
were asked to complete the Short Temperament Scale
for Toddlers (STST) and the Child Behavioral Checklist
(CBCL) in order to assess the child’s socio-emotional
development. The STST, placed children into one of three
temperament categories, easy, average or difficult. The
CBCL answers questions about the child’s emotional and
behavioral problems. Parents answered if the problem
presented is ‘not true’, ‘somewhat or sometimes true’ or
‘very true or often true’ of their child, with item scores
of 0, 1 or 2. A total score of 60 is at the bottom of
the clinical range, and a score of 64 or more represents
larger issues. Language comprehension and production
were rated according to the McArthur Communicative
Developmental Inventories.
The CBCL scores showed no difference in the proportion of children above the clinical threshold points
according to mothers and fathers. After controlling for
socio-demographic variables, PGT and ICSI mothers
reported significantly fewer problems than the NC cohort. According to the STST scores, a similar proportion
of parents from all three conception groups reported
their child’s temperament as easy, average or difficult.
This remained true even after controlling for socio-demographic variables. Additionally, the mean Language
Comprehension score and Language Production score
did not differ significantly among the cohorts.
This study had some weaknesses. Firstly, results were
obtained exclusively from parental reports and more valid
reports could have been obtained from a multiple informant approach.Additionally, the PGT cohort had members
that had undergone PGT-M and PGT-A. Since these procedures are usually done for different reasons, PGT-M and
PGT-A populations have different medical histories and
family backgrounds, which may influence socio-emotional
and language results (Nekkebroeck, et. al. 2008a).
Additionally, the study by Banerjee et al. (2008) found
that the PGT cohort had significantly higher scores on
the Hearing and Language subscale, than the NC group.
These studies suggest that PGT does not cause adverse
neurodevelopmental outcomes.
Mental and Psychomotor Development
In the study by Banjeree et al. (2008), children up to age
four were evaluated with a focus on neurodevelopmental
screening which was measured using the Griffiths Scales
of Mental Development. The mean Griffiths quotient for
both the PGT and NC groups were in the normal range
and did not differ significantly. The only significant differences were for the Locomotor subscale, where the PGT
group was significantly lower than the NC group.

A similar study aimed at assessing the mental and psychomotor developmental outcomes in two-year-old children conceived through PGT compared to children born
after IVF/ ICSI and natural conception (NC). ICSI and NC
controls were matched for gender, maternal education,
birth order, and native language. All PGT subjects had a
blastomere biopsy at the eight-cell stage of the embryo.
At two years of age, the children were all tested by a psychologist using the Dutch version of the Bayley Scales of
Infant Development (BSID). The psychologist was blinded
to the status of the subject’s conception while conducting the evaluation. Parents were questioned regarding
socio-demographic characteristics. The BSID consists
of two major scales. The mental scale measures visual
and auditory information procession, imitation, memory,
hand-eye coordination, and problem solving. The motor
scale appraises control of gross and fine motor skills.
There were no significant group differences regarding
mental and motor scale scores.Additionally, equal numbers
of PGT, ICSI, and NC subjects were represented in each
level (accelerated, normal, delayed) of psychomotor and
mental development. Interestingly, when compared across
all three cohorts, psychomotor and mental development
scores were very similar for males and females. However,
when compared within each cohort, ICSI boys obtained
lower scores on both scales than the ICSI girls (P = 0.061).
The mode of delivery had no impact on psychomotor or
mental development even after controlling for sociodemographic factors. (Nekkebroeck, et. al. 2008b).
From the results of these two studies, it can be concluded that the embryo biopsy done in PGT has no impact on the mental and psychomotor development of
two-year-old children, compared to ICSI and NC children
Parent-Child Relationship
The study by Banerjee et. al. (2008), used the Parental
Stress Index and the Parental Acceptance-Rejection
Questionnaire to assess differences in the parent-child
relationship. The Parental Stress Index, which asked parents about parental distress, parent–child dysfunctional
interaction, and the difficulty of the child, showed no
significant difference between the PGT and NC groups.
In the Parental Acceptance-Rejection Questionnaire,
the PGT group had significantly higher scores on the
warmth-affection subscale, and significantly lower scores
on the aggression-hostility and rejection subscales than
the NC group.
In another study parental stress and health status were
measured with the Parent Stress Index and the General
Health Questionnaire (GHQ). No differences in parental
stress were found for mothers and fathers among the
11
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three groups. However, after controlling for socio-demographic variables, the ICSI mothers and fathers reported
less stress from parenting (P = 0.048). These results are
similar to findings in other studies and may be because
greater efforts are made by ICSI parents to have a child
compared to parents who conceive naturally. Another
theory is that ICSI parents may be inclined to underreport behavioral issues because of their need to demonstrate their abilities as parents and move on from the
issue of infertility where they struggled. On the other
hand, there was an equal proportion from all three cohorts that experienced low, moderate or high levels of
parenting stress. Scores on the GHQ measuring parental
health were not significantly different, even after controlling for socio-demographic factors. Parents from all
three conception groups obtained similar scores on the
subscales: somatic symptoms, anxiety, social dysfunction
and severe depression. The results from these studies
imply that parents seem to cope with the extra stress
of PGT without it affecting the parent-child relationship
(Nekkebroeck, et. al. 2008a).
Conclusion
Overall, it does not seem that preimplantation genetic
testing causes adverse clinical outcomes. This is especially important since the majority of couples who undergo
PGT usually do not have fertility issues and have the option of natural conception with invasive prenatal testing.
The results of these research studies show no significant
increased risk of perinatal death or malformations, especially when compared to IVF/ ICSI births, indicating that
the embryo is able to recover from the cells removed
during the biopsy and it therefore adds no additional risk.
Furthermore, children conceived through PGT seem to
be on the same developmental level as their peers and
show no growth retardation in follow up studies. While
some studies show an increased risk of preterm delivery,
low birth weight and some obstetric outcomes, it is important to determine whether this is because of the embryo biopsy or because of the underlying health condition
of the parents such as the fertility issues or the genetic
disease for which they chose to undergo PGT in the first
place. However, since this technology is fairly new, there
are few follow up studies that investigate the long-term
effects of PGT. Additional follow up studies are necessary
to ensure the long-term safety of this technology. Future
studies can also investigate the specific outcomes for
each method of PGT, since most of the research is either
regarding a blastomere biopsy or combines all methods
of PGT in the PGT cohort. Furthermore, future studies
should focus on determining the outcome differences
12

between PGT-M, PGT-A and PGT-SR since parents who
undergo the different forms of PGT have different medical backgrounds which can affect the results of these
studies. Couples considering PGT should consult their
physician or a genetic counselor to determine whether
PGT is the correct option as well as which method of
PGT should be used.
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Abstract
Bilateral, profound-severe, congenital deafness causes widespread structural and functional changes of the auditory system. In
humans, the consequences of these changes are extensive and often include detriments to language acquisition and auditory
perception. Fortunately, early intervention methods, such as cochlear implantation, can significantly mitigate inevitable auditory
deficiencies. This review begins by briefly addressing early stages of brain development and associated anatomical discrepancies
observed in congenitally deaf subjects. Considering the deleterious effects of congenital deafness, neuroplasticity, the ability of the
brain to rewire itself, is of paramount importance in reversing the auditory impairments. Hence, its incorporation into the methods
required for successful auditory rehabilitation. Despite this phenomena, assistive devices such as the cochlear implant have shown
a marked decrease in efficacy after a critical period has elapsed. Although the scientific community has made incredible gains in
the understanding of neurogenesis and congenital deafness, additional research is required to concretize age-related limitations
inherent in neural plasticity and provide further advances in congenital deafness intervention methods.
Introduction
Hearing loss is the third most common health problem
in the United States. It is estimated that thirty million
Americans struggle to hear.The disability is not only prevalent in America; it is estimated to affect 8.8 percent to
12.5 percent of the worldwide population (Burkey, 2015).
The most common cause of this disability which affects
approximately 2 out of every 1,000 children is sensorineural hearing loss (Sharma, Campbell, 2011). Sensorineural
hearing loss is often caused by damage to the inner ear
or as a result of non-functioning or missing sensory hair
cells that normally operate within the cochlea. Without
these cells, an individual is unable to detect and transmit
auditory sound wave stimuli through the auditory nerve
to the brain. As cortical development is contingent upon
stimulus-driven learning, individuals born with sensorineural hearing loss are at risk for abnormal neurological
development and brain connectivity needed for optimal
auditory sensory function. In 1978, Dr. Graeme Clark
introduced a revolutionary multi-channel cochlear implant that has developed into an incredibly effective and
transformational neural prosthesis that allows severe and
profoundly deaf individuals to achieve similar function to
their unaffected peers. This device converts sound waves
into patterns of electrical impulses that bypass the outer
and middle ear, thereby directly stimulating Cranial Nerve
VII fibers. The cranial nerve then carries the impulses to
the brain, which converts and interprets these impulses
as sound.Although different from typical acoustic stimulation, this electrical stimulation is able to mimic the coding
of the cochlea and enable recipients to process speech
and environmental stimuli (Hartmann, Kral, 2000).
As technology and implantation techniques improved
in the 1990’s, cochlear implant surgery gained FDA approval for use in younger subjects. As of 2010, approximately 80,000 of the 300,000 cochlear implant users
worldwide were either infants or young children (Kral,
O’Donoghue, 2010). Research studies quickly established
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that “when these children receive a cochlear implant at a
relatively young age (for example, at 18 months) followed
by intensive therapy, they tend to hear and speak better
than those who received implants at an older age (fda.gov,
2017).” The success associated with such early cochlear
implant intervention is often assumed to be related to
a brain characteristic known as neuroplasticity. This fascinating neural capability allows neurons in the brain to
compensate for injury or disease by restructuring and
reorganizing neural pathways that affect function. It is
the aim of the following analysis to explore the nature
of age-related changes in neuroplasticity as they might
specifically relate to the efficacy of cochlear implantation
in subjects at various stages of development.
Methods
Critical analysis of the literature on age-related neuroplasticity in relation to cochlear implantation was conducted and compiled via access to the Touro College
Library’s online database, using PubMed and ProQuest
search engines. In addition, Google Scholar was utilized in
obtaining related research.
Discussion
Early Stages of Brain Development
Brain development begins around the eighteenth day
after conception and continues into early adulthood.
Approximately 2 weeks after conception, part of the ectoderm of the back of the embryo thickens and forms a
neural plate. As the edges of this neural plate curl toward
each other, eventual fusion occurs thereby forming the
neural tube. The inner cells of this formation will comprise the central nervous system whereas the outer cells
break away to create the autonomic nervous system. As
the tube closes and matures, different areas become distinctive brain structures. In particular, the rostral end of
the neural tube develops three interconnected chambers
which become the three major parts of the brain: the
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forebrain, midbrain, and the hindbrain (Carlson, Birkett,
2017). Any remaining cells will develop into the spinal
cord. As the tube undergoes its metamorphosis, progenitor cells, descendants of stem cells, lead to the brain’s
multifaceted and sophisticated cellular network. Given the
cerebral cortex’s inside-out developmental pathway, the
most recently formed neurons are more proximal to the
cortical surface. The six layers of the cortex are formed
by approximately 25 weeks after conception. The end of
cortical development is observed when the progenitor
cells receive a chemical signal which induces apoptosis.
Once neurons have migrated to their proper locations,
synaptogenesis occurs. The first synapses are usually detected around the 23rd week of gestation (Molliver et. al.,
1973). Typically, synaptogenesis is followed by a gradual
reduction of neurons known as pruning due to neural
overabundance in the ventricular zones. Although this
process occurs throughout an individual’s lifespan, an initial explosion of synapse formations occurs during early
brain development. Synaptic reduction is then significantly
dependent on environmental exposure. Regions that are
stimulated by these factors are strengthened and stabilized, whereas reduction occurs in synapses that are not
sufficiently stimulated (Tierney, Nelson, 2009).
During the prenatal and early childhood years, the basic
structure and functional capacity of the brain are formulated with refinement of neural networks persisting over
time. Research suggests that brain development is hierarchical in nature. Higher level processes build on lower level
processes. For example, language development depends on
sensory and perceptual development. Infants are born with
a brain wired for various types of experiences and abilities
such as speech, language, and facial recognition. Newborns
are initially programmed to perceive all languages, but with
environmental experience, become focused and cognizant
of their native language and lose the ability to perceive
language that they are not exposed to. In this way, exposure drives subsequent learning (Kuhl, 2004). Research in
2004 supports the concept that healthy brain development
requires adequate environmental exposure and that lack
of these experiences could lead to underspecification and
miswiring of brain circuits. This study found that children
raised in Romanian institutions with a lack of stimulating
experiences demonstrated underdeveloped brain and
cognitive growth. Further research (Marshall et al., 2008)
noted a critical time frame, suggesting that after age two the
effects of decreased exposure on brain function worsen.
In early development, external stimulation is an important means through which significant neural connections
and networks are created to facilitate behavioral growth
and development. An absence of any one of the body’s

senses can have major implications on brain development.
Animal studies have found that early deafness greatly affects auditory cortical development. Baker et al. (2010)
performed a research study utilizing deaf cats to determine
hearing loss related auditory brain stem pathology. Altricial
animals, cats are born with closed ear canals that only open
approximately 30 days after birth.The process of ear canal
opening is the same in deaf and hearing cats; therefore, researchers hypothesized that abnormalities in the deaf cats
would coincide with the development of hearing in typical-hearing cats. This would support the notion that lack
of sound stimuli leads to pathological changes.Through the
use of intracellular dyes, the Endbulb of Held in deaf white
cats were examined. Large and complex synaptic endings,
the Endbulbs of Held provide a coordinated release of
neurotransmitters from presynaptic terminals onto the
soma of bushy cells in the anteroventral cochlear nucleus (postsynaptic cell). They are considered to be centrally
involved in the precise transmission of timing information
from auditory stimuli. It was discovered at birth that the
cochlea of the congenitally deaf white cats was void of
abnormal morphology. The presence of a collapsed scala
media and a degraded organ of corti appeared one week
after birth. As time progressed, the deaf cats’ endbulbs
exhibited flattened and elongated postsynaptic densities
(PSDs) and increased synaptic vesicle density. Cochlear
abnormalities in cell synapses and circuitry as a byproduct
of sound deprivation were exhibited. Human studies have
subsequently arrived at similar findings. Using cortical auditory evoked potentials (CAEPs) with non-invasive EEGs on
deaf children, these studies have found delayed or absent
auditory responses supporting the theory that brain maturation is dependent on appropriate and adequate stimulation (Eggermont et al., 1997; Eggermont & Ponton, 2003).
Neuroplasticity and Developmental Periods
In addition to genetics, environmental factors also play an
important role during the critical period of brain development.While genetics ostensibly play a larger and more significant role in prenatal development, environmental exposure is a key contributor to postnatal progression. Neural
plasticity is the central nervous system’s ability to attempt
to support optimal performance by recovering functional
abilities and enabling the body to adapt and learn in changing
anatomical conditions. The nervous system’s ability to reorganize its structure, connections, and functional abilities
in response to intrinsic and extrinsic stimuli is complex. It
can occur on a variety of levels from molecular to cellular
during regular development and learning, or in response to
disease or injury (Cramer et al., 2011). Plasticity of a brain
region is affected by the area’s peak synapse production.
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This occurs at different times for various structures of
the brain. For example, peak synaptogenesis for the visual
and auditory cortices occurs between 4 and 12 months,
whereas the prefrontal cortex that controls reasoning and
planning increases more slowly and peaks at one year of
age. The later the peak synapse production, the longer the
area’s plasticity (Goswami, 2004).
Neuroplasticity is an area of continuous research and
hope in many clinical contexts. It is, for instance, widely
researched in relation to stroke, trauma, and spinal cord
injury. Associated studies have highlighted the brain’s
incredible ability to form representational maps with
spontaneous intra-hemispheric and inter-hemispheric
changes. For instance, when brain lesions of the left hemisphere damage important language centers, other areas
in that hemisphere may be recruited for language function
(Karbe et al., 1998b; Karbe et al., 1998a; Warburton et al.,
1999). Moreover, in situations where severe impairment
exists in the left hemisphere region, the right hemisphere
appears to be capable of assuming some language functions (Warburton et al., 1999; Cramer et al., 2011).
The central nervous system’s ability to adapt to pathology is affected by several parameters. One of the primary
contributing factors is the age of onset, including critical
developmental periods (Staudt, 2010). The greatest forms
of neuroplasticity are available during early development.
This is thought to relate to the overabundance of neuronal cells and synaptic connections present during early
childhood which decrease through the pruning process
with environmental exposure and aging.Additionally, other
developmental events like inhibition and myelination can
affect the developmental critical period. In the case of
early neurological injury, research has found significant
cross modal plasticity - the ability to reorganize and form
new sensory maps and pathways. For example, successful
changes in function from across brain hemispheres have
led to highly successful behavioral advances for children
(Cramer et al., 2011). Staudt’s (2002) research supports
this phenomenon showing that unlike adults, children
demonstrate moderate to good right hemisphere control
of language and movement following a significant injury to
their dominant left hemisphere.
Data Defining Critical Periods for
Cochlear Implantation
Adaptive plasticity and its relationship to age-dependent
recovery of language is an active area of study. Research
on children with a hemispherectomy showed a remarkable shift in motor and language function to the remaining
hemisphere. Children under six years of age had the most
significant level of reorganization (Chen et al., 2002b).
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Similar findings have been seen with congenitally deaf
children. Cortical Auditory Evoked Potential (CAEP) testing - the time it takes for the brain to respond to auditory
stimulation - was found to increase with age as a result
of maturation and refinement of the central auditory
pathways. These markers were tested in a variety of deaf
children who received cochlear implants at different ages.
In a study with a subject body of 245 congenitally deaf
children with cochlear implants, researchers found that
children implanted prior to 3.5 years of age had normal
response times within 6 months of implant use. However,
children whose initial stimulation occurred after age 7
demonstrated abnormal response times even after years
of implant usage. Children who received cochlear implants
between 3.5 and 7 years of age had variable responses
(Sharma et al., 2002; Sharma & Campbell, 2011).These results have been supported by other studies utilizing PET
scan brain imaging and behavioral measures. In addition,
speech and language studies have demonstrated that children implanted under 3-4 years of age display significantly
better speech and language skills as opposed to those
children implanted at 6-7 years of age and older (Geers,
2006; Kirk et al., 2002). These results influenced the FDA
to lower their age for approval of cochlear implantation
for children to approximately 12 months.
Research reports that auditory cortex synaptogenesis
begins in the first two months after birth with maximum
density between 4 and 12 months followed by pruning
(Goswami, 2004). This early synaptogenesis supports the
need for early implantation and stimulation of the auditory nerve to allow maximal usage of the brain’s regional
plasticity and ability to learn to process auditory stimuli.
Research has reinforced this theory. Electrical stimulation
had a restorative effect on the Endbulb of Held synapse,
and early electrical stimulation with a cochlear implant
had significant positive results in congenitally deaf cats
(Baker et al., 2010; Ryugo, 2015). Ryugo et al. (2005) reported decreased synaptic vesicle density and PSDs following cochlear implantation of congenitally deaf cats statistically similar to those of normal hearing cats. Auditory
nerve activation at 3 months of age restored many key
features of synaptic morphology, whereas less significant
effects were seen at 6 months and on (Ryugo, 2015).With
regard to humans, studies illustrate that those children
who became deaf before the developmental onset of
language and received early cochlear implant technology
were successful in their acquisition of spoken language.
However, those with late implantation displayed less benefit and ability to discriminate complex everyday sounds
and speech (Svirsky, et al. 2004; McConkey, et al., 2004;
Tong et al., 1988).
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Cochlear Implant Considerations After
Critical Periods
Early implantation, within the sensitive and critical period, is integral for speech and language development
and necessary to avoid potentially deleterious re-organization of the cortex. Kral, 2007 found that in animal
studies, the primary auditory cortex was partially or
completely disconnected from the surrounding higher
order cortex at the end of the sensitive period. This
leaves the higher order auditory cortex at risk for
recruitment from other sensory modalities. This has
been seen in deaf adults where their visual processing may begin to take place in their auditory cortical
areas. Although cross modal reorganization may allow
for some enhanced processing, it could also result in
significant deficits. For example, while deaf adults may
have enhanced peripheral vision, they may suffer from
severely impaired auditory processing and auditory-visual integration (Sharma & Campbell, 2011). Numerous
studies have consistent data demonstrating notable
improvement in speech perceptual skills in adolescents
who received cochlear implants. However, adolescents
with earlier implantation and shorter lengths of deafness exhibited significantly greater results in word and
sentence testing. Children who were implanted after age
7 were found to demonstrate abnormal brain responses
to auditory input and poorer language skills. Some relate
these results to cortical plasticity where colonization of
the auditory cortex occurs from other sensory modalities during critical periods of central nervous system
development (Sharma et al., 2009; Zeitler et al., 2012).
In post-lingual adults, studies relate that the duration of
auditory deprivation has a negative impact on auditory performance with a cochlear implant, either due to
cross modal plasticity or due to the limited capability of
the superior temporal cortex (Anderson et al., 2017)
Cochlear Implant Benefits Before and After
Critical Periods
Results from human studies report that uncorrected deafness results in fundamental change in the central auditory
system so much so that benefit from a cochlear implant
in later life is hindered. Adult recipients report cochlear
implant benefits including increased environmental sound
awareness, better quality of life, and increased psychological wellbeing. The area most variable is improvements
in auditory speech perception. Specifically, the trajectory and rate of auditory performance vary across adult
individuals (Anderson et al., 2017). Several abnormalities
that arise in the auditory system include reduced number
of spiral ganglion neurons, abnormal synaptic structure,

ectopic projections in ascending pathways, and physiological alterations of auditory nerve responses in the cochlear nucleus. These affect synaptic transmission and result
in decreased responsiveness in the inferior colliculus
and auditory cortex. These fundamental changes inhibit
older cochlear implant recipients from gaining true benefit. Although environmental sounds may be processed
in adult recipients, language recognition is more difficult
(Ryugo, 2015). Data from the Mayo Clinic’s testing on
259 adults revealed that adult cochlear implant recipients
had preoperative scores of 8% on tests of monosyllabic
words and 7% on sentence recognition. After one year
of implantation, these scores increased to 58% for word
recognition and 75% for sentence recognition (Carlson,
2020). These results support the usefulness of cochlear
implants in adulthood; however, when compared to the
percentages and quality outcomes in children with early
implantation they are markedly low.
Relevant Associated Neural Plasticity Research
For decades, scientists believed that neurogenesis was a
process that existed in the brains of embryos and infants
only to cease in adulthood. In the 1980’s, this notion was
challenged when researchers showed that neurogenesis
occurs in the brains of certain adult animals. Further traction against the initial, misguided belief was made when
signs of newly formed neurons in the adult human brain
were observed. Alvarez-Buylla and colleagues studied the
olfactory bulb in rodents and found continuous formation
of new neurons. However, in humans the formation of
new olfactory neurons occurs exclusively in infants. This
dichotomy was also found in the frontal lobe where new
neurons migrate during early childhood but cease migrating as age progresses (Pignatelli and Belluzzi, 2010). The
most thorough study was done by Sorrells and colleagues
on postmortem and postoperative hippocampal tissue
from humans.The subjects ranged from fetuses at 14 gestational weeks to 77 years of age. Samples were stained
with fluorescent marker antibodies to identify progenitor
cells and young neurons. Definite signs of new neuronal
formation in the hippocampus of infants and children
were observed, whereas no such signs were exhibited
in adult brains. Additionally, young neurons decreased in
density as age level progressed (Sorrells et al., 2018).
In humans, it is theorized that neurogenesis occurs
in the subgranular zone (SGZ) of the dentate gyrus of
the hippocampus which maintains a neurogenic stem
cell (NSC) niche. Some propose that the SGZ is an environment fit for NSC proliferation into granule cells
from which migration to the granule cell layer occurs.
Granular cells progress through the developmental
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stages when specific protein markers are expressed,
thereby revealing lineage specific cells in the neurogenic
niche.This occurs before the cells integrate into the hippocampal circuitry and can influence the functions such
as learning, memory, and spatio-motor performance
(Kumar et al., 2019).
There is some research, albeit scarce and preliminary,
that supports adult neurogenesis. One such study tested
the brains of 5 cancer patients who had been injected
with a chemical that incorporates into newly created
DNA: Bromodeoxyuridine (BrdU). Traces of this chemical were found in the dentate gyrus of the hippocampus,
thus supporting the theory that cells in this region are
continuously dividing and creating new neurons (Eriksson
et al., 1998). Another study also reported evidence of
neurogenesis after identifying protein markers for various
stages of neurogenesis in subjects 0 to 100 years of age
(Knoth et al., 2010). In 2013, using carbon dating methods,
Jonas Frisén’s lab at the Karolinska Institute reported that
up to 700 neurons are added each day to the dentate
gyrus (Kumar et al., 2019). Although these are groundbreaking findings, many researchers question their validity.
Asserting the possibility that BrdU can occasionally label
dying cells instead of cells undergoing division, as well as
the possibility that protein markers can accidentally label
brain cells as glia instead of neurons, a body of researchers remains hesitant regarding claims of neurogenesis in
adulthood. Nevertheless, the most robust study supporting adult human hippocampal neurogenesis was done by
Boldrini and colleagues. Autopsying hippocampi of people ages 14 to 79, they found the production of intermediate neural progenitors, immature neurons, mature
granule neurons, and glia to be similar between all age
groups. Adhering to biological parameters and utilizing
unbiased stereology, the researchers ensured that their
samples were taken from healthy individuals (Boldrini et
al., 2018). On the other hand, some studies have found results to be inconclusive. Kumar and colleagues used bioinformatic methods to study the differential expressions
of neurogenesis signature markers in the hippocampi of
prenatal to adult age subjects. Persistent but minimal hippocampal neurogenesis was observed. In addition, they
initiated the criticism that newborn adult hippocampal
cells could be glial cells (Kumar et al., 2019). The vast majority of research points to the stark difference between
the human brains of infants and adults, with inadequate
concrete knowledge and inconsistent evidence of adult
neurogenesis. It is the hope of many scientists that future
technology with the ability to provide imaging of new
neuronal formation in the adult human brain will shed
light on this debate.
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Areas of Interest for Future Inquiry
Many factors limit the availability of research and tangible knowledge of adult neurogenesis, including sparse
availability of ideal human brain tissue and limitations of
study methods. A clearer understanding of the evidence
surrounding adult human neurogenesis is crucial, as its
presence or absence will have significant theoretical and
practical effects on learning, age-related memory, pathology, and injury. Research and innovation are needed to
produce safe investigatory methods to perform neurogenesis related research in living humans. Safe neuroimaging approaches to detect growth of newly formed cells
in neurological niches and their integration into existing
neural circuitry is needed. Possible stem cell methods of
generating neural stem cells from the patient’s own cells
is another area of potential innovation.
Although the mechanisms of neurogenesis are not fully
understood, there are a variety of avenues for further research and application. Some researchers have proposed
a deeper investigation into the role of corticosteroids in
reducing hippocampal neurogenesis. Others have suggested avenues related to trophic factors such as the brain
derived neurotrophic factor, fibroblast growth factor, and
epidermal growth factor, as well as the neurotransmitter
serotonin, which have shown enhancement of neurogenesis. Additionally, studies have pointed to stress as the
reason for increasing the production of glucocorticoids
and decreasing trophic factors, thereby decreasing neurogenesis. On the other hand, environmental enrichment
increases the secretion of trophic factors which, in turn,
may facilitate neurogenesis (Kumar et al., 2019). These
factors, along with further research, could conceivably
be used as catalysts to promote adult neurogenesis and
allow for greater recovery of learning and memory in the
deaf population and beyond.
Limitations in conventional neuroimaging techniques
to evaluate cortical plasticity pre- and post-implantation
have hindered our ability to adequately study the effectiveness of cochlear implantation in the adult population.
Given the application of powerful magnetic fields in MRI
scanning, straightforward examination isn’t feasible with
the ostensible high-risk factor for the magnetic component of the cochlear implant. Surgically removing the
magnet prior to MRI is risky and inconvenient. Removal
would also impede auditory stimulation through the
cochlear implant and would consequently distort the
imaging of auditory cortical function. Unconventional
neuroimaging techniques such as EEG and MEG are safe
for cochlear implant users; however, they are unable to
provide data about cortical processing of speech at the
level of word identification and sentence comprehension.

What Role does Age-associated Neuroplasticity Play in the Efficacy of Cochlear Implantation?

In contrast, PET can be used to measure neural activity
based on changes in cerebral blood flow and metabolism.
Independent of electrical or magnetic cortical signaling,
PET imaging allows for artefact free functional imaging
in cochlear implant users. However, due to the use of a
radioactive medium, testing repetition is limited and impedes on the adequate assessment of cortical changes
that occur rapidly over a short period of time.The use of
functional near infrared spectroscopy (fNIRS), a non-invasive optical imaging technique, is a possible area that,
with further modifications, can be a promising means
of data collection from cochlear implant recipients. This
technique does not provide a direct measure of neuronal
activation. Instead, it measures the consequential hemodynamic response seen in stimulus evoked changes in
levels of oxygenated haemoglobin (HbO) and deoxygenated haemoglobin (HbR). Through the application of optodes, an optical sensor device with fiber-optic bundles,
on the subject’s scalp, the changes in HbO and HbR can
be monitored and evaluated using a stimulus presentation paradigm. Although some limitations currently exist
and further research is needed, multiple benefits of this
technique include non-invasive and portable testing nature, high level of resilience to patient’s head and body
movement, and safe and flexible testing across a diverse
population. Testing utilizing this technique has displayed
an ability to measure cross-modal responses within the
temporal lobes in cochlear implant recipients (Anderson
et al., 2017).
Another area for further research is the therapeutic
technique of speechreading prior to implantation. It is
thought that speechreading in post-lingual deafness has
the ability to maintain amodal linguistic functions and left
hemisphere specialization for speech processing. Vision
may facilitate the restoration of auditory function with
modifications to the auditory cortex. This audio-visual synergy may enable adult cochlear implant users to
capitalize on heightened levels of visual cortex activity
to compensate for decreased auditory input from the
implant. Consequently, sustainable close cooperation between the auditory and visual modality that post lingual
deaf individuals can capitalize on during auditory rehabilitation is attainable. Evidence suggests that a synergy
between modalities within the left temporal lobe may be
a significant neural correlate in cochlear implant success
(Anderson et al., 2017).
While cochlear implantation has opened a whole new
world of hearing opportunities to the deaf population, the
success rate is highly variable and still remains somewhat
unpredictable. Although some basic markers for success
are noted and understood, more sensitive prognostic

tools are needed to accurately predict clinical outcomes.
Growing research supports factors such as cortical plasticity within the temporal and temporo-occipital brain
regions and synergistic relations between the auditory
and visual modality and temporo-occipital interaction.
Investigation on safe, sensitive, and thorough techniques
to study brain changes pre- and post-implantation is an
area of research that continues to expand.
Conclusion
Bypassing damaged peripheral structures, the multi-channel cochlear implant has provided profound to severe
hearing-impaired individuals the ability to achieve similar
auditory function to their unaffected peers.As anatomical
and functional auditory integrity is of paramount importance, early cochlear implantation is a crucial determinant
in the probability of a congenitally deaf individual attaining
maximum auditory capacity. As supported by extensive
data, implantation prior to the completion of the critical
period plays an outsized role in neuroplasticity’s ability to
rewire one’s neural circuitry while consequently preventing further recruitment of auditory cortical structures
by other sensory modalities. As human sensory hair cells
are incapable of regeneration, further research is needed
to pursue avenues yet explored in the quest to further
mitigate the deleterious side effects of congenital, early
and late onset deafness.
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Abstract
In the developed world, the trend toward women of advanced age bearing children is very prevalent and seems likely to continue.
For a variety of reasons, women are delaying pregnancy until 35 years and older when they suddenly seem keenly aware that their
biological clocks are ticking. A review of various studies obtained from the Proquest and EBSCO databases indicates that there are
definitely certain risks associated with advanced maternal age (AMA). As females age, the reduced number and quality of their remaining eggs contribute to reduced fertility. Congenital anomalies involving the number of chromosomes in the embryo increases as
well.The risk of miscarriage gradually climbs with the mother’s age and stillbirth is more likely than in younger women.The health of
the older women prior to pregnancy is often compromised and birth-related complications are more common. Studies of mice have
shown that maternal age influences the structure and functionality of the uterus. It has been suggested that delayed childbearing
has an effect on the gene frequency in the general population since the zygotes best able to adapt to the Advanced Maternal Age
(AMA) uterine environment were favored (Gloria-Bottini et al., 2005). Although women who postpone parenthood should take the
increased risks into account, findings suggest that maternal age, per se, should not be a deterring factor when considering bearing
a child. Individual health circumstances and behavioral choices are more important than age.With proper prenatal counselling and
care, AMA women can hope to have normal pregnancies and deliver healthy babies.
Introduction
Advanced maternal age is defined as pregnancy in women
equal to or greater than thirty-five years of age. It is becoming a growing trend, especially in high-income countries, to delay childbearing. Pregnancy in AMA mothers
constitute 20% of pregnancies in the UK and 16% of
pregnancies in the US as of 2014. Many women marry
later, spend a decade or more building up their careers,
pursue higher education, or enjoy the single life before
deciding to have a family. Others may find themselves having their first child in their thirties because of previous
fertility complications. Although better socio-economic
conditions and developments in assisted reproductive
technology are allowing women to have babies later in
life, this new trend can possibly present clinical risks both
to the mother and baby (Lean et al., 2017a).
Prenatal concerns for AMA mothers include fetal
loss, chromosome anomalies such as Down’s Syndrome,
multiple births, hypertension, and gestational diabetes.
Complications in labor and delivery might include placenta previa (when the placenta covers the opening in the
cervix), caesarean birth, preterm birth, placental abruption (when the placenta detaches from the womb), low
birth weight, trisomies, and other non-disjunction problems. Abnormal functioning of the placenta, due to aging,
can result in fetal growth restriction and even stillbirths
(Radhakrishnan, 2016).
It is important to point out that women who are pregnant and are older than 35 have some distinct advantages. They are more likely to follow the regimen outlined
for them by their obstetrician, such as taking a folic acid
supplement before conception and throughout their first
trimester which helps decrease the risk of neural tube
defects. These mothers are more likely to be diligent
about keeping prenatal appointments. They are usually
more established in their personal and professional lives
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and are more mature and knowledgeable, with a higher
degree of personal control and coping strategies. Their
higher income tends to contribute to more positive results in terms of their health. Lastly, AMA mothers tend
to breastfeed more than younger mothers. Breastfeeding
is considered the most optimal way to feed the infant.
Its benefits include protecting the baby with passive immunity to infections of the respiratory and gastrointestinal tracts. Breastfeeding has maternal benefits as well;
it reduces postpartum bleeding, returns the mother to
pre-pregnancy weight faster, and decreases the risk of
breast and ovarian cancers (Radhakrishnan, 2016).
Notwithstanding all of the above advantages, the ideal
time for a woman to give birth remains up until the age of
35, during which time fertility is at its peak. Women who
are older have a harder time conceiving. They usually also
have longer work hours and stressful work environments
and tend to drink more alcohol, putting the fetus at risk
of Fetal Alcohol Spectrum Disorder, which can cause
birth defects and neuro-developmental disorders. They
have also been exposed to environmental toxins for a
longer time. Most importantly though, their increased age
makes medical conditions such as cancer, diabetes, hypertension, and arthritis more likely.These conditions, as well
as their associated treatments and medications, can harm
the fetus (Radhakrishnan, 2016).
Many studies have been done in various developed
countries, investigating the impact AMA has on perinatal
and neonatal outcomes in these women. These studies
are important for both the mothers and the healthcare
providers. The effects of AMA on maternal and fetal morbidity and mortality is of great concern.
Methods
The research was obtained from the online Touro College
Library. Articles were collected from the Proquest and
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EBSCO databases. The studies presented a comprehensive analysis of the topic and allowed for a conclusion to
be reached regarding the research question.
Discussion
A systematic review and meta-analysis were done to determine the risk of stillbirth and other negative pregnancy outcomes in AMA women. It was the largest and most
comprehensive review investigating pregnancy outcomes
of AMA mothers and the only one specifically focusing
on the increased risk of stillbirth. The studies in the review were significant considering that in 2013 the rate of
births in England and Wales to women of 35 years and
above was 20% as compared to a rate of 6% in 1980
(Lean et al., 2017a).
In the review, 63 cohort studies and 12 case control
studies were included. The studies incorporated control
groups of mothers younger than 35 years of age and AMA
groups greater than or equal to 35 years. Primary outcomes studied were stillbirth and fetal growth restriction. Secondary outcomes were neonatal death, small
for gestational age, neonatal intensive care unit (NICU)
admissions, preeclampsia (blood pressure > 140/90 with
significant amount of protein in the urine), placental
abruption, preterm birth, and gestational diabetes mellitus. Studies that involved pregnancies of multiple fetuses
or those that focused on chromosomal abnormalities or
substance abuse were eliminated. Correlations between
stillbirth rates and maternal obesity, diabetes, hypertension, and assisted reproductive therapies were recorded
(Lean et al., 2017a).
AMA was found to increase the rate of stillbirth in the
population to 4.7%. In addition, AMA increased the risk
of fetal growth restriction, neonatal death, NICU admission and gestational diabetes mellitus. The relationship
between AMA and stillbirth was not found to be associated with maternal morbidities, with the exception of
hypertension which was positively correlated with AMA
in women between the ages of 35 and 40. The use of
assisted reproductive therapy (ART) showed no relationship to stillbirths in women equal to or under 35 years
of age and was negatively correlated to stillbirth rates in
women over 40. AMA only significantly increased the risk
of fetal growth restriction in women over 40. The majority of secondary outcomes were more prevalent in AMA
women but only NICU admissions and neonatal deaths
had a substantial correlation to the increasing age of the
mother (Lean et al., 2017a).
Stillbirths in advanced countries are presently thought
to be related to placental dysfunctions. Accelerated aging
of the placenta, altered vascular function and altered

transport of nutrients compared to a control group have
all been detected. Another theory for the cause of stillbirths is the diminished genetic quality of the aging oocyte (Lean et al., 2017a).
Another consideration that may contribute to fetal
health with an AMA pregnancy is advanced paternal age.
Research in this area is sparse. One study found a 24% increase in stillbirth rate with paternal age between 40-45
years old and a 50% increase with paternal age over 45,
independent of maternal age. More studies are needed
where paternal age is a co-variate to determine how it
contributes to increased risk of stillbirth in AMA mothers
(Lean et al., 2017a).
Future studies should be done to understand the mechanisms contributing to the increased risk of stillbirth in
AMA, specifically in mothers over the age of 40, so that
proper intervention can be applied to improve positive
outcomes to those at greatest risk (Lean et al., 2017a).
The increased risks of fetal growth restriction and
stillbirths in AMA mothers have been found to be independent of co-morbidities. These risks also do not seem
to correlate with factors such as socio-economic status,
nutritional supplementation prior to conception, good
prenatal care, and the mothers being non-smokers. A hypothesis was offered that maternal aging was associated
with utero-placental dysfunction which contributed to
negative fetal outcomes (Lean et al., 2017b).
Dysfunction of the placenta is a major cause of fetal
growth restriction and placental causes are noted in up
to 65% of stillbirths. In both conditions, major changes
in placental morphology were found, including lower
placental weight, irregular shape to the placenta, and
irregular insertion of the umbilical cord. Placentas from
fetal growth restriction pregnancies had less vascular
branching and fewer capillaries. These structural abnormalities were found even more in stillbirths related to
fetal growth restriction (Lean et al., 2017b).
Abnormal function of the placenta was also apparent
in fetal growth restriction and stillbirths. Among these
were reduced amino acid transport in the placenta and
impaired endocrine function (Lean et al., 2017b).
A study was done to test the hypothesis that AMA is
associated with dysfunctions of the uterus and placenta.
Women of AMA were studied along with young controls
(20-30 years) with normal pregnancies. Investigations
into these pregnancies identified multiple placental and
utero-placental dysfunctions, potentially linking those
mechanisms and increased fetal growth restriction and
stillbirths in AMA women (Lean et al., 2017b).
The studies revealed increased placental weight but reduced placental efficiency in pregnancies of AMA women
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with changes in placental morphology and function similar to the phenotype of placentas in fetal growth restriction and stillborn pregnancies. This phenotype was seen
even in normal pregnancy outcomes which indicate both
the negative effects of aging on the placenta and potential
adaptation to achieve a normal birthweight.The abnormal
placental phenotype was more evident in women >40
years of age who have a higher risk of adverse pregnancy
outcomes (Lean et al., 2017b).
AMA mice displayed an even more exaggerated abnormality in placental phenotype than humans, with reduced
number of offspring, late fetal deaths, and over half of offspring in the category of fetal growth restriction. Many
similarities were found in the placental phenotype in the
mice and human pregnancy models, including increased
placental weight, decreased placental efficiency, and altered vascular function (Lean et al., 2017b).
All of these support the hypothesis that maternal aging
is associated with placental dysfunction, which may result
in higher rates of fetal growth restriction and stillbirths
in AMA pregnancies. Abnormal cell turnover, abnormal
nutrient transport, and increased relaxation of placental arteries all helped contribute to the less than ideal
functioning of the placenta in AMA mothers (Lean et al.,
2017b).
Another study was done to determine whether advanced maternal age in mice has a bearing on their
pregnancy outcomes. The purpose of this study was to
evaluate whether negative reproductive outcomes in
aged female mice are a result of a dysregulation of methylation, and thus expression, of imprinted genes in their
reproductive tissues. Tissues from the fetus, placenta, and
ovaries were collected from young pregnant mice (4-5
weeks old) and aged mice (15 months old) and compared
to matured oocyte and uterine tissue from non-pregnant
ones (Paczkowski et al., 2015).
Results showed fetal growth restriction and overgrowth of the placenta in the older pregnant mice.
Placental tissue showed aberration in methylation and
transcript abundance of imprinted genes. Methylation and
gene expression were severely dysregulated in the ovaries and in the uterus, including nutrient transport genes.
There was also increased transcript abundance in oocytes obtained from older females, compared to younger
ones (Paczkowski et al., 2015).
Major alterations in methylation and gene expression
in the older ovary suggests that the environment in the
follicle may not be optimal. This affects oocyte growth
and quality, leading to compromised embryonic and fetal
development.Aberrant methylation and expression of imprinted genes in the uterus obtained from aged mice may
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cause reduced implantation. Even though AMA mothers
have an equal chance of becoming pregnant after ART
cycles when using donor eggs, this study shows that the
environment in the uterus may be compromised. If using
their own eggs, the environment of the follicles may be
compromised, indirectly effecting the development of the
oocyte (Paczkowski et al., 2015).
Overall, AMA in mice changes methylation patterns of
imprinted genes in reproductive tissue, which results in
dysregulated gene expression associated with poor reproductive outcomes. This study is significant in that it
suggests a possibility that the same factors in aged human
females might cause negative outcomes in their pregnancies as well (Paczkowski et al., 2015).
A study was done where associations of maternal age
at childbearing with gestational age (number of weeks
fetus was in the womb) and fetal growth (birthweight
adjusted for gestational age) were examined. Those features are important to study because these problems
predict mortality and morbidity across the lifespan of
the human, including psychological, health, academic, social, and economic difficulties. Preterm birth is associated
with decreased cognitive functioning in childhood and the
use of psychiatric medications in adults. Poor fetal growth
has been found to be linked to psychiatric diagnoses in
childhood (autism and ADHD) and adult health problems
(cardiovascular disease and diabetes). Given these major
health concerns, it is imperative to obtain a better understanding of the possible causes of these adverse perinatal
outcomes (Sujan et al., 2016).
The study was designed in such a way as to rule out
genetic and environmental factors that might contribute
to the results. To assess potential familial confounding,
two genetically informed designs were used comparing
cousins and siblings. To be able to generalize results, data
was taken from two samples with different cultures, races,
ethnicities, economic backgrounds, and healthcare coverage. Some covariates were offspring birth order, and
parental characteristics such as levels of education, history of severe psychiatric problems, history of substance
abuse, household income, maternal race, and maternal
age at first childbirth (Sujan et al., 2016).
There was strong evidence that AMA at childbirth was
associated with a shorter gestational age. The gestational
age of offspring born to 30-34 year old mothers, 35-39
year old mothers, and mothers of 40 years and above,
were all less than the gestational age of offspring born to
25-29 year old mothers. Even after accounting for shared
familial factors, the data pointed to a strong link between
mothers who are older at childbirth with shorter gestational age. This did not hold true for lower fetal growth.

Should Advanced Maternal Age be a Deterrent for Attempting a Pregnancy?

Results from the study supported a causal association
between AMA at childbearing and shorter gestational age
(Sujan et al., 2016).
Further research is needed to explore specific factors
that might account for the findings. Some possibilities
might be maternal diseases, such as hypertension, diabetes, and the quantity of oxygen and nutrients received
during the prenatal period (Sujan et al., 2016).
Another study tested the hypothesis that reduced fetal
weight and lower success of pregnancy outcomes in AMA
rats may be attributed to sex-specific changes in the morphological development of the placenta and in its nutrient
transport function. It was found that the sex of the fetus
did indeed influence the placenta and offspring outcome
in response to the adverse environment in the uterus
during gestation (Napso et al., 2019).
Young (3-4 months old) and aged (9.5-10 months old)
Sprague Dawley female rats were mated with young male
Sprague Dawley rats (3-5 months old) and were evaluated on gestational day 20. The study demonstrated that
advanced maternal age caused modifications in the phenotype of the placenta and in this way, altered its ability
to support the growth of a fetus. In particular, it modified
the expression of genes and proteins that are crucially
important in placental growth, transfer of nutrients, endocrine control of maternal physiology, and control of
exposure of the fetus to glucocorticoids. AMA causes oxidative stress and cell death in the placenta, in a manner
that is partially dependent on the sex of the fetus. The
study also indicated that gene expression changes in the
placenta of female fetuses were mostly beneficial, with
an up-regulation of genes that support the function of
the placenta. Gene expression changes in the placenta of
male fetuses, though, were mostly detrimental for placental growth and functional phenotype in older rats. There
was similar growth restriction in both male and female
fetuses, although the absolute weight of male fetal heart,
brain, and liver were more reduced in fetuses of aged rats
than younger ones (Napso et al., 2019). There were previous studies that demonstrated poorer cardiovascular
outcomes for adult male rats born from aged mothers
(Shah et al., 2018 as cited in Napso et al., 2019).
The sex-dependent changes in glucocorticoid handling
in the placenta of AMA mothers affects health outcomes
of offspring later in life. Elevated prenatal exposure to
glucocorticoids affects development of the fetus and permanently alters the structure and functions of its organs,
predisposing the offspring to certain diseases later in life
such as hypertension (Napso et al., 2019). Even though
the fetal weight for male and female fetuses of aged rats
was compromised similarly, studies showed that adult

male offspring of aged rats have a greater chance of developing cardiovascular dysfunction as adults, as compared
to female offspring (Shah et al., 2018 as cited in Napso
et al., 2019).
In summary, AMA affects the phenotype of the rat placenta in a sex-dependent manner. In female fetuses from
aged rats, there were larger beneficial changes in structure
and/or expression of genes related to placental transport
of nutrients from mother to fetus and improved handling
of glucocorticoids. In male fetuses of aged rats, there
were no beneficial changes in the transport system and
there was less protection from glucocorticoids, greater
oxidative stress, and elevated levels of apoptosis. These
sex-dependent changes in placental response to the environment in the uterus of the aged mother play a role in
the future health of female and male offspring.The results
of this study have implications for managing human pregnancies, especially in developed countries where women
are becoming pregnant at an older age. Targeted interventions can be developed to improve placental development and function which, in turn, will aid fetal growth and
development for mothers of AMA (Napso et al., 2019).
Although women of AMA are a growing population
in all developed countries with greater obstetric risks,
women who live in the Mediterranean have specific characteristics that are different than other areas. A study
was done to establish an AMA cut-off age in a selected
Mediterranean population in Barcelona. Although most
studies define AMA as being above 35 years, this study
defined AMA in Spain as being above 40 years. The average age of women delivering their first baby rose from
25.2 years in 1975 to 30.7 years in 2016. Models predict
that by 2050, the average age of a first pregnancy will
be 33 years. In 2016, 38.7% of deliveries in Spain were
to mothers over 35 years, and 8.39% were to mothers
over 40 years. The average age of women at childbirth in
2017 was 32.5. The scientific community is interested in
gaining information about the impact of AMA on obstetrical outcomes so that they can better assess risks in this
increasing population (Nieto et al., 2019).
The cohort in this study were women who gave birth
between January 2007 to June 2017. A total of 25,054
pregnancies were included. The average maternal age was
34.7 +/- 4.2 years. In this study, 2,807 patients were between 40-44 years and 280 patients were >45 years. Of
the total pregnancies, women above the age of 40 accounted for 12.3% of the deliveries. Confounding factors were
considered, which included chronic hypertension, pregestational diabetes types I/II, use of ART, obesity, smoking,
previous C-sections, and multiparity (having more than
one child). Over 97% of the women were Caucasian and
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99.8% were from the Mediterranean area. After adjusting
for confounding factors, age proved to be a significant
risk factor in developing gestational diabetes, especially in
women >40. The risk of placenta previa increased as well
in women >40 years. Preeclampsia and prolonged hospitalization were only associated with women >45 years.
The risk of these negative outcomes increased as the age
of the women increased (Nieto et al., 2019).
It was suggested that the reason for the increased risk
of gestational diabetes in women >40 might be endothelial damage. Age is known to be a cardiovascular risk factor
that produces structural and functional changes in the
vascular system. Dysfunctional endothelium increases the
risk of developing insulin resistance, which then increases
the risk of hypertension, type II diabetes, and other metabolic syndromes (Nieto et al., 2019).
In summary, in this study, women >40 were the most
positively associated with complications of gestational diabetes, placental previa, caesarian delivery, and prolonged
hospitalization. They were the ones with the highest clinical risks. These patients were also at greatest risk for
iatrogenia (effects from medical interventions) since they
have high elective C-section rates. Future investigations
should therefore address medical interventions and pregnancy surveillance to improve outcomes in AMA patients
(Nieto et al., 2019).
Another cross-sectional study tested the hypothesis
that there is an association between AMA and maternal
and neonatal morbidity. The study was based on data
obtained from 3,315 births. It compared the births of
women who were 35 years and older, with a reference
group of women between the ages 24-27 (Casteleiro et
al., 2019).
Results of the study confirmed the hypothesis. Repeated
spontaneous abortions were 2.2 times more frequent
in the older age group compared to the younger reference group. There was a greater incidence of gestational diabetes in AMA women, particularly in primiparous
women where the risk was eight times more prevalent.
The possibility of giving birth with the help of instruments
was multiplied by 1.6 and the possibility of a cesarean
delivery was multiplied by 1.5 in both primiparous and
multiparous AMA women. Lastly, there were correlations
between preeclampsia, preterm birth (<37 weeks) and
low birthweight in the older age group, although the numbers were not high enough to have statistical significance
(Casteleiro et al., 2019).
The cause of repeated abortions in AMA women may
be attributed to alterations in the chromosomes, which
increase along with increasing maternal age. The cause
of gestational diabetes is being continually researched.
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One theory is that diabetogenic hormones, such as the
growth hormone that releases corticotropin, produce an
increased insulin resistance which AMA women are not
able to overcome (Casteleiro et al., 2019).
A study was done to ascertain the effect of advanced
maternal age on singleton pregnancies in nulliparous
women. Records of obstetric patients were reviewed
from routine fetal ultrasonograms that were taken in
the middle trimester of pregnancy. Three groups were
included in this study: a control group of ages 18-34 years
old, advanced maternal age women of 35-39 years, and
very advanced maternal age women over 40 years of age.
Altogether, 957 women met the criteria to be included in
the study (Kahveci et al., 2018).
The study clearly demonstrated that AMA nulliparous
women with no previous chronic diseases (including obesity) had higher rates of adverse perinatal and neonatal outcomes such as gestational diabetes, gestational hypertension, preeclampsia, small for gestational age, spontaneous
late preterm delivery (between 34-37 weeks of gestation)
and cesarean delivery. Gestational diabetes, gestational hypertension and cesarean delivery rates were more common in the VAMA group compared to the AMA and young
age group. No increased risk was found for spontaneous
preterm delivery before 34 weeks, prolonged rupture of
membranes, placenta previa, large for gestational age, and
operative vaginal delivery (Kahveci et al., 2018).
It has been suggested that poor oxygen exchange may be
a factor in the association between AMA and small for gestational age.This stands to reason because when an unborn
baby doesn’t get enough oxygen during pregnancy, its organs
don’t grow as much as they should (Kahveci et al., 2018).
Concerning neonatal outcomes, admission to a NICU
was more likely to occur in the AMA groups, but there
was no major difference in APGAR scores, occurrences
of low birth weight, and neonatal morbidity between the
groups (Kahveci et al., 2018).
During the last few decades, there has been a significant
increase in the amount of pregnancies involving multiple
fetuses due to the use of ART. Even in singleton pregnancies, AMA poses a risk for more maternal and neonatal
complications. Multiple gestation drives this risk up even
more (Gluck et al., 2018).
A study was done with the goal of comparing obstetrical and neonatal outcomes between women older than
35 years and women younger than 35 with the same type
of twin pregnancy. Records were reviewed of all dichorionic-diamniotic pregnancies (in which each fetus has
its own placenta and amniotic sac) between 2009-2016
where the babies were delivered after 24 weeks gestation. Pregnancies with abnormalities in the chromosomes
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and those with fetal malformations were excluded. The
older women were divided into two groups: age 35-39,
and those >40. The control group consisted of women
younger than 35. Altogether, 716 women were studied.
The rate of in-vitro fertilization for conception was higher in the study groups (older women) than in the control
group (Gluck et al., 2018).
AMA was found to be independently associated with
cesarean section after adjustments were made for nulliparity, in-vitro fertilization, and hypertensive disorders.
The rate of hypertensive disorders was significantly higher in women over the age of 35 (Gluck et al., 2018).
Twins born to women over 35 also tended to stay longer in the NICU than those born to the younger women.
Other neonatal outcomes in women age 35 or older
who were carrying twins were similar to the younger
group (Gluck et al., 2018).
A retrospective cohort study was done to evaluate
whether AMA was independently associated with an increased risk of childhood cancer in the offspring. There
were three maternal age groups studied: 35-39, 40-50,
and a control group of 20-34. A comparison was made
between the three age groups for incidences of malignant
morbidity in the offspring. Pregnancies lacking prenatal
care, gestations of multiple fetuses, pregnancies originating with fertility treatments, and pregnancies with fetuses
displaying congenital malformations were not included in
this study. The offspring were followed up to the age of
18 years. The three most common malignant forms of
childhood cancer which were traced included leukemia,
brain tumors, and lymphomas (Imterat et al., 2018).
Theoretically, advanced maternal age might correlate
with childhood cancers due to DNA damage and decreased repair pathways in oocytes of older mothers.
Several previous studies (Ross et al., 2005 as cited in
Imterat et al., 2018) showed a connection between AMA
and meiosis errors leading to trisomies (particularly trisomy 21 or Down’s Syndrome) which are known to predispose for malignancies in childhood. Additionally, ART,
which is increasingly used to offset infertility disorders
in older women, is suggested as increasing the risk of
childhood cancers such as retinoblastoma, by altering
gene expression. Finally, changes in maternal hormones
during pregnancy that are age-related, such as higher intrauterine exposure to endogenous estrogen and insulin
growth factor-1, have been shown to help initiate cancers.
Considering all the above hypothetical effects of AMA on
childhood cancers, this study was important to conduct
(Imterat et al., 2018).
In the study, 201,738 deliveries were included. Results
showed that advanced maternal age did not increase the

risk of future malignancies in the offspring up to 18 years
old. There was some association, though, between maternal age and leukemia of the offspring which warrants further investigation (Imterat et al., 2018). However, overall,
childhood cancer of offspring does not seem to be a
major concern for AMA women planning to conceive.
A study was done to investigate what effect AMA has
separately in nulliparous and multiparous women on obstetric and neonatal outcomes in singleton pregnancies.
The study was a hospital-based analysis of 6,619 births
between January 2004 and May 2007. AMA was defined
as 35 years and older. Nulliparity was defined as women
who had not delivered a viable fetus (greater than 24
weeks of gestation in the past) and multiparity was defined as women who had at least one pregnancy in the
past that progressed beyond 24 weeks of gestation. The
actual parity number wasn’t considered. Of the study
participants, 42.7% were nulliparous and 57.3% were
multiparous. Of the nulliparous, 21.8% were of advanced
maternal age and of the multiparous, 42.1% were of advanced maternal age (Wang et al., 2011).
Among nulliparous women, AMA was associated with
higher rates of cesarean sections both before and during
labor, as well as vaginal deliveries assisted by instruments.
Among multiparous women, however, AMA was only associated with a higher rate of cesarean sections before
labor. This might be due to a greater percentage of multiparous women requesting cesareans (Wang et al., 2011).
A study was done in order to assess how pre-pregnancy
weight (or body mass index) and gestational weight gain
affect pregnancy outcomes in AMA women. This retrospective analysis was conducted on postpartum and hospital delivery data in China. A total of 1,015 women were
included in the study who gave birth from January-June
2017. In China, 60% of all pregnancies are in women greater than 35 years of age and half of these women are above
40 years of age. AMA women are often overweight before
pregnancy and are more likely to have internal diseases.
They are also more likely to be multiparas having had at
least one previous child. Age is also an independent risk
factor for adverse pregnancy outcomes (Lin et al., 2019).
The women were divided into an advanced age group
(35-40 years) and a super advanced age group (>40
years). Body mass indices prior to pregnancy were divided into underweight, normal weight, overweight and
obese groups. Gestational weight gain was subdivided
into three groups (Lin et al., 2019).
Results showed that being overweight prior to pregnancy increases gestational diabetes mellitus, hypertensive disorders complicating pregnancy, and fetal macrosomia where a newborn is significantly larger than average.
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Poor weight gain during pregnancy increased the risk of
preterm births, but excessive weight gain during pregnancy increased macrosomia in the babies of AMA women
(Lin et al., 2019).
The women in the super advanced maternal age group
had higher incidences of both being overweight and
obese than those in the AMA group. The super advanced
maternal age group had more incidences as well of gestational diabetes mellitus, hypertensive disorders, and macrosomia than in the advanced age group (Lin et al., 2019).
Overall, controlling weight gain both prior to and
during pregnancy reduced adverse pregnancy outcomes
in AMA women (Lin et al., 2019). It is good advice for
older women who are planning to conceive to get their
weight under control beforehand.
A study was conducted with the objective of determining whether there was an association between AMA and
race on pathology of the placenta in very low birthweight
infants. A retrospective cohort analysis was done on placental pathology on very low birthweight singleton infants born between July 2002 and June 2009. There were
739 cases included in this study (de Jongh et al., 2015).
The placenta is the area where maternal-fetal oxygen
and nutrients get exchanged and so it has an important
influence on birthweight and is necessary for a successful
outcome to a pregnancy. Placental growth, which can be
measured in terms of placental weight, is a good indicator of how well the placenta is functioning. The placenta
weight/birthweight ratio is used to indicate neonatal outcomes (de Jongh et al., 2015). Both high and low ratios
have been associated with an increased risk for stillborn
and other negative neonatal outcomes (McNamara et al.,
1998 as cited in de Jongh et al., 2015).
The subjects of the study were divided into two groups:
maternal age <35 and maternal age >35. Mean placental
weights, mean birthweights, and placental weight/birthweight ratios were calculated for each age group (de
Jongh et al., 2015).
In the final analysis, AMA was seen to be associated
with a decrease in placental weight and placental weight/
birthweight ratio. AMA, and not race or ethnicity, remained independently associated with placental weight/
birthweight ratio. It could not be determined, however,
if older maternal age directly causes reduced placental
weight/birthweight or whether it represents confounding
variables not tested for. Further research is necessary to
discover possible causal mechanisms that can explain the
relationship between AMA and lower placental weights in
very low birthweight babies (de Jongh et al., 2015).
In Denmark, the rate of cesarean sections increased by
49% between the years 1998-2015 and occurred in 21%
28

of all births.This is a cause for concern since cesarean sections can have short and long term consequences for the
mother and child and can present risks in future pregnancy.
A possible cause of the increase may be the delaying of
pregnancy until advanced maternal age. AMA at childbirth
has been found to be linked to pre-pregnancy morbidity
that might account for the increased risk of cesarean section.The goal of this study that included one million Danish
women was to examine the relationship between AMA
and cesarean section, taking demographics, health and
obstetric factors into the equation. There were three age
groups (30-34, 35-39, >40 years) with a reference group of
maternal age less than 30 (Rydahl et al., 2019).
A positive association was found between AMA and
cesarean section. When adjusting for confounders, there
were only minor changes in the risk factor. When compared to the reference group, nulliparous women aged
35-39 had twice the risk of cesarean section, while women
of 40 and above had three times the risk. For multiparous
women, the risk was more moderate (Rydahl et al., 2019).
Cesarean sections are one of the most intrusive
obstetric interventions and is becoming much more
common in industrialized countries. The increase in cesarean sections is mainly a result of AMA, especially in
nulliparous women. Morbidity tends to increase as age
increases, so AMA women will include more individuals
with prenatal risk factors such as hypertension, diabetes mellitus, and higher body mass index than younger
pregnant women. More women of advanced age will also
develop pregnancy related complications, including gestational diabetes, preeclampsia and placenta previa.There is
also evidence that there is a decline in the physical ability
to maintain uterine contractions which can cause labor
dystocia. Future studies on the possibility of advanced age
affecting the ability to maintain progression of labor is
recommended. Placenta previa in AMA women, as well as
non-vertex fetal presentations might also necessitate a
cesarean delivery (Rydahl et al., 2019).
The higher cesarean section rate may be a result of
these comorbidities related to AMA. It is possible, though,
that the lower threshold for cesareans may be influenced
by the attitudes of the healthcare professionals treating
AMA women who may view them as high-risk patients or
by the mothers themselves who choose a cesarean birth
because they are more anxious about the health of the
fetus (Rydahl et al., 2019).
A study was done regarding the association between
maternal age and offspring adult health. There is increasing documentation associating AMA with negative health
outcomes in their offspring.This association is considered
to be a reflection of aging physiological processes of the
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mother, such as the decreasing quality of her placenta or
eggs (Myrskyla & Fenelon, 2012).
In this study, the role of socioeconomic selection and
lifespan overlap between the generations is examined,
as they are related to the association between maternal
age and offspring adult health. It was found that offspring
born to mothers younger than 25 or older than 35 have
the worst outcomes regarding health, height, obesity,
and even mortality. The reason for the young maternal
age-offspring health link may be due to the physiological
immaturity and socioeconomic disadvantage of young
parenthood. Regarding the older age group, the results of
the study showed that negative outcomes are not due to
the mother leaving a physiological imprint in the offspring
that causes a predisposition to diseases in adulthood.
Rather, maternal education (which is strongly connected
to socioeconomic status) and the age at which the child
loses the parent are two important factors that affect
the correlation between AMA and offspring adult health
(Myrskyla & Fenelon, 2012).
Mothers of advanced age have generally had the opportunity to obtain a higher level of education which translates into greater affluence. Childhood socioeconomic
status has been found to be strongly connected to adult
health and mortality (Myrskyla & Fenelon, 2012).
The age at which a child loses a parent is directly related to maternal age. If all other factors are held constant, a child born to a younger mother will have many
more years of lifespan overlap with the mother than a
child born to an older mother. The psychological shock
of losing a parent at a younger age is one factor that may
affect the adult child’s health. Another factor might be the
loss of parental involvement with the offspring. Thirdly, a
shorter lifespan overlap might indicate a genetic frailty
that runs in the family (Myrskyla & Fenelon, 2012).
Maternal age, therefore, is related to the mother’s education, socioeconomic status, and lifespan overlap with
the offspring, all of which were found to be confounders
in the maternal age-offspring health association. These
factors all help explain the mechanism behind the association of AMA and negative health outcomes in the offspring and challenge the standard interpretation for that
association. The reason this study is important is because
today’s parents, even if they reproduce at an older age,
will likely live longer due to medical advances and therefore have a longer lifespan overlap with their offspring.
If biological aging is indeed not the factor to influence
the adult health of offspring but rather lifespan overlap is,
AMA women can be reassured going forward that their
late childbearing will not adversely affect their offspring
(Myrskyla & Fenelon, 2012).

In the latter half of the last century, the delay of childbearing in Western cultures has affected the biology of
the mother-fetus relationship. Data obtained from experiments, as well as clinical observations, have ascertained
this change. As an example, there has been an increase in
type 1 diabetes in developed countries during this time.
This trend parallels the tendency to give birth at a later
age which might suggest a causal relationship between
the two events. Delayed childbearing might therefore
have a detrimental effect not only on the development
of the fetus in the uterus but may possibly be causing a
predisposition to certain severe disorders. The change to
the reproductive organs due to age, along with changes
in hormone activity, may be the causes of this negative
relationship (Gloria-Bottini et al., 2005).
A study done in Italy might also suggest that delayed
childbearing is causing a change in the genetic composition of the population. Gene frequency refers to the
proportion of a population that carries one type of allele,
or gene variation, at a particular point on a chromosome.
Certain phenotypes either increase or decrease with maternal age. These changes in the genetic composition of
AMA women were found to be similar in the mothers
and newborns studied (Gloria-Bottini et al., 2005).
The hypothesis of the study, which included over 600
women giving birth, was that advanced maternal age may
influence intrauterine selection by favoring genotypes that
are best able to adapt to the intrauterine environment of
the older mothers. Zygotes that are more resistant to the
changes in the maternal environment of older women will
be the ones to survive. Maternal and neonatal genotypes
were found to be similar in the AMA women studied.
Maternal age was, therefore, having an effect on the gene
frequency in the offspring (Gloria-Bottini et al., 2005).
Very Advanced Maternal Age (VAMA)
In Australia, as in most other high-income countries, childbearing age has been rising to 35 years and above. A new
trend is emerging of pregnancies in women even 45 years
and older which comprise 0.1% of all births in the country and is continually rising. This is driven partly by assisted reproductive technologies such as oocyte donation.
There were few studies examining perinatal outcomes in
this age group. A state-wide population-based study was
done in Victoria, Australia covering the years 2005-2006
to determine maternal health and the outcomes of pregnancies of women in this age group compared to women
aged 30-34 years (Carolan et al., 2013).
The study revealed prenatal complications of at least
one of the following: gestational diabetes, antepartum
hemorrhage (bleeding from or in the genital tract),
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placenta previa, and multiple births. There was weak evidence for increased risk for preeclampsia. Women >45
were also more likely to have caesarian sections. They
were not found to be more likely of having a postpartum
hemorrhage (Carolan et al., 2013).
Pre-existing medical conditions of the mothers, as well
as parity and use of ART, were taken into account.Women
aged 45 and older were most likely to have pre-existing
hypertension, but there was weak evidence of pre-existing diabetes. Women in the group were 12 times more
likely to have used ART (Carolan et al., 2013).
Babies born to these VAMA (very advanced maternal
age) mothers were at a higher risk for preterm birth
(between 32-36 weeks gestation) regardless of parity,
low birth weight (less than 2,500 grams) for primiparous
women and had higher odds of being small for gestational
age. Rates of preterm birth were very high for multiple
births and for those who used ART (Carolan et al., 2013).
The findings in this study have ramifications for
the women as well as for their healthcare providers.
Although results displayed higher rates of pregnancy
and perinatal negative outcomes for the women aged
45 and older in Victoria, Australia, nevertheless, the
findings were reassuring as the vast majority of these
women of very advanced age gave birth to healthy babies. The rate of perinatal death was low (less than 10
per 1,000 births). This suggests that with good prenatal
care, most women in this group can achieve a live birth.
Future studies should include investigations into the future health of these children who were preterm birth
or were of low birth weight or small for gestational age
(Carolan et al., 2013).
A study was done to investigate the interplay between
very advanced maternal age (>43 years) and assisted reproductive technology on adverse perinatal outcomes.
Data was taken from a cohort of women who delivered babies in Ontario, Canada between 2012-2015. In
Canada, the number of births in women over 40 years of
age tripled from 2005-2014. Even though fertility declines
as a women ages, ART has allowed many more women
of VAMA the chance to become pregnant. ART, though,
has been considered a risk factor for adverse pregnancy
outcomes as compared to spontaneous conceptions.This
particular study aimed to assess the pregnancy outcomes
of women who were both of very advanced age and who
used ART to conceive. Singleton pregnancies of women
>20 years who delivered at 20 weeks of gestation and
above and whose offspring’s birthweight exceeded 500
grams were included. The women were put into three
categories of age: 20-34 years, 35-42 years, and >43 years
of age. VAMA was defined as >43. All the subjects used
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were noted as either having used ART or having spontaneously conceived (Wu et al., 2019).
The mothers age was the independent variable. The
type of conception (ART or spontaneous conception)
was the main covariate. ART conceptions included intrauterine insemination, intrauterine insemination with ovulation induction but without in-vitro fertilization, in-vitro
fertilization, and vaginal insemination. Many potential confounders for adverse maternal and neonatal outcomes
were included, such as parity, income, education, bodymass index, drug/alcohol use, and maternal preexisting
health issues (Wu et al., 2019).
Women at VAMA had a higher risk of a composite outcome which included preeclampsia, intrauterine growth retardation, stillbirth, and placental abruption than the mothers in a younger age bracket.The fact that ART was used did
not add to the adverse effect of VAMA, even though ART
may play an independent role for adverse perinatal outcomes. These outcomes were found in 10.41% of women
under 35 and in 13.35% in women of VAMA. Regardless
of the conception method, women of VAMA had a higher
incidence of adverse outcomes (Wu et al., 2019).
Another study was done to evaluate if the adverse pregnancy outcomes in women of very advanced age differed
by parity and by conception method. According to a national perinatal database in Japan, women of VAMA giving
birth rose to 28.1% of all births. A total of 365,417 women
over the age of 30 were included. The women were divided into four age groups: 30-34, 35-39,40-44, and >45.
Pregnancies involving multiples, as well as fetuses with congenital abnormalities, were excluded (Ogawa et al., 2017).
Compared with the 30-34 year reference group,
women aged 45 or older showed a higher risk for cesarean sections, preeclampsia, placenta previa and preterm
birth. Placental abruption, very preterm birth, low
APGAR score and perinatal death were not seen as being
of increased risk in VAMA. The effects of older age on the
negative outcomes were significantly higher among those
women who conceived naturally, compared to those who
used ART to conceive. However, the possibility that abnormal embryos were removed during ART could have
skewed the results. The effect of advanced age on cesarean deliveries was stronger among primiparous women,
but the risk for preeclampsia was significantly stronger
among multiparous women (Ogawa et al., 2017).
The effects of advanced age on preterm birth were significantly greater among women who conceived without
ART than among those who used ART to conceive. To
clarify, while the risk of preterm birth generally increased
with age in women who conceived without ART, it decreased in women who conceived with ART. Therefore,
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younger women who conceived through ART, may have a
greater risk of preterm birth than women who are older
and conceive through ART (Ogawa et al., 2017).
The greater risk of cesareans in primiparous women of
advanced age may be due to higher rates of elective cesarean sections requested by primiparous older women. It might
also be due to prolonged labor or compromised fetal status
requiring emergency cesarean section with increasing age,
but these hypotheses were not tested (Ogawa et al., 2017).
While the greater risk of preeclampsia in multiparous
older women in this study contrasted to a previous study
(Bianco et al., 1996 as cited in Ogawa et., 2017) which found
no change in risk of preeclampsia in both primiparous and
multiparous women of age, this might be explained by the
recent use of low dose aspirin in women with a higher
risk of preeclampsia. Since both primiparity and advanced
age are both strong risk factors for preeclampsia, these
women may be more likely to receive the medication than
multiparous women (Ogawa et al., 2017).
Regardless of the way VAMA women conceive, the
need for preconception counselling, and greater prenatal
care in these women should be a priority. Regular prenatal visits and testing can help address potential concerns early on and reduce the risk of pregnancy and birth
complications which can be even more devastating, both
emotionally and financially.
Conclusion
Many studies have been done in various developed countries investigating what impact AMA has on perinatal
and neonatal outcomes. The consensus is that advanced
maternal age increases the mother’s risk for developing
medical conditions such as cancer, diabetes, hypertension,
and arthritis. The probability of pregnancy complications
increases as well. Among these complications are chromosome anomalies, placenta previa, placental abruption,
caesarean birth, preterm labor and low birthweight.
Abnormal functioning of the placenta and impairment in
oocyte development potential, both due to aging, can result in fetal growth restriction and even stillbirth. Women
who are of very advanced maternal age (over 40 and especially over 45 years of age) seem to be at even greater
risk of pregnancy and perinatal difficulties, although risks
differ by parity and conception method.
Results of studies have been conflicting at times. The
reason for this might be differences in homogeneity in
study groups or failure to adjust for potential confounders such as maternal diseases, obesity, assisted conception, pregnancies of multiples, and parity. Differences in
definitions of pregnancy outcomes might also be a reason
for incompatible conclusions. It is vital to determine if age

effects are direct and have a causal relationship with adverse outcomes or if they are indirect since other factors
are at play. In order to accomplish this, future studies need
to have control groups for age-dependent confounders.
Inconclusive results concerning the ramifications of
delayed childbirth must be resolved so that women of
advanced age can make informed choices when deciding
whether to bear children.
Information regarding chromosome anomalies and
the availability of prenatal screening tests are vital for
any women over the age of 35 who are planning to become pregnant. Those who receive positive results for a
screening test can be sent for genetic counselling. Other
emotionally supportive forms of help might come in the
form of bereavement counselors, adoption services, or
information on support groups for parents of multiples
or for those who suffered a perinatal loss.
Preconception care is especially important for women
of advanced age planning a pregnancy. Fertility concerns,
pre-existing health conditions and risks for chromosome
anomalies can be discussed. The importance of folic acid
during pregnancy to decrease the risk of neural tube
defects, reducing workplace risk and avoiding alcohol
use and medications are all important topics to address.
Older first-time mothers may need counselling regarding
their transition into parenthood which may be more difficult for them as opposed to younger, first-time mothers.
Most importantly, pregnancy surveillance in this older age
group must be stressed in order to improve outcomes
for both mother and baby.
The trend of increased advanced maternal age is
expected to continue and thus the effects of AMA on
maternal and fetal morbidity and mortality is, and will
be, of great concern. The unique needs of this population must be addressed not only to benefit the mothers
and babies themselves but for the implications that it
has for the healthcare system and for service providers.
Promoting the health of these women and their offspring
and preventing negative outcomes reduces healthcare
costs overall and will have an impact, going forward, on
employment policies which will, hopefully, become more
pregnancy-friendly.
Overall, older women who are in generally good health
can hope to have favorable outcomes to their pregnancies with good prenatal care. Advanced technologies in
perinatology have improved their chances of giving birth
to a healthy child. If the needs for preconception counselling, targeted surveillance and early medical intervention
are met, then there is no definite medical reason for excluding AMA women from attempting a pregnancy on the
basis of age alone.
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Abstract
Organ and limb regeneration might seem like something out of science fiction, but research has been ongoing since the late 1960s
and has greatly increased at the turn of the century. It is an understatement to say that this has the potential to be life changing.The
need for donor transplant organs and transplant waiting lists can become obsolete and the use of immunosuppressants post-transplant will become unnecessary (leading to higher survival rates). Should this happen, trauma patients will be able to achieve complete
recoveries and the reign of some congenital disorders will come to an end. Nature has provided several opportunities for us to study
this subject. Many species have a natural ability to regenerate complete organs. Human fetuses display a tremendous power of
regeneration and healing in utero. The struggle has been in determining how and why this ability disappears after birth as well as
applying the lessons we have learned from other species to humans. (However, great progress has been made and this paper will
discuss where science is holding in terms of being able to give a human the ability to regenerate complete organs and limbs.) This
paper will discuss whether science has been able to determine which lessons to learn from nature and how and when to apply it.
Introduction
In 2008, nearly 2 million amputees have been reported
in the United States and its prevalence is estimated to
escalate more than 3‐fold by 2050 (Ziegler-Graham, et
al., 2008). Although great strides have been made in treatments for amputees which have in turn greatly increased
their ability to lead productive lives, there are many side
effects and frequent compromises that affect the quality
of life (i.e. the adverse effects of long‐term immunosuppression) need to be accepted. In addition, current therapeutic approaches, such as allogeneic hand transplantation, suffer from a limited donor supply (Schneeberger,
et al., 2007). Besides for injuries and congenital diseases,
regenerative medicine therapies have the potential to
allow us the ability to treat (or even replace) failing organs which have begun to decline due to age (Heidary
Rouchi, Mahdavi-Mazdeh, 2015; Ranjeet Singh, 2016). This
will allow for a great increase the general quality of life,
especially for the elderly. Regenerative medicine has the
potential to provide treatment for a tremendous variety
of currently intractable diseases and ailments (Upadhyay,
2015).
Methods
Data was collected using Google and PubMed databases through Touro College’s online library. Among the
key-phrases used were “regeneration”, “limb regeneration”,“human regeneration”, and “regenerative medicine.”
Discussion
To begin the discussion of regeneration we must first
gain a clear understanding of the conditions and processes that are required for it to occur. There are a few
species that have a natural ability to regenerate organs
and limbs. All known livings things can be classified into
three groups concerning their natural ability to regenerate. This paper will refer to the three groups as “complete”, “partial”, and “minimal”. “Complete” refers to a
lifelong, absolute ability to regenerate complete organs
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and limbs. Examples include urodeles such as newts and
axolotls such as salamanders (Bensoussan-Trigano, et
al., 2011; Dinsmore, 1996; Brockes, Kumar, 2002; Roy,
Lévesque, 2006). “Partial” refers to an absolute ability to
regenerate but only for a portion of the lifespan, after
which the capacity is lost. For example, anurans such as
frogs and toads can completely regenerate a limb in the
larval stage, however, once passed metamorphosis they
lose this ability (Satoh, et al., 2005; Suzuki, et al., 2006).
“Minimal” refers to a very limited capacity for regeneration (only very simple organs and/or simple portions
of complex organs) and only for a small portion of the
lifespan. Neonatal mammals for example, have been
shown to be able to regenerate the tips of digits, however, this ability fades with aging (Sánchez Alvarado, Tsonis,
2006; Farah, et al., 2016).
Differences
Wound healing is a necessary component of regeneration and is comprised of four stages (a) hemostasis (blood clotting), (b) inflammation, (c) proliferation
(growth of new tissue including the formation of wound
epidermis (WE)), and (d) maturation (remodeling)
(Fernando, et al., 2011; Simkin, et al., 2013; Yokoyama,
2008). Wound healing occurs in all groups, regardless
of their ability to regenerate (Raz, Mahabaleshwar,
2009). However, there are important variances within
the exact mechanisms for each of the groups (Borgens,
1982; Han, et al., 2008; Takeo, et al., 2013). Variances include the duration of wound closure (Mu, et al., 2013;
Stocum, 2011), inflammatory response (Ferguson, et al.,
1996;Wulff, et al., 2012), and wound maturation (remodeling) (Bellayr, et al., 2009; Ravanti, Kähäri, 2000; Xue,
et al., 2006). Understanding these variances is essential
for developing regenerative capacity in humans (Mu, et
al., 2013). The differences will be highlighted here, for a
more thorough review of the mechanism for limb regeneration refer to “New Insight into Functional Limb
Regeneration: A to Z Approaches” (Taghiyar, et al., 2018)
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Wound Closure
Unlike adult anurans and mammals (postnatal) who form
scar tissue during wound healing, urodeles, embryonic
and fetal anurans, and neonatal mammals do not (Dang, et
al., 2003). One difference is the length of time it takes for
wound closure in each of these groups. In adult mammals,
epidermal closure takes between 8- and 12-days post amputation (DPA) (Reginelli, et al., 1995; Simkin, et al., 2013).
Embryonic mammals, however, take much shorter time. A
study found it takes only up to 24 hours for an embryonic
mouse (McCluskey, Martin, 1995). In addition, urodeles
take only between 10 and 24 hours (Campbell, Crews,
2007; Murawala, et al., 2012) and a study conducted on
early post-metamorphic anurans found the wound closure time to be between 2 and 3 days (Goode, 1967).
Last, a study on embryonic tadpoles (which are anurans)
found wound closure took only 30 mins though the paper
does admit that this rate seems “extremely high” (Yoshii,
et al., 2005). It logically follows that scar tissue formation
is related that the length of time required for complete
wound closure (Manuel, Gawronska-Kozak, 2006; Wilgus,
2007). Though it seems the differences between those
with scar formation and those without must manifest
sometime after 24 hours, this is not the case. The first 24
hours of each of the groups are not the same. In fact, in
(adult) mammals, it can take more than 24 hours for the
first migration of epithelia to begin to cover the wound.
There seems to be a fundamental difference in the wound
healing process that must be explored..
Immune System
One such fundamental difference seems to be the immune system. Urodeles have a weak immune system
compared to anurans and mammals (G. Chen, Robert,
2011; Kaufman, et al., 1995) who seem to share the same
immune system in terms of complexity, specificity, and
memory (du Pasquier, et al., 1989; Mescher, Neff, 2005).
This isn’t the only place where anurans and mammals are
grouped together. Interestingly, the changes that occur in
mammals as they mature and shift from fetal scar-free
repair to adult scar-based repair have a close resemblance to the changes that occur in anurans as they begin
metamorphosize and lose their regenerative ability and
in both cases immune signaling has been identified as a
key regulator. In mammals specifically, scar-free healing is
associated with an immature immune system. (Kishi, et
al., 2012; Wilgus, 2007). Also, note that although most of
what we know about urodeles immunity has been obtained from studies on axolotls specifically, it appears it
can be inferred to the many different species and genre
of salamanders (Cohen, 1971).

Past research indicates that there is a correlation between the level of maturity of an immune system and the
regenerative capacity. As an anuran undergoes metamorphosis (a developmental period referred to as “refractory period”), we find an inverse relationship between
the maturation of their immune system and the loss of
scarless healing (Bertolotti, et al., 2013; Godwin, Brockes,
2006; Mescher, Neff, 2005). In fact, the suppression of
the more potent immune response that develops during
the refractory period restores a metamorphosizing anuran’s regenerative ability (Fukazawa, et al., 2009). This is
backed up by another study that found that the decrease
in regenerative capacity that an anuran experiences as it
matures is negatively correlated with the intensity of the
inflammatory response as well as structural modifications
in the thymus (Franchini, Bertolotti, 2012).
Comparison of Systems
The immune system of adult anurans and mammals is intricate with a wide range of adaptive immune responses
in addition to a complete innate immune response. By
comparison, urodeles are considered immunodeficient
relative to adult anurans and mammals though they have
a strong innate immune system (G. Chen, Robert, 2011).
This is because, despite their reasonable B-cell and sizable T-cell reserves, their humoral response is extremely
slow (60 days), not able to facilitate anamnestic responses, and only has one unique IgM class (Kaufman, et al.,
1995; Tournefier, et al., 1998). In addition, immunization
with soluble antigens gives negative results and its B cells
are not triggered by T-helper cells; in fact, thymectomy,
X-ray irradiation or corticosteroid treatment has shown
to improve the humoral response (Charlemagne, 1979;
1981; Tournefier, 1982).
A urodeles cytotoxic immune response is very slow
as well (21 days) and shows weak mixed lymphocyte
reactions (MLRs) (Kaufman, et al., 1990; Koniski, Cohen,
1992) causing there to be no acute xenograft rejection
reactions. However, since they have reasonable B-cell and
sizable T-cell reserves they have a large diversity of B and
T cell antigen receptors which, over time, causes rejection to ultimately occur. Therefore, xenograft rejection
appears to be dependent on the thymus (Tournefier, et
al., 1998). Due to the weak adaptive immune response
of urodeles they are extremely susceptible to viral infections relative to anurans. Although they display a complex
immune response, they fail to generate adequate T cell
proliferation in the spleen early on. By comparison, anurans are able to generate adequate T cell proliferation
in the spleen early on and therefore are capable to clear
viral infections (Cotter, et al., 2008).
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There are further differences, specifically in terms of
innate vs. adaptive immunities (Godwin, Rosenthal, 2014)
that are beyond the scope of this paper. However, clearly
there are differences that seem to correlate with the ability for regeneration. The specific aspect(s) of the immune
system that is/are responsible is still not known, but it
appears that the more sophisticated the immune system
is, the less of a regenerative ability there is. Perhaps this
is the way species have evolved; prioritizing survival (by
prevention of infection) over function and aesthetics of
damaged organs and limbs. However, now that we have
antibiotics, perhaps both can be achieved.
Wound Maturation
Analogous to the cytoskeleton in cells the extracellular
matrix (ECM) allows for individual cells to come together
and create tissues and eventually organs by providing a
non-cellular structural platform upon which the cells adhere to. It is made up of macromolecular network composed of collagens, proteoglycans/glycosaminoglycans,
elastin, fibronectin, laminins, and several other glycoproteins (Bonnans, et al., 2014; Michel, et al., 2010;Theocharis,
et al., 2016). For organ or limb regeneration to occur, the
proper ECM form must be created for the cells to have a
place to go. In addition, the interaction between the cells
and the ECM allows for the control of growth by providing negative feedback when a sufficient number of cells
have been produced preventing an overgrowth.
Matrix Metalloproteinase (MMP)
During regeneration, for the proper structure to be
formed the use of matrix metalloproteinases (MMPs)
are employed. The main function of these molecules is
to degrade the matrix strategically and help sculp the
proper structure needed. There are other functions that
have been discovered but they are beyond the scope of
this paper. To keep things in control, tissue inhibitors of
metalloproteinases (TIMPs) keep the protease activity
of MMPs in check and therefore are the regulators of
wound closure, tissue regeneration and scar formation
(Mu, et al., 2013).
In adult mammals a severe inflammatory response and
high fibroblast activity results in collagen fiber accumulation between the epidermal layer and the transected
bone (Satoh, et al., 2012; Seifert, et al., 2012). The collagen
deposition hinders a reciprocal interaction between the
surface layer and most underlying mesenchymal tissues
preventing normal skin restoration and causing scar formation to occur (Satoh, et al., 2008). The discrepancy
between scar formation and epimorphic regeneration
is most probably attributed to the histolysis phase of
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regeneration in which MMPs are absent for ECM remodeling (W. Chen, et al., 2007).
In urodeles, pre-morphologic anurans, and fetal mammals, higher ratios of MMPs/TIMP have been observed
relative to those who do not have a regenerative capacity
(Parks, 1999; Ravanti, Kähäri, 2000). Studies have shown
that MMP1 specifically has a beneficial impact on muscle
healing (note: these studies were completed on those
that do not have a natural regenerative capacity) (Bedair,
et al., 2007; X. Chen, Li, 2009; Kaar, et al., 2008; Wang,
et al., 2009). In fetal mice, who are not able to regenerate complete limbs, introduction of MMP1 has been able
to cause complete regeneration (Muneoka, et al., 2008).
There have been many additional benefits observed
when the use of exogenous MMP1 has been employed.
Building on the results of the study by Chen et. al. (2007)
stated above, results of a study from 2013 showed that
in adult mice who underwent MMP1 treatment achieve
an increase in the formation of capillary blood vessels,
peripheral nerve fibers and neuromuscular junctions, as
well as a decrease in the formation of fibrotic scar tissues
in the amputated digits. However, the healing of skeletal
tissue and digit elongation was not significantly improved
(Mu, et al., 2013). A possible solution may be stem cells
which are able to form the segmented pattern of bone
and cartilage crucial needed for regeneration (more on
this later on) (Masaki, Ide, 2007).
Additional Hypotheses
Land vs. Sea
An anuran loses its regenerative ability as it transitions
from living in the water to living, at least partially, on land.
As noted above the changes to the immune system of anurans as they metamorphosize and transition from water
to land leave it with a much more powerful weapon, which
makes sense as terrestrial conditions require a more effective immune system (Alibardi, 2018). However, a study
on Xenopus laevis (anuran) embryos found that the
rate of wound closure tends to decrease as the osmotic
pressure approaches isotonicity (Yoshii, et al., 2005). The
authors suggest that perhaps the extremely rapid rate of
wound closure is a result of the stimulation of the osmotic pressure regulation system, something which amniote
embryos do not require and therefore why they have a
much slower rate of wound closure. This begs the question; why do urodeles have an increased wound closure
rate if they are terrestrial organisms? While it may be true
that osmotic pressure can affect an organism’s ability to
regenerate, it is unlikely for urodeles and pre-metamorphic anurans to have developed two completely distinct
methods of regeneration, especially since anurans and
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urodeles are part of the monophyletic Lissamphibians.
In addition, of the three orders included, anurans and
urodeles are more closely related to each other than to
the third order (the legless caecilians) (Elinson, del Pino,
2012). More likely, once an organism has the ability to
regenerate, the increased wound closure rate due to
osmotic pressure helps speed up the process. However,
research into this is unnecessary since we are looking for
a way to replicate the mechanism of regeneration in humans and since humans do not have an osmotic pressure
regulation system, increasing osmotic pressure to induce
regeneration would be futile. Though, perhaps once we
are able to regenerate maybe we can use the principles of
osmotic pressure to help speed up the process without
compromising on the regenerative ability.
Intrinsic and Extrinsic Cellular Properties
If there are fundamental cellular differences between
those with the ability to regenerate and those without,
then the potential for humans to achieve this capacity will
be considerably more challenging. In that case it would
require edits to the genetic code which we are a long way
from being able to do at this point. Fortunately, although
some evidence indicates that regenerative capacity stems
from intrinsic cellular properties, it is not much. For example, transplantation of limb blastemas from post-metamorphic (regeneration incompetent) to larval (regeneration competent) stages failed to regenerate despite the
conducive host environment. This seems to indicate that
there may be an intrinsic property of those post-metamorphic cells that prevents regeneration from occurring
(Sessions, Bryant, 1988). However, this conclusion is only
theoretical and evidence for manipulation of extrinsic
(specifically immunological) properties have yielded some
interesting results in mammals (Leavitt, et al., 2016; Satish,
Kathju, 2010). Genetic deletion of the anti-inflammatory
cytokine IL-10 induces scar tissue formation in fetal mice
(recall embryonic mammals heal scarlessly) (Liechty, et al.,
2000). Though, in all fairness, these results were achieved
by genetic manipulation. In order to be certain that there
is no intrinsic cellular property that is responsible for
regeneration, this study must be performed without any
manipulation of any intrinsic cellular properties (i.e. no
genetic deletion). For all we know, the deletion IL-10
caused some other effect, and which may very well be the
actual reason for the results that were achieved.
Treatment Proposals
With the above in mind we will now explore some of
the therapeutic approaches that been hypothesized to
enable humans to be able to regenerate organs and limbs.

These hypotheses include modulating the host environment, manipulation of the host immune system, and gene
manipulation. However, we must keep in mind that the
best possible solution might be to combine multiple approaches simultaneously. We will try to determine which
discoveries discussed above form the basis for the proposed treatments to build upon.
Cell-Based Approaches
Many of the concepts discussed above describe differences that develop because species are inherently different
down to the cellular level. This is true for all living things
on an individual level as well. For example, the liver contains two types of epithelial cells named hepatocytes
and cholangiocytes. However, both those cells originate
from a single cell type called hepatoblasts (which are
fetal liver stem/progenitor cells) during development
(Oertel, et al., 2003; Tanimizu, et al., 2003). To overcome
the lack of regenerative capacity of differentiated tissues,
many have hypothesized harnessing the power of stem
cells. Since stem cells are inherently able to develop into
multiple cell types, we can theoretically achieve an environment that is similar to a fetus (recall that mammal
fetuses do possess an ability to regenerate to some extent). However, due to ethical concerns related to the
use of embryonic stem (ES) cells as well as the desire to
move away from the use of immunosuppressant drugs
commonly used nowadays post allogeneic or even xenogeneic transplantations due to rejection, many have
turned to the use of the patients own cells and then
“reprogramming” them into a stem cell that behaves
like an embryonic one. ES cells are pluripotent, meaning
they can form tissues from all three primary germ layers
(ectoderm, endoderm, and mesoderm). Somatic cells
that have been reprogrammed to behave like ES cells
are called induced pluripotent (iPS) cells.This is achieved
through a number of techniques which artificially turn
on expression of specific pluripotency genes (Hackett,
Fortier, 2011). Last year, a study to trace the origin of
adult intestinal stem cells provided a direct link between
the observed plasticity and cellular reprogramming of
differentiating cells in adult tissues following damage
(Tetteh, et al., 2016; van Es, et al., 2012; Buczacki, et al.,
2013; Yui, et al., 2018; Nusse, et al., 2018). This indicates
that stem-cell identity is an induced rather than a hardwired property (Guiu, et al., 2019).
Amongst the various candidates for reprogramming,
mesenchymal stem (MS) cells are of central importance
for several reasons. MS cells are found in a majority of
adult tissues including, bone marrow, adipose, cartilage,
and dental pulp (Eslaminejad, et al., 2006; Karamzadeh, et
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al., 2012; Zomorodian, Baghaban Eslaminejad, 2012). The
benefit of being able to use cells that are derived from a
patient’s own body is that transplantation will not elicit a host immune response. In addition, several studies
suggest that MS cells induce immunomodulatory effects,
which suggests that even allogeneic transplantation of
these cells would not trigger the host immune response
(Shi, et al., 2011).
In the past MSC transplantation has been performed
for different diseased tissues (Emadedin, et al., 2012;
R. Fekrazad, et al., 2015; Reza Fekrazad, et al., 2016).
However, in 2007 Masaki et al. experimented with neonatal mice and compared the application of bone marrow
mesenchymal stem cells (BM-MSCs) and limb bud transplantation into amputated limbs. They demonstrated that
both BM-MSCs and limb bud transplantation form the
segmented pattern of bone and cartilage which is crucial
to regeneration (Masaki, Ide, 2007).
One issue with the stem cell approach is that stem cells
lack the positional information needed for regeneration
to occur. It doesn’t help to just have the cells grow; they
need to know where to grow. Without going into too
much detail, there have been a few studies that attempted
to help guide the stem cells to where they belong through
introducing different factors into the mix. One such study
showed they can induce the formation of multi-digit frog
limbs in post-metamorphic specimens (Lin, et al., 2013).
Another study attempted to replicate the in-vivo niche
of a multifaceted limb through genetic modification of
BM-MSCs to produce blastemal-like cells. After injecting
the blastemal-like cells they noticed the presence of digit
patterning and they achieved complete regeneration of
an amputated digit tip (Taghiyar, et al., 2017). According to
this author that cell sources with BC qualities are able to
provide a the highly complex signals required for regeneration (Taghiyar, et al., 2018).
Immune-Based Approach
Immune cells such as monocytes and tissue resident
macrophages seem to be an important element in the
regulation of tissue repair, regeneration, and fibrosis.
Post injury, these cells begin to function significantly different. They begin to produce inflammatory mediators
and growth factors that enable the regeneration process (Taghiyar, et al., 2018). In 2013 a study showed the
important part that macrophages play in the successful
development of new limbs in amphibians (Godwin, et
al., 2013).
Although we noted above that it seems the more sophisticated the immune system is the less of a regenerative ability there will be, there still seems to be a role for
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at least some immune cells to play. Systemic macrophage
depletion has been shown to prevent limb regeneration
in axolotls during the first 24 hours after amputation. A
study found that the depletion of macrophages caused
an increase in inflammatory factors and a decrease in
anti-inflammatory cytokines. In addition, certain growth
factor levels decreased significantly causing dedifferentiation markers to become dysregulated and disrupted
blastema formation (Godwin, Rosenthal, 2014). Another
study found that a wide arity of proinflammatory and
anti-inflammatory chemokines and cytokines can be
found immediately after an injury in axolotl limb tissue
(Godwin, Rosenthal, 2014). In addition, similar to mammalian wounds, various leukocytes travel to the site of an
injury and many of them persist throughout the beginning of blastema formation. Despite this we do know that
a severe inflammatory response promotes fibrosis and
therefore obstructs the successful patterning needed to
regenerate a new organ (Eming, et al., 2009) so it seems a
proper balance needs to be achieved.
While immune-based approaches will not be able to
induce a regenerative capacity in humans they may help
improve other approaches when used simultaneously.To
achieve the proper balance mentioned above we need
to be able to distinguish subpopulations of immune cells.
However, due to the lack of reliable markers we have
not been able to make good progress thus far.
Genetic-Based Approach
Although there has been a “proof-of-concept” studies
that indicates there is a link between genes and cell
therapy in terms of regeneration as well as tremendous
progress in gene-based strategies, I have not been able
to find any clinical trials that have used this approach.
The general idea of this approach is to genetically modify specific cells so that the cell can then regulate cell
differentiation. It could be the reason why we have not
seen any clinical trial is because of the lack of safe and
efficient methods of doing so. On one hand, viral vectors
achieve high transfection rate, but they have significant
safety concerns. On the other hand, although non-viral
vectors are relatively safe, they do not achieve efficient
transfection rates (Taghiyar, et al., 2018). However, as
new technological innovations, specifically CRISPR/Cas9,
begin to show promise they may allow for clinical trials
to begin. A review of gene-based therapies noted the opportunities that CRISPR/Cas9 holds because of its widely
acclaimed abilities and relative ease of use (Janssen, et al.,
2016). Today the vast majority of CRISPR/Cas9’s use case
has been in basic research (i.e. knockout mice) but that is
slowly starting to change.
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Conclusion
It seems probable that the future will see regeneration
of complete organs and limbs. Perhaps it will be in vitro
at first but eventually in vivo as well. New breakthroughs
have been able to apply many of the techniques employed
by species that have a natural ability to regenerate to
ourselves. Whether it is the biodome or the 3D printing
or tissue engineering, it seems that whatever final solution we come up with will require us to employ multiple
tactics. It also seems that different organs and limbs will
require different approaches a well.
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Abstract
Integrin α6β4 is a membrane protein which is expressed in both normal and cancerous epithelia. In normal cells, it is involved
in adhesion to the basal membrane. In carcinomas, however, it takes on cell signaling roles related to survival and migration. Due
to its key role in cancer progression, it is now being considered as a therapeutic target. This paper examines how we can affect
integrins, with a specific focus on integrin α6β4, to reinforce their ability to prevent migration of cancer cells and progress toward
metastasis.
Methods
Data was collected using ProQuest, PubMed databases,
and the National Library of Medicine. The images and diagrams can be found in the research articles referenced.
Introduction
Integrin α6β4 is a membrane protein found on the basal
side of epithelial cells. It is a member of the integrin family of proteins. Integrins are heterodimers which are imbedded in cell membranes and signal allosterically; ligand
binding to extracellular binding sites causes conformational changes in the integrin which ultimately affect their
cytoplasmic domains. These domains link to the cell’s
cytoskeleton and thereby perform signal transduction.
As much as their signaling works outward-inward, their
signaling also works inward-outward. Integrins’ position
in the cell makes them a key component in signaling, cell
migration, and cell adhesions. Each integrin has a distinct,
specific function, and, therefore, they have diverse ligands.
Many integrins, including α6β4, can be turned on or off
and need to be activated by tyrosine kinases or growth
factors in order to bind to their ligands.
Integrin α6β4 is different from other integrins because
it has a unique β subunit, with an atypically long cytoplasmic domain which connects to the keratin intermediate
filament system, as opposed to the microfilament system.
The α subunit binds to its ligand, laminin 332, in the extracellular matrix. Through mediating the interactions with
laminin and keratin, integrin α6β4 is the core component
of the hemidesmosome, a protein complex which attaches basal epithelial cells to the basement membrane.
Normally, integrin α6β4 is involved in hemidesmosomes and contributes to tissue stability. Cancerous cells,
however, lack hemidesmosomes and integrin α6β4 is localized at the leading edges of metastasized carcinoma
cells. Integrin α6β4 interacts with many cancer-related
growth factors such as epidermal growth factor receptor
(EGFR). Significantly, integrin α6β4 activates phosphoinositide 3-OH kinase (PI3K), a key signaling molecule for
carcinoma invasions.
Because of integrins’ unique positioning in the cell and
in cell signaling, they are highly involved in development
of cancers. At times, integrins can inhibit pathways, and

at times they can activate pathways instead. Therefore,
integrins should be considered as a possible target for
treating cancers. Integrin α6β4 can be considered as a
model, as it attaches cells to the basement membrane and
can contribute to invasion and metastasis of carcinomas.
However, before examining cancerous cells, it is necessary to understand the behavior of integrins in normal
epithelial tissue.
Integrin α6β4 in Regular Cells
In healthy epithelial cells, integrin α6β4 occupies a central
place in the hemidesmosome, a protein complex which
connects epithelial cells to the basement membrane.
There are two kinds of hemidesmosomes: type 1, which
is found in stratified and pseudostratified epithelia (such
as in the epidermis) and type 2, which is found in simple
epithelia (such as in the intestine). In the more complex
type 1 hemidesmosomes, integrin α6β4 facilitates the interactions with most of the proteins involved, including
the intracellular proteins plectin and BP180, the transmembrane proteins BP230 and tetraspanin CD151, and
the extracellular protein laminin 332, which is part of the
basal lamina (Walko et al, 2015). In the simpler type 2
hemidesmosomes, the only components are plectin, laminin, and integrin α6β4, which mediates the interactions
between the other two. Integrin α6β4’s presence even in
these simplified hemidesmosome proves that it is essential for the adhesion of epithelial cells to the basement
membrane below (de Pereda et al, 2009). Additionally,
mice missing β4 exhibited pathology similar to junctional
epidermolysis bullosa, a human disease characterized by
fragile skin that blisters quickly due to the basal layer’s
separation from the basement membrane. The epithelial tissues of the mice, both simple and stratified, lacked
hemidesmosomes and did not adhere normally (Dowling
et al, 1996).
The α6 subunit is homologous to other integrin α subunits. α6, like many other integrin protomers, associates
with more than one β subunit. For instance, α6β1 is an
integrin found in the retina and cortex, and is linked to
disorders of those tissues (Hynes, 2002).When it is found
in epithelial cells, however, it is exclusively associated with
β4 and binds to laminin as its ligand. α6 is made up of
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1,055 amino acids, with the first 1,011 outside the cell,
36 in the transmembrane region, and 19 in the cytoplasm.
(Tamura et al, 1990). The amino domain has 7 homologous repeats, which were found to make up a 7-bladed
β propeller (Kamata et al, 2001). It is made up of two
polypeptides, a heavy chain and a light chain, which originated from one polypeptide but which were cleaved using
post-translational modification. They are joined by a disulfide bridge, similar to α5, αv, α11b, and αP52. However,
it does not contain the insert domain near the amino terminus that other α subunits possess (Tamura et al, 1990).
β4 has 710 amino acids in its extracellular region, with
cysteine conservation of that region the same as that of
other β subunits. It has a 23 amino acids in its transmembrane region and has 1089 amino acids in its cytoplasmic
region (Tamura et al, 1990). The cytoplasmic domain is
made up of 5 globular domains. From the membrane toward the inside of the cell, they are: a Na+- Ca+ Calx-β
exchange motif, a pair of fibronectin type III domains
(FnIII-1,2), and another pair of fibronectin domains (FnIII3,4). Between the two pairs of FnIII domains, there is a
flexible connecting segment (CS), and after the second
set, there is a c-terminal tail (Walko et al, 2015). There
are 5 possible N-glycosylation sites, all of which are glycosylated (Tamura et al, 1990).
Over time, a clearer picture of α6β4 has been formed.
Scanning electron microscopy revealed that both subunits have a large globular head and a stalk portion which
then traverses the cell membrane. The two protomers
complex by binding their heads together (Luo, 2007). α6’s
amino domain contains a 7-bladed β propeller domain,
which is made up of 7 four-strand β sheets similar to
those found in other integrins, which is topped by a ligand
binding site. However, it lacks the “insert” domain, otherwise known as a Von Willebrand Factor A domain, which
has a MIDAS (a cation coordination site), that is found
imbedded in the propeller of the majority of integrins
(Kamata et al, 2001).This makes sense because only integrins that are exclusive to chordates have this domain, and
α6β4 is homologous to that of more primitive species.
When an integrin has this insert domain, cation coordination to the MIDAS site causes a conformational change in
the protein, pulling part of the α6 head further down and
allowing the ligand to bind to its binding site.
Ligand binding occurs differently in integrins lacking this
insert domain like α6β4. In this integrin, β4 has its own
insert domain with a MIDAS motif, which, when inactive,
is in contact with α6’s propeller. When the C-terminus
of β4 moves downward, or when a cation binds to the
MIDAS, it pulls the rest of the protein, exposing more of
the propeller surface to allow for a greater affinity for
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ligand binding (Hynes, 2002). When priming and ligand
binding occur, a large-scale conformational change overcomes both subunits. In their resting, low-affinity phase,
both subunits’ stalks are bent downward in the middle
in a genuflected position, with their intracellular domains
touching. When ligand binds, the subunits straighten in a
switchblade-like motion and the legs separate, exposing
binding surfaces.This is one instance of allosteric signaling
in integrins (Luo, 2007).
The majority of connections in the hemidesmosome
occur with the large intracellular domain of β4. The four
FnIII domains have a conserved hydrophobic core, with
9 out of 11 identical residues, but their outer surfaces,
which are exposed to solvent, are entirely different, so
they can bind to different groups (Alonso-Garcia et al,
2015). The critical interaction within the hemidesmosome is between β4 and plectin. Plectin binds to the IFs
in the cell, while α6’s interaction with β4 allows it bind
to its ligand, laminin. The two proteins join at β4’s second
Fn-III domain and at plectin’s actin-binding domain (ABD).
This complex is formed by three sets of ionic interactions: between R1225 of β4 and D151 of plectin, between
R1281 of β4 and E95 of plectin, and between E1242 of
β4 and R98 of plectin. Missense mutations in one of the
residues involved in these salt bridges disturbs the interaction with plectin. The first 7 residues of the connecting
segment also play a part in this interaction by extending
the binding surface of the Fn-III domain. The first FnIII
domain also contributes to the interaction through a hydrophobic pocket made up of I1163, Y1187 and C1190,
which interacts with an R-side chain in plectin. When β4
binds to plectin, a conformational change is triggered in
β4; in unbound β4, part of the CS is folded over FnIII-2
and engages in antiparallel H-bonding with it. In bound β4,
that part of the CS is unbent and may reveal binding sites
for other proteins in the hemidesmosome, like BP230
and BP180 (de Pereda et al, 2009).
Integrin α6β4 in Wounded Cells
Although integrin α6β4 is associated with cell adhesion,
it is also involved in signaling pathways associated with
cell migration, differentiation, and proliferation. These
processes assist in healing wounds. This is indicated by
its localization to the front edge of cells migrating into a
wound. Additional proof can be seen in an experiment
involving A549 (adenocarcinomic human alveolar basal
epithelial) cells. When the β4 gene was knocked down,
the cells migrated less processively than the controls.
When the α6 gene was knocked down, the cells migrated
both less processively and more slowly. Examination of
keratinocytes has revealed that wild-type keratinocytes
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move on a straight line along their matrix of laminin, while
β4-deficient keratinocytes move in a circular fashion. All
of this shows that integrin α6β4 plays an essential role in
healing wounds (Colburn, Jones, 2017).
In order for cells to migrate toward a wound bed, the
hemidesmosomes need to disassemble, a process that
begins from the cytoplasmic domain and then continues in the extracellular domain. β4 serine residues are
first phosphorylated by tyrosine kinases to separate β4
from its binding partner, plectin; this is stimulated by
epidermal growth factor (EGF) (Mainero et al, 1996), as
well as protein kinase C (Rabinovitz, et. al. 1999). After
β4’s phosphorylation, the rest of the connections in the
hemidesmosome are then severed (Walko et al, 2015). At
this point, α6β4 detaches from the intermediate filament
(keratin) cytoskeleton and instead associates with the
actin cytoskeleton. It becomes involved in the formation
of lamellae and filopodia, which are protrusions of the cell
membrane that give the cell motility.
Epithelial cells involved in wound healing are similar to
metastasizing carcinoma cells, allowing comparisons to be
drawn between them. In both cases, there is a lack of
polarization in the cells and an induction of migration.
(Rabinovitz et al, 2015). Importantly, many of the same
mechanisms are involved, including the coordination with
growth factors, the disassociation from the hemidesmosome, and the formation of lamellae and filopodia.
Integrin α6β4 in Carcinoma
In many types of carcinomas, high levels of integrin α6β4
correlate with the invasiveness of the cancer, as well as
the patient prognosis. For example, in basal-type breast
cancer, which is a highly aggressive form of breast cancer, a β4 “gene signature” was associated with decreased
time to tumor recurrance and a smaller chance of patient survival (Lu, 2008). Other research shows similar
correlation with elevated β4 expression in other invasive
phenotypes of squamous cell carcinomas, including some
kinds of bladder (Grossman et al, 2000), cervical (Jeffers
et al, 1997), head and neck (Kurokawa et al, 2008), lung
(Stewart et al, 2016), and pancreatic (Cruz-Montseratte
et al, 2007) carcinomas. Interestingly, although thyroid
cells do not normally express α6β4, it has been found
in thyroid carcinomas (Kitajiri et al, 2002). In addition to
overexpression of α6β4, it is also located throughout
multiple layers of cells in tumors, as opposed to its normal concentration of the basal side of the epithelial cells
(van Waes et al, 1995).
However, in some varieties of cancer, integrin α6β4
expression is correlated with tumor suppression. For
example, in prostate carcinomas, α6β4 is downregulated

(Nagle et al, 1995). Also, when α6β4 was added to cells
from the RKO cell line, a colon carcinoma cell line which
is missing β4, the result was partial G1 arrest and apoptosis (Clarke et al, 1995). Because this integrin is associated
with both growth and migration, but with suppression as
well, it may be hard to target as a treatment for cancer. In
order to examine treatment options, an in-depth look at
the mechanism of action of integrin-implicated signalling
pathways must take place.
Integrin α6β4 Signalling Mechanism
When integrin α6β4 is released from hemidesmosomes,
it leads to altered signals promoting tumor cell growth,
invasion and metastasis (Lipscomb, Mercurio, 2005). Once
free from the hemidesmosome interaction, integrin α6β4
can bind or cooperate with many different molecules or
growth factor receptors to activate various cell signalling pathways. Integrin α6β4 can bind directly to its regular ligand, laminin, activating both phosphatidylinositol
3-kinases (PI3K) and RhoA small GTPases. Alternatively,
it can cooperate with various growth factor receptors,
including those in the EGFR (epidermal growth factor
receptor) family, such as ErbB-1,2, and 3 (Guo et al,
2006), as well as c-Met (Chung et al, 2004), Ron, LPA1
and LPA2 (O’Connor et al, 2012). This leads to intensification of signaling through PI3K, AKT, MAPK and the Rho
small GTPases, as depicted in Figure 1. Integrin α6β4 can
also promote tumor progression through transcriptional
regulation. It has been shown to increase the expression
of invasive and metastatic proteins such as the epithelial to mesenchymal transition (EMT)-associated protein
S100A4 (Stewart, O’Connor, 2015).

Figure 1 (Stewart, O’Connor, 2015)
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Integrin α6β4 is involved in the PI3K pathway, a signaling pathway known for promoting carcinoma progression
(Shaw et al, 1997). However, the cytoplasmic domain of
the integrin β4 subunit does not have a consensus-binding motif for the regulatory subunit of PI3K , so direct activation of the pathway does not seem possible. One possible mechanism for integrin β4-mediated activation of
PI3K involves insulin receptor substrate-1 and −2 (IRS-1
and IRS-2), which act as signaling intermediates facilitating
integrin α6β4-mediated PI3K activation. Ligation of integrin α6β4 promotes phosphorylation of IRS-1 and IRS-2,
and then activation of PI3K (Shaw, 2001). Additionally, integrin α6β4 cooperates with ErbB-2 to promote PI3Kdependent invasion (Gambaletta et al, 2000). Integrin
α6β4 has also been shown to localize to lipid rafts in the
membrane, allowing it to recruit other receptor tyrosine
kinases, and thus allowing it to activate PI3K (GagnouxPalacios et al, 2003).
ErbB-2 is one of the members of the EFGR family which
signals for invasion and aggression in breast carcinoma.
Integrin α6β4 has been shown to associate with ErbB-2 in
multiple breast carcinoma cell lines (Falcioni et al, 1997).
Although ErbB-2 is implicated upstream of PI3K, ErbB-2
does not have a binding site for the regulatory subunit of
PI3K. ErbB-2, as a receptor tyrosine kinase, must dimerize
with another receptor to function. In this case, it dimerizes with an ErbB-3, a different EGFR receptor. Erb-B3 has
a binding site for PI3K’s regulatory subunit, and this heterodimer is a strong activator of PI3K. There is a positive
association between integrin α6β4 and ErbB-3 expression in patient-derived tumors (Folgiero et al, 2008).
Other receptor tyrosine kinases that cooperate with
integrin α6β4 include c-Met, which is activated by HGF
(hepatocyte growth factor); a complex of α6β4 and
c-Met was shown to promote HGF dependent invasion
(Trusolino et al, 2001). Ron, a tyrosine kinase receptor
closely related to c-Met, has been shown to form a complex with integrin α6β4 that induces hemidesmosome
disassembly and the relocation of integrin α6β4 to motility structures. Ron activation is important in pancreatic
carcinoma progression, and it interacts with the integrin
β4 subunit in this setting to disrupt the association between integrin β4 and plectin (Yu et al, 2012).
Integrin α6β4 also upregulates the Rho family of small
GTPases. The Rho family of small GTPases control the
reorganization of the actin cytoskeleton required for cell
motility (Machacek, et. al. 2009). The activation of RhoA
leads to lamellae formation, as well as the generation of
contraction forces that enable cell migration (O’Connor
et al, 2000). Significantly, RhoA generally controls the generation of stress fibers rather than lamellae formation,
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suggesting that integrin α6β4 changes RhoA’s function to
facilitate tumor invasion (Stewart, O’Connor, 2015).
Integrin α6β4 can also stimulate angiogenesis by enhancing signaling through the protein kinase ERK and
transcription factor NF-κB. Studies using knockout mice
carrying a deletion in the signaling domain of the integrin β4 subunit displayed reduced angiogenesis in a retinal
neovascularization model, and developed smaller and less
vascularized tumors after subcutaneous implantation.The
same study demonstrated that the integrin β4 subunit
could promote both bFGF (basic fibroblast growth factor)- and VEGF (vascular endothelial growth factor)-induced angiogenesis by enhancing signaling through ERK
and NF-κB (Nikolopoulos et al, 2004).
Cell Survival and Tumor Suppression
Returning to the paradox above, integrin α6β4 promotes
either cell survival or apoptosis, depending on context.
For instance, in normal epithelial cells, integrins promote
survival when in contact with the extracellular matrix.
However, once separated, the loss of integrin signaling can
inhibit cell growth and promote anoikis, a form of apoptosis (Ruoslahti, Reed, 1994). Similarly, in cancer, at times
integrin α6β4 acts as a promoter of cell survival, while at
times it acts as a tumor suppressant.
To discover why these two different scenarios exist,
a group studied two cell lines. In the RKO cell line, β4
led to increased apoptosis, while in the MDA-MB-435
cell line, β4 did not induce apoptosis. They discovered
that the difference lay in the cells’ p53, a protein which is
often implicated in cancer when mutated. RKO cells have
wild-type p53, while MDA-MB-435 cells have mutant p53
(Bachelder et al, 1999). Integrin α6β4 can trigger apoptosis through p53 activation in cells harboring wild-type
p53; however, in carcinoma cells deficient in p53, integrin
α6β4 promotes cell survival by activating the PI3K pathway and through growth factors such as VEGF (vascular
endothelial growth factor). This discovery suggests that
tumors expressing high levels of integrin α6β4 in conjunction with mutated p53 are resistant to apoptosis and
will therefore display a more aggressive clinical course.
Interestingly, an association between p53 mutations and
integrin α6β4 overexpression is present in a number of
aggressive human malignancies, including basal-like breast
cancer, head and neck squamous cell carcinoma, and
pancreatic ductal adenocarcinoma (Stewart, O’Connor,
2015).
Treating Carcinomas Through Integrin
Modification
Since integrins were discovered as molecules involved in
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cancer, there has been a move to target them in cancer
treatment. However, drugs developed to impact integrins
have largely been unsuccessful. It’s possible that it is because the integrin-targeting drugs may only have moderate affinity in vivo for integrin receptors, as shown by the
doses used in clinical trials. Another reason may be that
integrin antagonists work best when inhibiting early metastatic spread and not in advanced cancer stages, when
cancer cells are already widespread (Paolillo, Schinelli,
2017)
Another issue may be that the wrong integrins have
been targeted. Not all integrins have been thoroughly
explored as therapeutic targets, including integrin α6β4.
That said, a common issue for all the integrins is that
cells express multiple integrins at the same time, and if
one would be targeted in treatment, the others might
compensate for it.That explains why the drugs given were
well tolerated with few ill effects, but also did not impact the cancer. The solution would be to try and impact
multiple integrins at once, but that might be difficult to
achieve in a patient (Alday-Parejo et al, 2019).
The issue may also not be the stage or affinity, but the
drug target itself. Most drugs designed for integrins target
the integrin-ligand interaction; in this case, they would
try to competitively inhibit the interaction between the
integrin’s extracellular side and laminin 332.This could be
a problem because integrins signal allosterically, so if an
inhibitor would bind to the integrin’s ligand binding pocket, it could actually turn on the integrin and the signalling
cascades could begin. The cytoplasmic domain may be a
better option (Alday-Parejo et al, 2019).
Thus far, one group has worked on an inhibitor targeting the cytoplasmic side of integrin α6β4. They found
that curcumin, a yellow pigment derived from turmeric,
inhibited the interaction between the cytoplasmic tail and
EGFR, which is implicated in the PI3K pathway related
to survival, invasion, and metastasis. EGFR is activated
when the residues Y1068 and Y1045 are phosphorylated;
when α6β4 was knocked out, there was significantly less
phosphorylation, showing a connection between the two
structures.They added curcumin to other cells and found
that it had a similar effect on EGFR phosphorylation as
knocking down α6β4. The hemidesmosomes in cells with
curcumin remained stable upon stimulation with EGF
(Soung, Chung, 2011).
Discussion/Conclusion
Integrin α6β4 plays an essential part in both regular and
cancerous cells. Significantly, it contributes to the PI3K
pathway, related to cancer aggression and survival. Integrin
α6β4 should definitely be studied, both as a diagnostic

tool and as a target for therapeutic intervention. As discussed above, it is a predictor of the cancer’s severity and
can be used in a diagnostic setting. More research should
be put into targeting its intracellular interaction with
growth factors so that these pathways can be inhibited.
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Abstract
Those who suffer from infertility, either due to a congenital or acquired cause and cannot or are opposed to other means, such as surrogacy or adoption, to have a child, are potential candidates for uterine transplantation. Uterine transplantation is a form of allograft
transplantation, meaning that it is a transplant of tissue from a donor who is genetically different from the recipient. Additionally, it
is a vascularized transplant, including donor blood vessels that will be sutured to the vasculature of the recipient (Testa et al. 2017).
This procedure has been attempted around the globe with varying levels of success ranging from delivery of a healthy child to
necrosis of the graft and rejection of the transplanted tissue. While there does not seem to be one specific reason that can account
for the rejection of a uterus transplant, the main factor responsible for failure is problems with arterial inflow or venous outflow in
the recipient. Other potential factors that may contribute include cervix-vaginal size differences between donor uterus and recipient,
pathology of the donated uterus, immunosuppressants, and wait time from transplant to embryo transfer. Advancements in robotic
assisted hysterectomy to procure the donor uterus, using ovarian veins instead of uterine veins for venous outflow, and deceased
donor uteri instead of living donor uteri are all promising ways that can streamline the transplant process and help transition the
experimental procedure of uterine transplantation to an accepted clinical one.
Introduction
Uterine transplantation is a procedure where a uterus
from either a live or deceased donor is surgically implanted temporarily in a recipient, in order that the recipient can carry her own child in the transplanted uterus.
The transplanted uterus is subsequently removed, either
when a baby is born, if the pregnancy is terminated due
to complications, or due to rejection of the transplant.
Uterine Transplantation is an innovative treatment for
those who are unable to carry a fetus in their own respective uteri, either due to a congenital disorder, such
as the absence of or an underdeveloped uterus, hysterectomy, due to disease, cancer, endometriosis, elective
hysterectomy, or for transgender individuals who do not
have a uterus (Testa et al., 2017). Since uterine transplantation is not considered a life-saving procedure, many are
ethically opposed to the promotion and investment into
such an experimental and costly surgery.
In this paper we will try to determine if the uterus
can be transplanted successfully with childbearing results,
and which factors are responsible for the rejection of a
uterus transplant.
Materials and Methods
The Information contained in this review was found by
searching the Touro online library general search, Ebsco,
and Proquest databases using key terms such as “uterine
transplantation.” Pubmed and Google Scholar were also
searched utilizing similar key words and phrases.
Candidates for Uterine Transplantation
People who express interest in uterus transplants generally suffer from what is known as uterine factor infertility,
UFI (Arian et al., 2017), also known as absolute uterine
factor infertility, AUI (Branstrom et al., 2020), This can be
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due to a congenital cause, such as a condition known as
Mayer-Rokitansky-Kuster-Hauser syndrome (MRKH), or
Mullerian agenesis, which is caused by the “underdevelopment of the Mullerian duct, with resultant agenesis or
atresia of the vagina, uterus, or both” (Oelschlager, 2018).
Agenesis refers to the failure during embryological development of an organ and atresia is where there is either
an obstruction to the lumen, or an opening is abnormally
narrowed. Since the Mullerian duct in utero is responsible
for the development of the uterus, fallopian tubes, cervix,
and the upper part of the vagina, when it fails to develop in MRKH, all those structures, aside from the ovaries,
are affected, and this often results in infertility. Patients
with MRKH are good candidates for uterine transplantation because they have functioning ovaries, which are
not included in the uterus transplant. Their oocytes can
be extracted for in vitro fertilization, and they can have
a biological child of their own genetics. Another class of
those who are interested in uterine transplants include
those who have absolute uterine factor infertility due to
an acquired cause which resulted in hysterectomy, such
as fibroid tumors, endometriosis, chronic pain, abnormal
bleeding, malignancy, and obstetric complications. In one
study, out of the 239 people screened, one third sought
treatment due to congenital UFI, while the other two
thirds had acquired UFI. Of the acquired group, half were
due to benign conditions, 25.3% were due to gynecologic
malignancies, and 24.7% had had prior obstetric complications that resulted in hysterectomy. Although there
were five transgender and one intersex individual, they
were not included because they did not fit the inclusion
criteria of the screening (Arian et al., 2017). In another 2017 study, candidates similarly included those with
MRKH, acquired conditions such as irreversible intrauterine adhesions, fibromas that could not be operated
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on, and those who had lost their uterus from either benign or malignant pathologies or postpartum complications (Testa et al., 2017).
Donor Eligibility
Different studies had varied qualifications included in their
inclusion criteria. Firstly, age was a consideration. In one
study, age was determined to be from 40-60, though those
under the age of forty were considered if a candidate had
successful pregnancies in the past and did not want to have
another pregnancy in the future (Testa et al., 2017). Similarly,
in other studies, with successful live-birth outcomes, a 32
year old uterus was used, having borne 2 children prior to
transplantation (Testa et al., 2018), and a 24 year old nulligravid uterus was also used in successful transplantation
(Chmel et al., 2019). However, in the first successful transplant in 2014 that resulted in childbirth, a 62 year old uterus
was used, and another a successful live birth resulted from
a 63 year-old uterus at the time of birth, indicating that although older uteri are not necessarily considered ideal, they
have yielded live births. (Brannstrom et al., 2020). Since
often enough recipient’s mothers want to be donors for
their daughters, in some studies an older upper limit is given
at 55-65 years of age (Kisu et al., 2018).
Additional donor requirements in some studies included criteria such as testing negative for gonorrhea, chlamydia, syphilis and HPV, or previous vaccination against
HPV. Previous history of HSV-2 was considered if there
were no current symptoms, and previous HPV was considered as long as a negative history was shown since
the case of HPV. Last, one prior full-term live birth was a
qualification (Testa et al., 2017).
Other requirements included normal-shaped uteri,
proper perfusion through uterine vasculature, and the absence of uterine damage or disease (Chmel et al., 2019).
Nulliparous, Nulligravid, or Multiparous Donor Uterus
In choosing between a nulligravid uterus, one that has
never carried a fetus, a nulliparous uterus, a uterus that has
never born offspring, and a multiparous uterus, one that
has born offspring, different studies included multiparity in
the inclusion criteria while others did not. According to a
2019 study using a nulliparous deceased donor, nulliparity
was considered an advantage in terms of graft recovery because the uterine veins and arteries were straight and not
varicose, as opposed to what they noted with multiparous
donors (Chmel et al., 2019). However, that was an observation made using few subjects, and would need to be
further investigated to determine if a significant difference
between the straightness of vasculature exists between
nulliparous and multiparous uteri.

Live vs. Deceased Donor
Before investigating the differences between a living as
opposed to a deceased donor, it is important to define
who is considered “deceased.” In this paper, deceased is
used to mean brain-dead.
There are certain advantages to using a deceased
donor over a live donor. Firstly, using a live donor to
procure a graft includes certain risks associated with any
surgical procedure, such as the use of anesthesia, and surgery, and specifically possible urological, psychological or
sexual dysfunction that may result, which are not considerations that need to be taken with a deceased donor.
Secondly more radical surgical dissection can be done
using a deceased donor than a live donor, which enables
surgeons to procure larger vessels, decreasing the risk
of graft thrombosis. Additionally, a longer vaginal cuff can
be procured from a deceased donor, allowing a better
vaginal–vaginal anastomosis between the donated uterus
and the recipient’s vagina (Chmel et al., 2019).
A clear disadvantage of using a deceased donor is the
practicality; the nature by which deceased donor uteri
become available is unpredictable. Also, multidisciplinary
teams and the recipient must go to the location of the
donor. Moreover, in many countries, physicians have less
access to deceased vascularized composite allografts, and
there is more restricted access to deceased donor uteri
due to the complicated nature of surrogate consent if the
deceased has not expressly stated the desire to donate
before death (Chmel et al., 2019).
However, new innovations in procurement of the donor
uterus, such as using robotically-assisted minimally invasive
procedures, can likely decrease risks to live donors by minimizing tissue trauma and bleeding compared to open surgery, which would favor using live donor uteri (Brannstrom
et al., 2020). In one minimally invasive, robotic surgery, the
estimated blood loss of the donor was 400 mL, compared
to the researchers previous surgeries using laparotomy in
nine cases, which ranged from estimated blood loss values between 300-2400 mL, with an average of 920 mL
(Brannstrom et al., 2020). Using robotic technology can
also provide more dexterity and seven degrees of freedom for the surgeon, not to mention micro-suturing can
be done more efficiently through laparoscopic ports (Wei
et al., 2017). Also, minimally invasive robotic procedures
can minimize both surgery and recovery time for the
donor (Carbonnel et al., 2020). Surgery time in one robotic assisted surgery took 6 hours, which is the shortest
surgery duration time recorded for uterus procurement
for transplant. That may be partially due to the choice of
vasculature that the researchers procured with the graft,
but nonetheless they were able to drastically reduce
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surgical time (Wei et al., 2017). In addition to a reduction
in bleeding and trauma, minimally invasive surgery yields
better cosmetic results, which may influence a candidate’s
readiness to donate (Carbonnel et al., 2020).
Steps involved in Uterine Transplantation
The process of uterine transplantation can be summarized briefly, according to Testa, et al., as follows. First,
the successful transplantation of the graft, including perfusion, or blood flow through the grafted vasculature,
and the assessment of vital tissue present on the cervix
in cervical biopsy to determine if the tissue is accepted
by the recipient. Next, a normal menstrual cycle should
result, which means that the grafted uterus is responding
to the recipient’s hormones. Stable immunosuppression,
suppression of the recipient’s immune system toward the
foreign uterus should be maintained. Once immunosuppression is achieved, a fertilized ovum is implanted. After
implantation that results in pregnancy, the last step is the
successful delivery of a hopefully healthy child. At any of
these steps, complications can occur that would result in
the failure of the uterine transplant (Testa et al., 2017).
Removing the donor uterus can be done through either
laparotomy or laparoscopy. In a 2017 clinical trial on five
individuals, the laparotomic removal of the donor uterus
is detailed. The hysterectomy performed on the donor,
however, is more complicated than a regular hysterectomy, due to the vasculature that needs to be connected
to the recipient to allow graft inflow and outflow in the
recipient. To allow that, the vascular pedicles, tissues containing the arteries and veins of the donor uterus, were
dissected completely. The arterial vascular pedicle of the
graft included the uterine artery, which supplies blood
flow to the uterus, and a part of the internal iliac artery.
The graft uterus was drained by the uterine and utero-ovarian veins, located between the uterus and ovary.
A transverse cut was made below the cervix, in order to
obtain a cuff that could sufficiently be anastomosed to the
upper vagina of the recipient.After removal, arteries were
reconstructed, when needed, through microvascular surgery (Testa et al., 2017).
As for the recipient, the external iliac artery and the
external iliac vein were dissected and the internal iliac artery patch of the donor was grafted to the external iliac
artery of the recipient. For venous outflow, the uterine or
utero-ovarian vein, depending on which provided better
venous outflow, was sutured to the external iliac vein of
the recipient. Once blood flow was reperfused, the cervix
of the new uterus was connected to the vaginal vault of the
recipient. Blood flow was subsequently monitored by a
doppler blood flow monitor to assess arterial inflow to the
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transplanted uterus. Postoperatively, for the first five days
Doppler ultrasounds were performed, cervical biopsy was
done on the fifth day, MRI of the uterus was performed to
evaluate blood flow, and cervical examination under anesthesia was done to determine if rejection of the transplant
tissue occurred. To suppress the immune response of the
host to the allograft, immunosuppressive drugs such as thymoglobulin, tacrolimus, mycophenolic acid, and a steroid
taper were administered (Testa et al., 2017).
Vasculature Involved
The common iliac artery bifurcates into the internal and
external iliac arteries. A branch of the internal iliac artery
is the uterine artery, which supplies blood flow to the
uterus. Blood flow from the uterus is via the uterine
veins, internal iliac veins, inferior vena cava, and to the
heart. Figure 1 shows a diagram of the vasculature where
blood vessels attached to the allograft are connected
slightly differently in the recipient than expected. At point
A, the uterine artery, with a branch of the internal iliac
from the donor is anastomosed to the external iliac artery, instead of the recipient’s own internal iliac artery. At
point B, the uterine vein of the donor uterus is attached
to the external iliac vein of the recipient, instead of the
internal iliac vein.
One of the most difficult parts of uterus transplantation is securing a good venous outflow. In most cases,
the uterine veins are used, which often have thin walls,
can vary in number, and often are not shown sufficiently
in preoperative imaging. During surgery, their dissection
can be tedious, can increase the risk of bleeding, and increases surgery time (Testa et al., 2018). Moreover, the
uterine vein has multiple branches and is close to the

Figure 1.This schematic diagram portrays the blood vessels
supplying and draining the allograft uterus. Point A is the
anastomosis of the uterine artery to the external iliac artery. Point
B is the anastomosis of the donor uterine vein to the external iliac
vein (Testa et al., 2017).
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ureter, which could result in accidental bleeding or injury to the ureter (Carbonnel et al., 2020). In one 2018
successful trial, researchers sustained an allograft through
the utero-ovarian veins alone, without uterine veins. The
researchers recommended using the utero-ovarian veins
instead of the uterine veins, which are easier to identify,
dissect, and provide for safer surgery on the part of the
donor. In another clinical trial, the proximal portions of
the utero-ovarian veins were dissected as potential extra
venous outflow, and ended up being used along with the
uterine veins as well, due to the thinness of the uterine
veins of the donor (Brannstrom et al., 2020). Further, by
using the utero-ovarian veins instead of uterine veins, a
robotic laparoscopic approach is more feasible, which will
again increase the safety and ease for the donor (Testa et
al., 2018). Also, the ovarian veins are more distant from
the ureter, so surgeons will not be concerned about inadvertent damage to them (Carbonnel et al., 2020). There
can, though, be negative repercussions for the donor associated with using the ovarian veins as venous outflow.
In transplant procedures done in both India and China,
removal of the ovarian veins required bilateral oophorectomy, removal of the ovaries. The donor women were
premenopausal, which increases their risk of morbidity
and mortality (Brannstrom et al., 2020). However, using
ovarian veins for venous outflow still need to be further
researched in the future to determine whether uterus
outflow can in all cases be sufficiently maintained using
the ovarian veins alone (Carbonnel et al., 2020).
Wait Time Between Transplant and Surgery
Common convention for many of the different uterus transplant trials has been to wait one year between
transplantation and attempt at pregnancy, similar to
other solid organ transplants. In a 2019 study, for example, embryo transfers were done starting at least 12
months post-transplant, and were done in months 13,
16, 19, and 23, until the last transfer resulted in clinical
pregnancy (Chmel et al., 2019). This convention arose
out of a recommendation from the American Society of
Transplantation which suggested that recipients of organ
transplants wait one year between the transplant and
conception to decrease any risks that may result, such as
acute rejection to the recipient, infection that could harm
the fetus, immunotherapy that could potentially be toxic
to the fetus, and to be sure that the allograft is functioning
properly (Johanesson et al., 2019).
However, women who receive uterus transplants
are generally healthy individuals whose surgical recovery should resemble that of any surgical intervention.
There is no reason to believe that tissue healing would

be impaired, and immunosuppression does not seem to
hinder tissue healing (Testa et al., 2018). Further, a uterine
transplant, unlike other organ transplants, is not meant to
be a long-term functioning transplant. Its longevity is for
about five years and for a maximum of two pregnancies
(Johanesson et al., 2019). Some suggest that there is no
scientific basis for waiting a year between transplant and
embryo transfer, especially because immunosuppression
must be terminated as soon as possible, to avoid renal
failure, which could be a risk of long-term immunosuppression. Decreased time on immunosuppressants also
reduces costs and decreases waiting time for the recipient to give birth to her baby. In their clinical trial, embryo
transfer was done before the six month post surgery
mark, and yielded successful results (Testa et al., 2018).
To provide a groundwork for the amount of time to be
waited, researchers laid down conditions to be met in the
recipient, which if achieved, should be a signal to begin
embryo transfer, as opposed to giving a generalized time
recommendation for all uterine transplant procedures.
The patient criteria are given in order as follows. First,
graft function should be stable. An indication of graft stability would be menstruation, as it is a sign that the foreign
uterus is responding to the recipient’s hormones. Next,
the absence of any acute rejection, which is determined
via cervical biopsy. Finally, stable immunosuppression
achieved with low teratogenic, or carcinogenic, risk, and
the recipient is at low risk for opportunistic infection,
which is generally associated with those who undergo
transplantation. Once these conditions are met, embryo
transfer should begin as soon as possible, even as early
as three months post-transplant if the recipient is ready
(Johanesson et al., 2019).
Complications in Pregnancy and Post-Operatively
Generally, pregnancies resulting from uterine transplantation do not reach full-term. However, many studies have
been successful in which participants have carried close
to term. In the first successful clinical study in Sweden,
mean delivery for the six patients was at 35 weeks gestation. Besides the difficulty in reaching full term, there
are some other pregnancy complications that have arisen. Some patients from the previously mentioned study
experienced preeclampsia. It is possible though, that the
preeclampsia, preterm delivery, and delivery by cesarean
section may be related to the original infertility; MRKH
sometimes presents with renal defects, such as having
a solitary kidney, which could cause extra stress to the
recipient during pregnancy, and has been generally associated with higher risk for preterm delivery, preeclampsia,
and cesarean section (Kisu et al., 2018).
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Other major complications that have arisen post-operatively in recipients include urinary tract infections, thrombosis, and hematoma. The risk of thrombosis is because
the vessels that are anastomosed are generally narrower
and can get obstructed more easily than vessels attached in
other organ transplants. Hematoma could be the result of
inadequate hemostatic processing, or cessation of bleeding. Care must be taken with re-bleeding from capillaries
that are unligated or bleeding from the vaginal cuff (Kisu
et al., 2018). Also, in one particular clinical study, vaginal
stenosis, vesicovaginal fistula, herpes, and cytomegalovirus
were complications experienced by some of the recipients.
Vesicovaginal fistulae can occur more frequently in patients
with MRKH who have a neovagina, which is constructed
due to an underdeveloped or absent vagina, and which
needs to be separated from the bladder during surgery.
This could lead to a fistula, or an opening between the
bladder and vagina (Kisu et al., 2018).
Immunosuppressants During Pregnancy
Since the transplanted uterus is from a foreign donor,
the recipient needs to be on immunosuppressive drugs
to prevent her own immune system from mounting a
response against the uterus. There have been different
recommendations as to the type of drug, based on trials
from both pregnant women on immunosuppressants due
to uterus transplants and other organ transplants. The
importance here is that the immunosuppressive drug
should not be toxic to the developing fetus. Therefore
care must be taken to either prescribe immunosuppressants that are not fetotoxic, or at least halt fetotoxic
immunosuppressants when the uterus recipient begins
embryo transfer. One immunosuppressive drug that has
been implicated in spontaneous abortion in the first
trimester and congenital abnormalities of the fetus is
mycophenolate salts, which come in two different prodrugs, mycophenolate mofetil and mycophenolate sodium,
that release the compound mycophenolic acid. The FDA
classifies this drug as a Category D drug, meaning that
there is evidence that it can cause risk to the fetus during
pregnancy (Ponticelli et al., 2018). Therefore, if it is used
following the transplant, there must be a waiting period
afterward before embryo transplant begins. In one uterine transplant trial, mycophenolate mofetil was taken out
entirely from the maintenance immunosuppression to
decrease the time exposed to toxic medications for the
fetus. They were thus able to expedite the waiting time
before embryo transfer. Another drug, thymoglobulin,
is considered a category C drug, meaning it is currently unknown if risk exists to the fetus. Therefore, there
should also be a wait time between pregnancy and usage
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of thymoglobulin in immunosuppressive therapy. Other
common immunosuppressants such as corticosteroids,
azathioprine, and calcineurin inhibitors appear to be safe
in doses prescribed for transplant recipients and are
not associated with increased risk of congenital defects
(Johanesson et al., 2019).
Reasons for Rejection of Transplanted Uterus
Although in some cases there is not a clear reason why
the graft failed and rejection occurred, different studies
have hypothesized reasons for the difference in outcome.
A conclusion was that uterus pathology and venous outflow were largely responsible for three graft failures that
occurred. The authors explained that assessment of vasculature preoperatively could be improved. Thus, imaging
could be used to eliminate uteri with vasculature that is
unsuitable for a uterus transplant. They explain that using
a CT angiogram, while helpful in showing arterial blood
flow, was not sufficient in their study to tell the length and
diameter of veins.This was significant because a large part
of the donor hysterectomy surgery time was spent in dissection of the uterine vein, which can taper into thinner
tributaries where it joins with the internal iliac vein, even
though it may appear satisfactory near the uterine body.
The researchers concluded that MRI with venous phase
would have been a better choice in imaging to view the
uterine veins (Testa et al., 2017). Similarly, the researchers explained that the arterial vasculature was not of the
expected quality; in some patients arterial pathology was
present. In the preoperative imaging, the vessels appeared
patent, however; in the three grafts that failed in their
study, there was severe arterial disease present. In one
donor specifically there was thickening that resulted in
over a fifty percent decrease in luminal size. Additionally,
the researchers noted that in the first two of the five
patients studied there was a downward kinking of the
vein if the anastomosis was to the superior aspect of the
host external iliac vein. In the other three patients they
switched the venotomy position of the external iliac vein
to the medial aspect to avoid kinking. Further, the researchers observed that procuring a patch of the internal
iliac with the uterine vein provided a vessel with thicker
and stronger walls.
Another potential reason that contributed to the failure
of one of the transplants was the variation in size between
the large cervix size of the donor and small size of the vaginal vault of the recipient, which made it difficult for vaginal anastomosis. The researchers believed that the limited
space, due to the larger cervix size contributed to the graft
congestion, poor venous outflow, and pathologies present
ultimately resulted in transplant rejection (Testa et al., 2017).

Uterine Transplantation Factors Accounting for Success or Failure

As far as immune-system induced rejection, ostensibly,
since the uterus carries a non-self, it would appear that
pregnant uterus should have some immune tolerance.
However, cervical biopsies have shown rejection in some
cases post-operatively. In one transplant study, 13 out of
163 cervical samples taken from seven patients showed
mild rejection after transplantation. Steroid therapy helped
patients reach remission, yet some developed rejection
complications again during pregnancy, which is more difficult to manage and measures need to be developed for
the future for treatment-resistant rejection. Some suggest
that the contact that the uterus has with the external environment, through the vagina, is responsible for the prospect of rejection of the allograft (Kisu et al., 2018).
Ethical Implications
The practice of uterine transplantation is a subject of
great ethical controversy. As a non-life-saving procedure,
it differs from other forms of organ transplantation, which
are considered essential. However, there are those who
categorize it similarly to face, hand, or other vascularized
transplants, which though not life-saving transplants, are
nonetheless justifiable organ transplants for improving
the quality of life of recipients. Additionally, although
uterine transplantation is considered an elective treatment, it stands as the only medical treatment for absolute uterine factor infertility. Surrogacy and adoption are
options for women with infertility, but for some women
they are not adequate substitutes for the experience of
pregnancy (Bayefsky and Berkman, 2016).
Once uterine transplantation transitions from an experimental procedure to a common clinical one, there
are multiple points that will need to be taken into consideration. There will likely be a shortage of uteri for
donation. While there are those who argue that uteri
from women who have had hysterectomies should be
used to supply organs for uterine transplants, often hysterectomies are done to remove unhealthy uteri, and
are done in a way that does not leave the organ fit for
transplantation, so those would not be feasible sources of
uteri. Uterine transplants must also come with sufficient
vasculature, which is generally not removed in an average
hysterectomy. Given that there will likely be a greater demand than the supply of uteri, there will need to be a way
to prioritize some individuals over others. As far as for
other organ transplants, such as heart, kidneys, or lungs,
pediatric or younger individuals are generally prioritized
over older adults, because adults have experienced childhood, and pediatric patients, if not given the transplant,
may never have that experience. In the same vein, it is
sensible to say that when prioritizing women for uterine

transplants, women who are of childbearing age should
be given precedence over both women who are older
and beyond reproductive age and adolescents who have
not yet reached childbearing age. However, in choosing
between younger and older individuals within the span of
child-bearing, women who are nearing the end of their
childearing years should be given priority over younger
individuals so that they can have their chance to have
children before they age out of their childbearing years,
while the younger individuals still have time. “Normal
childbearing age” is considered between the ages of
15-49 according to the World Health Organization, and
a standard for recipients should be within those limits. A
national standard, in limiting the age of recipients, should
reflect medical assessment of the surgical and obstetric
risks incurred to women of different ages, the risk to the
fetus, and the probability of successful pregnancy.
Further, there must also be some sort of child-rearing
capacity standard created that potential candidates will
demonstrate before allocating a uterus, similar to how
women who wish to adopt must meet certain criteria.
In differentiating between women with uterine infertility, different candidates have different needs with regard
to treatment. Some need only a transplant, while others
may need IVF, egg donation, or sperm donation. It is reasonable to suggest that those with the least interventions
necessary to achieve pregnancy should be given priority,
in the same vein as choosing candidates for transplantation who are more likely to have successful transplantation (Bayefsky and Berkman, 2016).
Putting aside the controversy associated with candidates for treatment, there is also dispute about the
source for donor uteri. Procuring a uterus from a live
donor can incur risk to the individual. While there are
innovations to the process of securing a uterus, through
laparoscopic robotic procedures, as opposed to open laparotomy, advancements will need to be made to decrease
the risks for the donor. Also, the advancement of using
cadaveric or nonliving donor uteri will be important in
fueling the future of uterine transplantation, though it will
be a source of contention as to whether a person who
has lost all brain function and is considered “brain dead,”
will be categorized as deceased along with those whose
circulatory and respiratory systems have failed.
Conclusion
Uterine Transplantation is a possible radical and innovative surgical option for those who suffer from absolute
uterine factor infertility. Many studies have been done
world-wide, which have contributed to the available data
on the risks and ways to improve the process. While
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there is no one factor that contributes to the rejection
or success of a uterine transplant, certain factors have
been implicated in the reasons for transplant failure or
success. Vasculature problems can account for some
reasons for rejection, such as sclerotic vessels, or using
thin-walled uterine veins that are difficult to dissect and
may not provide adequate venous outflow. Adequate imaging should be done to identify vessel pathology and the
acceptability of the donor vasculature. The possibility
of using the utero-ovarian veins might be a good alternative to the uterine veins, though it can cause the onset
of menopause and may increase morbidity in premenopausal women, due to oophorectomy. Also, mismatch in
vaginal-cervix size between the donor and recipient may
be problematic. Wait time between transplant and embryo transfer and immunosuppressants are other factors
to take into account. Advances in using deceased donor
uteri, which allows harvesting longer length of vessels, or
using live donor uteri procured through laparoscopic robotic assisted hysterectomy can streamline the process.
Although a promising treatment for those with absolute
infertility, more research needs to be conducted to ensure its safety and to standardize the procedure.
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Abstract
The term organoid refers to a miniature version of any organ of the body. An organoid is artificially produced in vitro from stem
cells or tissue that possess the ability to recapitulate and form the three-dimensional structure of the organ they were once a part
of. Scientists have learned to create a culture for the organoid that mimics its original micro cellular environment, allowing the
3-D structure to self-organize and develop into miniature organs.The purpose of this paper is to explore the many advancements
of organoid technology, and how this progress has benefited the medical field. Organoid technology allows for the observation of
human organ development and disease, while also providing scientists with the opportunity to test drug interactions with these
“mini-organs” (Barbuzano, 2017). Organoids also shed light on the future of artificial transplantation, providing replacements
for dysfunctional organs and tissue. The advancements of organoid technology can potentially revolutionize the field of medicine,
contributing to the progress of modern biology.
Introduction
The human body is composed of a variety of tissue-specific
adult stem cell populations.Adult stem cells of each organ in
the body possess the ability to self-renew and generate all
the different cell types present in that specific organ. Recent
studies allow scientists to apply this knowledge of stem
cells by culturing them in vitro. Through growing these cells
under the right conditions, the cells can assemble miniature
versions of the organs they were once a part of (Drost &
Clevers, 2017). Through the development of new 3-D technologies and these ideas, scientists were successful in producing artificial organs like the liver, placenta, stomach, lymph
nodes, and brain. (John D. Loike and Robert Pollack, 2019).
These miniaturized models that mimic real organs have
been termed ‘organoids’ (Huch, Knoblich, Lutolf, & MartinezArias, 2017). Cells of an organoid can be derived from tissue
stem cells, embryonic stem cells or induced pluripotent
stem cells (iPSCs).These cells possess the ability to regenerate, allowing the tissue to perform its original function (Prior,
Inacio , & Huch, 2019).
The ability to create and develop human tissue in a lab
offers a major breakthrough in modern biology. The advancement of organoid formation provides scientists with
the ability to study human development and disease and
test therapeutic medicine through a personal approach.
Organoids also offer hope for transplantation of functioning organs, eliminating the need for organ donations (Huch,
Knoblich, Lutolf, & Martinez-Arias, 2017). Organoid research
can also provide improvement when it comes to animal experimentation, bioethics, and gene therapy (Xinaris, 2019).
Method
This study was written by researching peer reviewed
scholarly articles and medical journals to obtain the most
accurate information on the advancements of organoid
technology. The data was analyzed and evaluated from
many different angles, using Touro College’s access to online publications. Additional searches were done through
Google Scholar, PubMed, and the Science Journal to accumulate relevant information for the study.

Discussion
In 1998, the first successful organoid culture system derived from adult stem cells was the small intestinal organoids of a mouse. This development in organoid research
led to many discoveries, among them the knowledge
that Wnt signaling is crucial for maintaining the stem
cell compartment of the mouse small intestine. Further
observation brought about the awareness that ectopic
expression of R-spondin, which communicates with Wnt
and acts as a Lgr5 ligand, is necessary to include in a culture of intestinal stem cells as well, for ultimate function
of the organoid (Drost & Clevers, 2017).
Following these observations and through his own research, Toshiro Sato of Keio University confirmed that the
artificial inclusion of growth factors present in the organ’s
original stem cell niche is crucial for optimum efficiency and
function of the organoid. Sato too researched and studied
intestine stem cells. He observed that the 3D organoid
forms from single Lgr5-positive Intestine Stem Cells. He retained the architecture of the authentic intestine, and included Wnt/R-spondin, epidermal growth factor (EGF), noggin
(BMP inhibitor) and an artificial laminin-rich extracellular
matrix in his in vitro culture. (Drost & Clevers, 2017).
In the body, cells are exposed to intricate and complex
surroundings where they are involved in many chemical
interactions (Prior, Inacio, & Huch, 2019). When creating
an organoid derived from adult stem cells in vitro, the
stem cell niche of the specific tissue must be duplicated. Common niche factors necessary when dealing with
healthy human tissue include, but are not limited to, Wnt,
R-spondin, noggin and EGF (Drost & Clevers, 2017).
Inclusion of the precise concentrations of growth factors
within the culture, and maintaining identical micro-architecture, allows stem cells to mature into organized tissues, healthy or diseased (Dumont, Heremans, Jan et.al.
2019). Incorporating these factors in the culture will
ensure natural interactions among stem cells. It is crucial to mimic these interactions when creating in vitro
phenotypes to maintain the functions of the cells. This is
a major advancement from 2D monolayer technology to
3D technology.
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To begin creating an organoid, stem cells must be isolated from embryonic stages or adult tissues and placed into
a media with these natural growth factors. Development
begins from a totipotent cell undergoing rapid cell division. The divided cells become more restricted as they
evolve. At the blastocyst stage, the outer cells mature
into extraembryonic cells, while the inner cell mass of the
blastocyst (ICM) is composed of pluripotent cells which
possess the ability to evolve into tissue of the embryo
proper. These pluripotent cells are isolated to form the
embryonic stem cells.The next step in the developmental
process is gastrulation. During this period, cells of the
ICM mix together and perform morphogenetic movements that are controlled by signaling factors like Wnt,
fibroblast growth factor (FGF) and transforming growth
factor-beta ligands. These signaling factors activate transcription and differentiation into the three germ layers:
endoderm, mesoderm and ectoderm. After forming the
three germ layers, the progenitor cells become more
specific and form the primitive structures of organs, thus
developing into any tissues and organs of the body (Prior,
Inacio, & Huch, 2019).
Transplantation and Xenotransplantation
The development of organ transplantation (OT) is “one
of the most successful advances in modern medicine.”
For struggling patients with end stage disease, transplantation is usually their last hope to survive. One major
problem we face today regarding OT is the lack of organ
availability. We are unable to meet the exceptionally high
organ demand (Bezinover & Saner, 2019). Arthur Caplan
of NYU Langone Medical Center reports that the space
between supply and demand of transplanted organs is
“worse than it appears to be” (Caplan, 2014).
The phenomenon of creating human 3D cultures that
duplicate authentic organs allows for extensive use of
these organoids for many cell therapies, and as a potential substitute for whole-organ transplantation (Huch,
Knoblich, Lutolf, & Martinez-Arias, 2017). Organoids have
been successfully transplanted both orthotopically, in the
organs, in vivo location, and ectopically, outside of the
organ’s natural environment. Through both methods of
transplantation, organoids were successful in undergoing
cell maturation. These advancements show that organoid
models can effectively mature and develop when in contact
with natural signals provided by the in vivo environment, a
crucial understanding for developing organoid transplantation. An abundance of research in the field of organoid
transplantation is done to further advance our knowledge
of its capabilities.The use of immunocompromised mice in
many experiments has paved the way for great progress.
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When transplanting organoids into these mice for maturation, the organoids were positioned at highly vascularized
sites, making it easier to control organoid engraftment and
growth. This allows the organoid to develop for several
months, without interfering with the mouse’s required
organ function. Some of these sites include epididymal fat
pads and underneath kidney capsules (Holloway, Capeling,
& Spence, 2019).
More recently, scientists were successful in orthotopically transplanting colonic epithelial organoids derived
from human primary tissue into the murine colon. This
study was supported by the Research Center Network
for Realization of Regenerative Medicine project from
the Japan Agency for Medical Research and Development.
The experiment was done by removal of epithelial tissue
from the mice. Results were most efficient when only
one side of the colon mucosa was removed, to prevent
obstruction of the murine colon. Following the removal
of the epithelial cells, human colon organoids were transplanted. The xenografted organoids were observed by
fluorescent endoscopic imaging. After many trials, longterm engraftment of the human colon organoids was
eventually successful and was monitored and observed
by endoscopy for over 6 months. Immunohistochemistry
of human-specific cytokeratin (KRT8/7) confirmed the
presence of the human donated epithelium in the colon
of the mouse. This study broadened our understanding of transplantation through organoids in general, but
also suggested that the location of the injury must be
significantly large to successfully create a niche for the
transplanted organoid. Small injuries requiring engrafted
tissue, although also allowing for engraftment, proved to
be more complicated. The tissue did not last as long as
the engrafted tissue of the case of the larger injury, and
eventually disappeared over time (Sugimoto, et al., 2017).
Personalized Medicine
Of the many exciting advancements brought about
through organoid research, the ability to model diseases
of specific patients in vitro can be of great benefit to medicine (Drost & Clevers, 2017). Scientists begin to predict a
future in which organoid cultures derived from a patient
can provide correct and effective therapeutic options for
that particular patient. Induced pluripotent stem cells
(iPSCs) are skin or blood cells that have been placed back
into an embryonic-like pluripotent state. This allows the
cells to mature and develop into any kind of human cell
and is commonly used for therapeutic purposes. (Huch,
Knoblich, Lutolf, & Martinez-Arias, 2017).
In regard to oncological patients, these organoids could
allow testing of drug response, minimizing the load of
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therapy. Organoids created from tumor-derived cells are
obtained from human tumor biopsies. Induced pluripotent stem cells or adult stem cells are taken from the
biopsy and develop into organoids that mimic the cancerous organs. These organoids display identical tumor
heterogeneity to their in vivo counterparts (Dumont,
Heremans, Jan et.al. 2019).
Marc van de Wetering, a senior researcher dedicated
to pediatric oncology, created a biobank of 20 tumor
organoids derived from patients with colorectal cancer
(CRC). He characterized the organoids by genes and performed drug testing to observe the correlation of specific
mutations with drug responsiveness. For example, only
one of the tumor organoid cultures reacted sensitively
to LGK974, an inhibitor of Wnt secretion. The sensitivity
toward this inhibitor was observed to be connected to
a mutation that was found in the negative Wnt regulator. This study indicated that characteristics of tumors,
histological and genetic, were mimicked precisely in the
organoid. These findings can offer a promising future in
understanding the correlation between tumor genetics
and drug response (Drost & Clevers, 2017).
Additional studies have also been done to create organoid models from normal and neoplastic murine and
human pancreas tissues. Pancreatic cancer is of the most
fatal malignancies because of its lack of improvement from
treatment and late diagnosis. Pancreatic organoids can
develop quickly from cells derived from resected tumors
and biopsies. These organoids display characteristics that
are helpful in understanding drug and therapy response of
the pancreas. Neoplastic organoids that are transplanted
back into the body, reperform the whole tumor development. The organoids develop from early-grade neoplasms into “locally invasive and metastatic carcinomas.”
Organoids are an ideal model for genetic analysis because
of their ability to be genetically duplicated. Close observation of murine pancreatic organoids presented altered
genes and pathways during the onset and progression
of the disease. After confirming these characteristics in
human tissue, organoids have been deemed as an effective
model system for discovering the nature of this deadly
malignancy (Boj, et al., 2015).
Gene Therapy
Incorporating organoids into gene-editing through the
use of tools like CRISPR/Cas9 technology offers the possibility of correcting gene mutations of patients.These repaired and healthy genes can then be transplanted into the
patient (Huch, Knoblich, Lutolf, & Martinez-Arias, 2017).
CRISPR/Cas9 also allows for manipulation of genes in organoid cultures, causing drug testing for specific genes to

be more definitive and reliable (Dumont, Heremans, Jan
et.al. 2019). Comparing a variety of organoids that are all
derived from the same iPSC line allows scientists to observe mutations in specific genes, and the effects on tissue
specification and development in organs when the genes
of a patient carry a specific congenital allele.The ability to
create organoids from the diseased tissue offers various
methods for clinicians to explore, like computerized drug
screening tests, or mirroring antibiogram tests to determine antibiotic susceptibilities (Huch, Knoblich, Lutolf, &
Martinez-Arias, 2017).
Studies were done to prove the benefits that can be
gained from adult stem cell-derived organoids with regard
to hereditary diseases (Drost & Clevers, 2017). Recently,
advancements in organoids have shown that CRISPR/
Cas9 technology can repair cystic fibrosis gene mutations
(Huch, Knoblich, Lutolf, & Martinez-Arias, 2017). Dr. J.M.
Beekman of the Regenerative Medicine Center Utrecht,
along with some colleagues, created a modeled cystic fibrosis (CF) in vitro culture. The model was composed of
cells obtained from CF patients through rectal biopsies,
creating intestinal organoids. The cystic fibrosis transmembrane conductance regulator (CFTR) gene is responsible for encoding an anion channel that is expressed
on the surface of epithelial cells. CFTR maintains fluid and
electrolyte homeostasis. Cystic fibrosis is the result of a
mutation in the CFTR gene. As a result of this mutation,
epithelial ion transport is weak, and a build-up of viscous
fluid becomes present in the respiratory and gastrointestinal tract. CFTR is activated by forskolin, which increases
intracellular cyclic AMP levels. In a healthy sample of intestinal organoids swelling was rapid. However, organoids
derived from cystic fibrosis patients presented minimal
swelling in comparison. It is now possible for researchers to test various drugs on different CF patient-derived
organoids, depending on specific CFTR mutations. These
findings shed light on a future of patient-specific treatment strategies (Drost & Clevers, 2017).
The Liver
There are many diseases associated with the liver, and
over two million deaths a year worldwide are related
to liver complications like cirrhosis, viral hepatitis and
hepatocellular carcinoma (Asrani, Devarbhavi, Eaton, &
Kamath, 2018). The amount of deaths associated with
liver disease calls for the advancement of liver organoids
as treatments for struggling patients. Researchers like
Meritxell Huch of Gurdon Institute and Takanori Takebe
from Yokohama City University present their progress in
the field of liver organoids. They were successful in creating ductal structures from adult liver and went further
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to activate these structures to differentiate into hepatocytes capable of producing bile acid and maintaining cytochrome activity (Muthuswamy, 2017).
The creation of the liver organoid has been further
developed through the use of co-culture systems. Many
studies reported that liver hepatocyte-like cells derived
from human pluripotent stem cells (hPSCs) in 2D resulted in the cells developing immaturely and did not perform
all functions of mature hepatocytes. Additionally, after
implantation of these hPSC derived hepatocyte-like cells
into immunocompromised mice, the cells operated with
little effectiveness. Due to these poor results, research
has been dedicated to creating more functional hPSC-derived hepatocytes, to produce a liver organoid model
that will function more efficiently. The use of co-cultures
is thought to be the answer to this progress. When observing mice, researchers found endothelial cells to be a
crucial cell type in the process of
liver organogenesis. Due to this finding, a hypothesis
was formed that placing endothelial cells and mesenchymal precursors with the hepatic endoderm in a co-culture will provide an environment that closely mimics in
vivo development of the liver. This will give rise to efficient hepatocyte differentiation, ultimately generating a
complex human liver bud organoid (Holloway, Capeling,
& Spence, 2019).
The liver is made up of epithelial, stromal, endothelial
and mesenchymal cells that all work together to carry
out its functions. Hepatoblasts are the embryonic progenitor cells of the liver. At the time of organogenesis, these
cells are set aside from the posterior foregut endoderm.
Hepatoblasts communicate with surrounding signaling
factors found within the mesenchyme, like FGF, BMP, hepatocyte growth factor (HGF) and Wnt. These communications cause the hepatoblasts to evolve and modify until
they can migrate into the adjacent mesoderm to form
the liver bud (Prior, Inacio, & Huch, 2019). After creation
of the hPSC-liver buds, transplantation of the liver buds
into immunocompromised mice tested the functionality
of these artificial structures. The hepatocytes of the liver
bud were proved to be functional due to the presence
of high sustained levels of albumin within the liver bud
(Holloway, Capeling, & Spence, 2019). After the liver bud
is formed, the hepatoblasts expand and differentiate to
form hepatocytes and biliary epithelium. Meanwhile, the
mesenchyme generates liver fibroblasts and stellate cells.
The structure of the liver is formed completely when the
hepatocytes and cholangiocytes mature further and the
endothelium and mesenchyme are integrated (Tremblay
& Zaret , 2005).
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Artificial Ovaries
Of all gynecological cancers, epithelial ovarian cancer
(EOC) is the fifth largest cause of cancer-related deaths in
European women. EOC patients frequently relapse, with
an expanding resistance to chemotherapy and targeted
therapy. Consequently, further research is crucial for the
advancement of therapy in EOC patients, and organoid
development seems promising. Models of EOC organoids
can contribute a constructive platform for drug testing
and screening, and can ultimately be utilized as a personalized in vitro prototype for an individual patient.
High-grade serous ovarian carcinoma (HGSOC) is a
tumor that arises from the serous tubal intraepithelial
carcinoma (Dumont, Heremans, Jan et.al. 2019). The fallopian tube epithelium (FTE) has been observed as the site
where HGSOC originates (Yucer, et al., 2017). Therefore,
observation of fallopian tube tissue can be very enlightening in discovering the nature of EOC. Mirjana Kessler of
the Department of Infectious Diseases and Respiratory
Medicine, through experimentation, created differentiated
ovarian organoids from a single fallopian epithelial stem
cell. These organoid models maintained their stability for
over several months. This experiment uncovered the existence of fallopian tube stem cells for the first time. The
creation of an ovarian organoid requires growth factors
and microcellular substances, particularly Wnt and Notch
pathways. The inclusion of Notch is especially important
because it primarily regulates and maintains the stemness
of these fallopian epithelial cells (Dumont, et al., 2019).
The urogenital system arises from the intermediate
mesoderm (IM) of a developing embryo. The Müllerian
duct within the urogenital system gives rise to the entire
female reproductive tract (Yucer, et al., 2017). Following
Kessler’s research, NurYucer of the Regenerative Medicine
Institute at Cedars-Sinai Medical Center was successful
in constructing Fallopian tube organoids (Dumont et al.,
2019). He created an in vitro culture of the Müllerian duct
from induced pluripotent stem cells.Yucer then generated
IM differentiation by adding pro-Mullerian growth factors,
causing the fallopian tube epithelium to develop. The differentiation of the cells was monitored by the addition of
cell-related markers such as PAX2, GATA3, OSR1, WT1,
and OVGP1. A 3D growth platform was set up for further
development and maturation of FTE, which successfully
caused the tissue to self-organize into an FTE organoid
structure. When forming the FTE organoid, the canonical
WNT signaling pathway proved to be crucial. Sub- set of
WNT gene family members were also included in the
culture, like WNT3a and WNT4. These genes were necessary for generating the different phases of development
and maturation of the Müllerian duct.WNT3a and WNT4

What is the Future of Organoids?

are also responsible for inhibiting male differentiation
pathways. After three days of forming the culture, epithelial buds formed from the flat cell sheets. The buds then
became spheroids, which were put in Matrigel beads with
pro-mullerian growth factors. The intermediate mesoderm matured most at day 4, so spheroids were observed
on days 3 to 6. Inclusion of a weak estrogen, phenol red, in
Matrigel caused the complete organoid structure to form
(Yucer, et al., 2017). This finding highlights the necessity
of estrogen for the differentiating and maturing of the
Fallopian tube. To maintain and stabilize fully developed
organoids, both estrogen and progesterone must be present. (Dumont, et al., 2019) This is because estrogen alone
did not maintain the organoids for long periods of time.
More progress has been made in regard to EOC organoid
research. Dr. Oded Kopper of NewStem efficiently produced
organoids with epithelial ovarian cancer characteristics. He
obtained cells from primary tumors or metastatic lesions.
The organoids he created successfully retained identical genomic landscapes as the tumors they were derived from.
Histological aspects and heterogeneity of the tumors were
also maintained. (Dumont, et al., 2019)
Ovarian cancer organoids can be utilized to observe
various tumor responses to chemotherapy and for
drug-screening assays. Xenografting OC organoids also
allows clinicians to test drug susceptibility in vivo. These
are some of the many advancements and applications of
ovarian cancer organoids (Kopper, et al., 2019).
Another major benefit of an artificial ovary is to preserve fertility in patients suffering from cancer. An artificial
ovary can allow women to fall pregnant after the damaging effects of chemotherapy. (University of ErlangenNuremberg, 2019) Ovarian tissue cryopreservation is the
process of preserving reproductive potential in oncological
patients after being exposed to gonadotoxic therapeutic
agents. (Liverani, et al., 2019) Ovarian tissue cryopreservation involves the removal of a section or of the complete
tissue of an ovary. This tissue is then preserved for use
in the future. (Ben-Aharon, et al., 2016) Cryopreservation
can be utilized by patients with aggressive malignancies
who must receive instant gonadotoxic treatment. These
women do not have the time to receive ovulation induction, and cryopreservation can be a great benefit. Although
ovarian tissue cryopreservation can be of great assistance
for many, cancer patients with moderate-to-high risk of
ovarian metastasis are at too high of a risk. The process
of cryopreservation introduces the possibility of malignant
cells being reimplanted back into the patient.
A promising approach for these high-risk patients is
the use of artificial ovaries. Isolating follicles from a patient’s ovarian tissue and reimplanting the follicles into

an artificial ovary can guarantee that no malignant cells
will be reintroduced to the patient. (Liverani, et al., 2019)
Because follicles are isolated in a basement membrane,
there is no interaction between capillaries, follicular cells,
white blood cells and nerves.Therefore, there is no threat
that malignant cells will be introduced back to patients.
Artificial ovaries make it possible to transplant primordial and primary follicles that were isolated to survive
and could mature into follicles after transplantation. This
permits sex hormones to be secreted, regulating oocyte
maturation to the point where they are capable of fertilization. In the artificial ovary, it is essential for the follicles
to be supplied with an environment that mimics the natural human ovary. In order for the follicles to survive and
develop, interaction with the ovarian extracellular matrix
(ECM), as well as surrounding ovarian cells must be present. For example, ovarian stromal cells are required to
activate primordial follicles, while endothelial cells are
necessary for vascularization, providing transportation
of oxygen and nutrients, paracrine factors, and removal
of metabolic waste. The presence of the ovarian ECM is
responsible for maintaining 3D follicle structure, as well
as other important roles.Therefore, all these factors must
be present. (Dolmans & Amorim, 2019)
Drs.Teresa Woodruff and Ramille Shah of Northwestern
University led a team of scientists in creating artificial ovary structures. The process utilized a 3D printer
to create the structure that would hold the follicles. A
stainless steel nozzle was used for the printer, which was
around the width of a strand of hair. Five layers of gelatin
filaments were printed at various angles. Tiny cylinders
were punched through the sheets, creating pores to hold
mice follicles. Nine mice were involved in the study, and
all ovaries were removed. Seven of the mice received the
structures with the follicles, and two received the artificial structures without follicles. Following the mating
of these mice with male mice, three mice with artificial
ovaries produced litters. The artificial ovaries also joined
with the blood vessels of the mice, allowing for female
hormones involved in milk production to be made. The
hormones successfully traveled the mouse bloodstream
to the breast tissue where it stimulated milk production
(Piazza, 2018). The ability of an artificial ovary to restore
endocrine function and provide an environment for follicular development can be extremely useful for oncological
patients in the future (Cho, Kim, Noh, & Ku, 2019).
Virology
The coronavirus disease-19 (COVID-19), caused by the
SARS-CoV-2 virus is responsible for over 250,000 deaths
globally. (Han, et al., 2020) The COVID-19 pandemic
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proved to the world just how threatening newly surfacing
viruses can be. Understanding the nature of these viruses
rests in the use of in vitro cultures capable of viral replication. The use of organoids is now demonstrating its
practicality when experimenting the tendencies of these
deadly viruses.
The novel coronavirus first infected humans in
December of 2019. Various research groups have been
experimenting with organoids to better understand the
nature and tissue tropism of SARS-CoV-2. Josef Penninger
of the Institute of Molecular Biotechnology, along with
his colleagues, created capillary and kidney organoids,
both derived from human iPSCs. Through this research,
Penninger proved that SARS-CoV-2 can infect both sites
in the body.These observations help explain the ability of
the virus to spread throughout the body and the damaging effects on kidney function in infected individuals.
Multiple studies were done to establish whether the
virus can infect the gastrointestinal tract. Intestinal organoids derived from adult stem cells were examined and
presented high levels of angiotensin converting enzyme 2
(ACE2), a receptor for SARS. The studies displayed that
enterocytes, the most common intestinal epithelium cell
type, were infected with the virus. These findings verified
that the intestine is a potential site for SARS-CoV-2 infection (Clevers, 2020).
Mart Lamers of Erasmus Medical Center, along with his
colleagues, further investigated the ability of SARS-CoV-2
to infect the intestines. The human small intestine epithelium is composed of multiple cell types. The experiment
consisted of 3D structures that displayed all cell types,
grown in four separate cultures. Each culture displayed
different amounts of ACE2, proving their ability to be
infected with SARS-CoV-2. Through the use of electron
microscopy, Lamers and his colleagues observed that the
virus caused infection in mature and progenitor enterocytes alike. This study suggests that the use of human
organoid models can provide researchers with beneficial
resources for examining the nature of SARS-CoV-2 and
other coronaviruses. (Aaas, 2020)
Since the primary infection site for SARS-CoV-2 is in
the respiratory organs, research was done to create a
lung organoid derived from human pluripotent stem cells
(hPSCs). Development began with the differentiation of
the hPSCs into definitive endoderm. The cells then further progressed into the anterior foregut endoderm
(AFE) and formed AFE/lung progenitor cells. Further
specification and maturation of these cells eventually
formed the lung organoids. The ability of these lung organoids to provide a platform for modeling COVID-19
was then put to the test. The cultures were introduced
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to the SARS-CoV-2 virus, and after 24 hours viral RNA
was detected. The use of immunostaining proved the
presence of SARS-S protein in the lung organoids. Based
on this research, scientists can utilize these organoids to
observe the effects of various drugs on the coronavirus,
by observing any decrease in the amount of markers
present from the injected virus. (Han, et al., 2020)
Conclusion
Organoids possess the ability to model tissue structure
and function with great accuracy, but more research is
required to take full advantage of organoids. Organoids
still lack vasculature, immune cells, and other cellular
components that tissues communicate with and depend
on in the body (Iakobachvili & Peters, 2017). Without all
the essential cellular components of an organ, the use
of organoid in human transplantation will be limited.
Studying processes where these components are necessary is therefore limited. (Souza, 2018) Efforts to improve
the vasculature of organoids will provide nutrient supply,
excretion of toxins and signaling that is present in the
body. This research is presently making progress, though
it is demanding and yet to be fully incorporated into standard tissue culture facilities. (Iakobachvili & Peters, 2017)
Organoid technology brings up many ethical questions
as well. For example, what might happen if scientists can
successfully create a brain organoid? Utilizing a brain organoid for drug testing would be helpful, but it may pose
an ethical issue to transplant this organoid into a patient.
These matters must be addressed in the future. However,
we do know that organoid technology is adding a whole
new dimension to the medical field.
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Abstract
Maternal-fetal cellular trafficking is the bidirectional passage of cells between the fetus and mother during pregnancy. The
presence of fetal cells in maternal circulation, brain, and muscles is known as fetal microchimerism. During pregnancy, fetal
cells can be obtained from the mother’s blood for prenatal diagnosis of the fetus. Furthermore, it has been confirmed that fetal
microchimerism persists decades later in women who have been pregnant. Investigation of the long-term consequences of fetal
microchimerism is a frontier of active study, with preliminary results pointing to both beneficial and adverse effects. This review
will examine the relevant literary information on fetal microchimerism during pregnancy and provide current knowledge regarding
the long-term effects of naturally acquired fetal microchimerism.
Introduction
Microchimerism is the presence of two genetically distinct cell populations in the same individual. Foreign
cells and DNA are found in an individual’s plasma or
tissues that originated from a genetically different individual. Naturally acquired microchimerism is commonly
observed and results from the maternal-fetal exchange
of cells and DNA during pregnancy. (Gammill & Nelson
2010) In pregnancy, there is transplacental two-way
trafficking of living fetal cells from the fetus into the
maternal circulation, and cells from maternal circulation
impart in the fetus. (Naik, Shrivastava, Suryawanshi, &
Gupta 2019) This paper provides an overview of the
role of fetal cell microchimerism in autoimmune and
cancerous diseases. The mechanisms by which fetal microchimerism is believed to modulate the protection
against cancer or tumor progression will be discussed,
along with future research directions.

Fetal microchimerism has been reported in the peripheral blood of women in cellular subsets, including lymphoid-lineage and myeloid-lineage cells.An experiment was
done to evaluate microchimerism in CD66b sorted granulocytes. Granulocytes were isolated from the peripheral
blood of healthy women. CD66b+ cells were then isolated
by fluorescence-activated cell sorting, and a panel of polymorphism-specific quantitative assays was employed to
investigate the presence of fetal and maternal microchimerism. One-third of the women tested positive for at least
one form of microchimerism. 40% had maternal microchimerism compared to 15% who had fetal microchimerism.
The maternal and fetal origin CD66b+ cells are strong evidence for an active microchimeric hematopoietic stem and
progenitor cell niche. Higher proportions of women might
test positive for even larger quantities of microchimerism if
more sensitive assays were available. (Sunku, Gadi, Lacoste,
Guthrie, & Nelson, 2010)

Methods
This document was written by researching peer-reviewed
scholarly articles and medical journals to assess the
newest research and methods in fetal microchimerism.
The information and data were gathered from numerous sources, including databases such as Google Scholar,
Touro Library, The National Center for Biotechnology
Information, and The National Institute of Health. Keyphrases searched included, “fetal microchimerism,” “the
effects of fetal microchimerism,” and “fetal microchimerism in autoimmune disorders.” All the content was
carefully selected, compared, and analyzed to assure its
validity and determine the articles’ standpoint.

Fetal DNA in Maternal Plasma During Pregnancy
Another study was undertaken to evaluate fetal DNA
in maternal plasma and urine. DNA was isolated from
plasma and urine samples of 80 pregnant women, ranging
from 7 to 40 weeks of gestation. Their DNA underwent
amplification for Y specific chromosome DNA via a nested polymerase chain reaction. The postpartum analysis of
fetal gender showed that 25 women carried female fetuses and 55 male fetuses. Among the 55 women bearing
male fetuses,Y chromosome‐specific signals were detected in 96% of their plasma and 38% of their urine samples.
(Al-Yatama et al., 2001) The detection of fetal sex chromosomes with Y-chromosome-PCR has a specificity of
100% and a sensitivity of 96%, which increases along with
gestational age.This minor lack of sensitivity explains why
Y-chromosome signals were only located in 96% of the
plasma of pregnant women. (Rijnders et al.) The analysis
of their results with respect to gestational age showed no
significant difference in the Y chromosome‐specific DNA
detection. These results showed that fetus‐specific DNA
was detected in the maternal plasma by nested PCR. (AlYatama et al., 2001)
Fetal DNA is present in low concentration in maternal
plasma increasing throughout pregnancy with a 0.1% increase each week from 10 to 20 weeks’ gestation, followed

Fetal Microchimerism
Microchimerism is the fetus’s cell legacy after pregnancy.
Fetal stem cells can leave the fetus and migrate across
the placenta to engraft in the maternal bone marrow and
other tissues. The transfer of fetal progenitor stem cells
begins four or five weeks after fertilization and continues
throughout the pregnancy. This form of microchimerism
occurs in both male and female embryos, but the detection of male microchimerism in maternal tissue is easier
to detect due to the unique presence of Y-chromosome
in the women. (Miech, 2010)
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by a 1% increase each week from the 21st week until term.
(Taglauer et al.) Clinical tests have tried to capitalize on
this DNA to identify the baby’s sex, determine whether
the child and mother have Rh incompatibility, and identify
chromosomal disorders. (LeslieDec, et al. 2017)
Many early investigations of fetomaternal cell trafficking sought to develop methods whereby noninvasive
prenatal diagnosis of genetic disorders could be achieved.
(Gammill & Nelson 2010) Noninvasive testing would
ameliorate the risk of fetal miscarriage associated with
current invasive procedures such as amniocentesis. This
non-invasive prenatal test is a blood test, and between
25 and 42.5 milliliters are collected. (Bianchi, Williams,
Pelletier, Klinger, & Shuber 1996) The main conditions for
which prenatal diagnosis is considered are monogenic diseases, when the causation of the disease results from one
gene, and therefore, is easier to detect and obtains conclusive results. Fetal DNA circulates in a high background
of maternal DNA and is isolated and amplified using polymerase chain reaction technology. However, even after
that, maternally inherited fetal alleles are very difficult to
identify from maternal plasma, therefore, scientists have
focused on the detection of paternally inherited fetal alleles that are not present in the maternal genome. The
diagnosis of autosomal dominant diseases transmitted by
the father could be made noninvasively. Also, by detecting
the paternally inherited fetal alleles, one can exclude the
fetal inheritance of autosomal recessive diseases. The discovery of free cellular fetal DNA in maternal plasma has
offered new approaches for noninvasive diagnosis, and
fetal isolation analysis is now possible. (Lun et al., 2008)
Fetal DNA in Maternal Plasma After Pregnancy
Microchimerism occurs as a result of the fetomaternal
transfusion of blood cells across the placenta during pregnancy. After delivery, once the placenta has been expelled,
fetal-origin cells should hypothetically depart from the
maternal circulation. Nevertheless, studies of women who
had given birth to a male child showed a high incidence
of male cells in their blood after delivery. Additionally,
some women have displayed male cells in their tissues
up to 27 years postpartum after having birthed a male
child. This event can be interpreted to mean that fetal
cells transferred from the fetus to the mother during
pregnancy established permanent microchimerism in the
maternal body.This permanency was reported in 30–50%
of women who gave birth to a male child. (Sato, Fujimori,
Sato, & Ohto, 2008)
There is an increased fetal-to-maternal transfer of progenitor cells during an abortion procedure as the placenta is being destroyed. Maximized fetal cell trafficking
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following a medical abortion was confirmed in an in vivo
model. Since the embryonic circulatory system is established in the first trimester of pregnancy, there is a greater
chance for the transfer of a larger number of progenitor
T cells during the first-trimester termination of pregnancy. Therefore, women who had an elective abortion in
their first or second trimester have a greater tendency
towards fetal microchimerism. (Miech, 2010)
Male microchimerism in women without sons and the
correlation of microchimerism to prior pregnancy history
was researched.Y-chromosome-specific quantitative PCR
was used to test peripheral blood mononuclear cells of
120 women. Women were categorized into four groups
based on their pregnancy histories. Group A was nulligravid and displayed 10% male microchimerism, Group B
had induced abortions and displayed 57%, Group C had
spontaneous abortions and displayed 22%, and Group
D had only daughters and displayed 8%. Male microchimerism prevalence was the greatest by a significant
amount in those with induced abortions. Other possible
sources of male microchimerism, such as those obtained
in Groups A and D, include unrecognized spontaneous
abortion or a vanished male twin. (Yan et al., 2005)
Autoimmune Effects on The Mother
It has been theorized that the persistence and abundance
of fetal microchimerism are dependent on numerous factors, including the immunogenetic relationships between
mother and fetus, and perhaps between and preexisting
inhabitants of the maternal system, from her mother or
previous children. (Gammill & Nelson 2010)
Fetal microchimerism, a form of trans-placental stem
cell transplant, helps to explain the etiology, diversity of
tissue pathology, predilection for females, and increase in
the annual incidence of autoimmune diseases in women.
(Miech, 2010) Fetal stem cells can differentiate into
mature and competent cells, such as lymphocytes and
monocytes. Fetal cells in maternal circulation or tissues
may mediate a graft vs. host disease, which can lead to the
development of autoimmune diseases. Women comprise
80% of people with autoimmune diseases. Researchers
have begun investigating the association of micro-chimerism with autoimmune diseases that predominately affect
women. (Naik, Shrivastava, Suryawanshi, & Gupta 2019)
Fetal microchimeric cells in maternal tissues led to the
discovery of a positive correlation between fetal microchimerism and autoimmune diseases in women. Progenitor
cells in the fetal immune system, such as T cells, monocytes, macrophages, lymphocytes, and NK cells, are among
the many fetal cell types that can be transferred to maternal tissues. In maternal tissues, the fetal microchimeric
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progenitor immature T cells are capable of self-renewal,
proliferation, and differentiation. Progenitor cell activation
can result in the production of autocrine and paracrine inflammatory responses in autoimmune diseases. Triggering
agents that activate these fetal microchimeric immune cells
to attack the maternal host cells resulting in autoimmune
disease have not yet been identified. Suspected triggers
include viral or bacterial agents, abnormal localized tissue
protein, and drugs. Microchimerism in affected tissues is
more likely to be abundant in women with autoimmune
diseases than in women with non-autoimmune diseases.
(Miech, 2010)
Pregnancy alters symptoms of autoimmune diseases.
The maternal immune system develops a tolerance to
the fetus, and the suppression of the maternal response is
lifted postpartum. Fetal tolerance may explain why some
autoimmune disease symptoms decrease during pregnancy in some women. (Boddy, Fortunato, Sayres, & Aktipis,
2015) Autoimmune diseases are often repressed during
pregnancy and exasperate postpartum. It was then hypothesized that fetal cells in maternal circulation might be
important in influencing autoimmune disease in pregnancy
and postpartum. (Ando, Imaizumi, Graves, Unger, & Davies,
2002) Systemic sclerosis provided the first evidence for
the involvement of fetal microchimerism with autoimmune diseases. Patients frequently had fetal cells not only
in peripheral blood, but also in skin lesions. The hyperthyroidism of Graves’ disease frequently abates during pregnancy and exacerbates after childbearing. (Ando, Imaizumi,
Graves, Unger, & Davies, 2002) Between 43 and 75% of
patients with rheumatoid arthritis exhibit amelioration of
some or all their rheumatoid arthritis symptoms during
pregnancy. Additionally, in rheumatoid arthritis patients,
symptoms tend not only to show improvement during
pregnancy, but an exacerbation of symptoms postpartum.
Correspondingly, the rate of relapse declines with pregnancy in women diagnosed with multiple sclerosis, with the
lowest rate in the third trimester. Relapse rates return to
pre-pregnancy levels postpartum. This framework suggests
that a contributor to autoimmune disease development
may be the maternal immune response to the presence of
fetal cells that invade maternal tissues. (Boddy, Fortunato,
Sayres, & Aktipis, 2015)
The risk of developing an autoimmune disease in parous
women is higher after the first year postpartum. Fetal cells
in the thyroid may contribute to thyroid cancer risk or
susceptibility to other thyroid diseases. Current research
suggests an association with postpartum thyroid tissue
and thyroid diseases. Fetal cells are more abundant in the
thyroid tissue and blood of women with Graves’ disease
and Hashimoto’s thyroiditis, compared to healthy controls.

Also, the risk of autoimmune disease in parous women
is significantly higher after the first year postpartum. This
knowledge suggests that the presence of fetal cells in the
thyroid is associated with a maternal disease rather than
health. (Boddy, Fortunato, Sayres, & Aktipis, 2015)
Autoimmune thyroid disease affects reproductive-aged
women. It commonly initiates or exacerbates postpartum,
and so the involvement of fetal microchimerism was suspected.Autoimmune thyroid disease does have e a profound
relationship with pregnancy.Autoimmune thyroid disease involves autoimmune antigens, such as the TSHR,Tg, and TPO.
Placental immune suppression during pregnancy lessens the
activity of autoimmune thyroid disease, as seen in the remission of Graves’ disease. However, exacerbation of preexisting autoimmune thyroid diseases or initiation of autoimmune thyroid disease is also common postpartum. Increased
titers of thyroid autoantibodies have been observed in the
postpartum. Graves’ disease has also been shown to be
most markedly suppressed by pregnancy itself, but; however,
up to 60% of Graves’ disease patients of childbearing age
have been reported to develop this disease within one year
of delivery. (Ando & Davies, 2003)
Cancerous Effects on the Mother
During pregnancy, fetal cells enter the maternal body,
cross the placenta, and are found frequently in the maternal lung. It was generally accepted that the fetal cells
in the lung were passing through the mother’s pulmonary
circulation; however, the presence of fetal cells in the lung
shows an association with cancer. A study reported higher levels of male DNA and significantly more fetal cells in
the lung and thymus tissue in the diseased lung compared
to healthy bone marrow from the same person. (Boddy,
Fortunato, Sayres, & Aktipis, 2015) Fetal cells have also
been detected as clusters in lung tumors in women decades after pregnancy. Their tumor frequency was higher
in lung tumors than in the healthy surrounding lung tissue.
The fetal cells may be recruited from the bone marrow
to the tumor sites where they assumed their role in
immunosurveillance and tissue repair. (Naik, Shrivastava,
Suryawanshi, & Gupta 2019)
Fetal cells are frequently found in normal breast tissue
postpartum women.The research presents a complicated
picture of fetal cell’s role in breast cancer. Fetal cells are
found less the tissue and blood of women with breast
cancer compared to healthy controls. (Boddy, Fortunato,
Sayres, & Aktipis, 2015) It was reasoned that naturally
acquired allogeneic immune cells in the form of fetal microchimerism might correlate with protection from the
development of breast cancer. Fetal microchimerism was
found in higher quantities in healthy women compared
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to breast cancer patients, 43% to 14%, respectfully. This
shows a correlation between the role of fetal allogeneic
cells as malignant cell immune surveillance and protection
from breast cancer. (Gadi & Nelson, 2007)
Reduced risk of breast cancer is recognized among
parous compared to nulliparous women. Eighty-two
women were tested for male DNA in peripheral blood,
presumed from a prior pregnancy with a male fetus. Fortyseven of the subjects were healthy, and 35 had breast cancer.The levels of male DNA were determined by real-time
PCR for a Y chromosome-specific gene in DNA extracted
from peripheral blood mononuclear cells. Fetal microchimerism was found in 43% of healthy women and 14% in
women with breast cancer.These findings suggest that allogeneic fetal microchimerism may contribute to a reduction
in the risk of breast cancer. (Gadi & Nelson, 2007)
Through the evolutionary history of fetal microchimerism in the maternal body, it is possible that it now has
a role in normal breast tissue physiology. The maternal
mammary gland hosts stem cells that contribute to the
development of normal breast tissue and can be transferred to the neonate during lactation. Mouse fibroblast
fetal cells have been shown to differentiate into mammary
epithelioid cells when exposed to lactation hormones in
vitro, and a functional mammary gland has been generated
from a single stem cell in a pregnancy mouse model. This
suggests that fetal progenitor cells play a role in breast
morphology and maternal milk supply. (Boddy, Fortunato,
Sayres, & Aktipis, 2015)
Pregnancy at older ages has been linked to risk for
ovarian cancer. Given the data that microchimeric cells in
parous women decline overtime after pregnancy, and that
ovarian cancer develops most commonly in postmenopausal women, fetal microchimerism may play a protective role in ovarian cancer as well. (Naik, Shrivastava,
Suryawanshi, & Gupta 2019)
Neurological Effects on the Mother
It was unknown whether fetal cells, which are capable of
crossing the placental barrier to enter maternal blood,
could also cross the blood-brain barrier and enter the
maternal brain. To determine if fetal cells could enter the
maternal brain during pregnancy, female wild‐type mice
were crossed with green mice.Their offspring ubiquitously expressing the enhanced green fluorescent protein.
Green mouse fetal cells were found in the maternal brain,
and quantitative real‐time PCR of genomic DNA for the
enhanced green fluorescent protein gene showed that
more fetal cells were present in the maternal brain for
weeks postpartum than on the day of birth. After an excitotoxic lesion to the brain, more fetal cells were detected
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in the injured region. For weeks postpartum, enhanced
green fluorescent protein‐positive green mouse fetal
cells in the maternal brain were found to adopt locations,
morphologies, and expression of immunohistochemical
markers indicative of astrocytes, neurons, oligodendrocyte, and macrophage-like cell types. The expression of
morphological and histochemical characteristics of these
cells was confirmed on the identification of fetal cells in
the maternal brain by Y chromosome fluorescence hybridization. The characterization of these cells that allow
them to cross both the placental and blood-brain barriers and to target the injured brain may improve selection
procedures for isolation of stem or progenitor cells for
brain repair by infusions. (Tan et al., 2005)
Several studies have found male DNA in human and maternal mouse brains, but the function of these cells is not
entirely known. One study found that fetal cell DNA in numerous regions of the maternal brain, even decades after
the woman had birthed a son, suggesting that fetal microchimerism in the human maternal brain may be long-lasting.
(Boddy, Fortunato, Sayres, & Aktipis, 2015) A team led by
autoimmunity researcher, J. Lee Nelson sought to discover
how leftover fetal cells affect the brain. They took samples
from autopsied brains of 59 women. Male DNA evidence
was found in the brains of 63% of the participants.The male
DNA was scattered across several brain regions. Studies
have hypothesized that the risk of Alzheimer’s disease increases with an increasing number of pregnancies, so the
team also examined the brains for signs of the disease. Of
the 59 women, 33 had Alzheimer’s disease. Compared to
healthy controls, fetal cells were found to be less common
in the brains of women who had Alzheimer’s disease. That
correlation suggests that the presence of fetal cells in the
maternal brains helps protect women against Alzheimer’s
disease. (PhillipsSep, et al. 2017)
Conclusion
The placenta is unique because it allows for intimate contact between maternal and fetal cells at the maternal-fetal interface throughout pregnancy. (Than et al.) During
pregnancy, the semi-allogeneic fetus is protected from
rejection by the maternal immune system. (Trowsdale and
Betz) It was hypothesized that the semi allogeneic fetus
could survive due to the regulation of the immunologic
interactions between mother and fetus. Such regulation
can be caused by functional suppression of the maternal
immune response or a lack of fetal antigen expression.
(Morelli et al.)
In the human placenta, fetal trophoblast cells do not
express MHC HLA-A and B molecules, which are responsible for allograft rejection in humans. (Chen et al.)
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Mixed hematopoietic chimerism, the state in which bone
marrow hematopoietic stem cells from two genetically
different animals coexist, remains the most robust tool
for tolerance induction. Unfortunately, bone marrow
or hematopoietic stem cell transplantation for patients
awaiting solid organ transplantation remains at highrisk, due to the dangers of graft-versus-host disease.
(Zavazava) Human embryonic stem cells express low
levels of (MHC)-I antigens and lack expression of MHC-II
antigens. These stem cells must engraft in the transplant
recipient, inducing tolerance to foreign cells, and reducing
the immune targeting of the transplant. Upon injection
into immunocompetent mice, human embryonic stem
cells are unable to produce an immune response. Human
embryonic stem cells may provide a potential tool for the
induction of immunotolerance. Further studies in human
embryonic stem cells immunobiology are warranted and
may reveal unique mechanisms that account for the immunological properties of human embryonic stem cells.
(Menendez et al.)
Fetal cells and DNA go beyond the womb and into
maternal blood and tissues during pregnancy and can last
long after birth. In some instances, fetal microchimerism
contributes to perturbations in maternal immunity that
may contribute to autoimmune diseases. In other cases,
these interactions seem to benefit long-term maternal
health by allowing fetal microchimerism cells to act as
allogeneic surveyors in her system. Fetal microchimerism has potential implications for the understanding of
women’s health and disease pathology postpartum. The
pregnant mother mshould never be viewed as merely an
incubator. Rather, microchimerism expands the biological
bonds that are established between the pregnant mother
and her fetus.
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Abstract
As an ever-progressing field of study, vaccine development has made headway over the past decades. By doing a comparative study
between development of the measles vaccine in the mid-20th century, and the ongoing development of the COVID-19 vaccine in
2020, many of the insights and advancements in the field can be easily highlighted. First, the knowledge and experience gained over
those decades has helped the vaccine developing process become more efficient.With more vaccines in production, or at least under
study, it is more likely to have a related precedent to build upon, as opposed to relying on a successful vaccine of some unrelated
disease. More to the point, different vaccine types have altered the way researchers attempt to formulate future vaccines. No longer
are inactivated and attenuated vaccines the only option; subunit vaccines, as well as innovative, (though yet to be proven), nucleic acid
vaccines are now additional approaches.These advancements have opened doors for researchers in their quest to fight diseases.This
paper will explore the advancements and their impact on the present-day COVID-19 vaccine development.
Keywords:Vaccine, Measles, COVID-19, mRNA
Advancements in Vaccine Development:
Measles vs. COVID-19
Though the majority of successful vaccines were developed in the 1900s, the challenge to develop vaccines still
exists today, with both known diseases, such as cancer,
as well as with novel infections that sweep the world.
Measles used to be a common childhood disease; one
which everyone contracted and with the majority of
patients recovering completely. It was practically inevitable until the late 1900s, when a measles vaccine was
introduced to the public. In the mid-1950s, after weeks of
trying, John Enders’s lab successfully isolated the measles
virus. Eventually, through implementation of routine measles vaccine—one dose at 12-15 months, and a second at
4-6 years—measles was successfully eradicated from the
U.S. in 2000, and from the Americas in 2016 (The College
of Physician of Philadelphia, n.d.). However, that milestone
of eliminating measles was not yet to be reached, as it was
another ten years from the isolation of the virus until the
measles vaccine officially debuted.
Contrastingly, it took Chinese researchers weeks to
sequence the genome of SARS-CoV-2, a feat way beyond
the simplicity of merely isolating the virus. Even more so,
a projected release date for a safe and effective COVID19 vaccine is only 12-18 months from the start of development, and one can only hope that the vaccine will eradicate the virus. Normally, vaccine development with FDA
approval can take anywhere from 5-10 years. Obviously,
vaccine technology has critically advanced in the decades
since the measles vaccine, thus allowing researchers to
expedite the vaccine development process for COVID19 and all future pandemics. This paper will explore some
of these advancements and their potential impact on the
COVID-19 vaccine development.
Methods
All of the information discussed in the paper was obtained through the PubMed database, as well as via
Google searches which led to government sites, like the

CDC and NIH, and also to known and established medical sciences related sites, like CHOP and The College of
Physicians of Philadelphia.
The majority of the amassed information pertained to the
techniques involved in developing both the measles vaccine
and the potential COVID-19 vaccine, so that I could compare and contrast the respective availability of resources.
One study explored in the paper included vaccine trial
studies in which the efficacy of various measles vaccines
were tested either alone, or in a series with other forms
of developing measles vaccines. At a designated interval
after each trial, measles titers were measured and eventually, the most effective vaccine was sought out.
There are currently over one hundred biotechnology
companies and universities developing vaccine candidates
for COVID-19. For the vaccine studies that are not yet
ready for human test trials, i.e. majority of the COVID-19
studies, this paper analyzed selected studies which elaborated on the numerous approaches towards an effective
COVID-19 vaccine.
Discussion
An Overview of Vaccines
How vaccines work
The purpose of a vaccine is to trigger the immune system
to stimulate an initial immune response and ultimately
create a cellular memory mechanism to fight future attacks by the pathogen. This way, when the body is exposed to the actual disease in the future, the body will
produce an immediate secondary immune response and
not a primary response (Clem, 2011). Secondary immune
responses are quicker and more specific, and are therefore better than a primary immune response.
Classically, vaccines are created by deactivating or attenuating the virulent part of the pathogen, while leaving the
antigenic portion of the pathogen intact so that the vaccine can induce an immune response without causing the
disease itself (The College of Physicians of Philadelphia,
2018).When the body detects a foreign antigen, the innate
immune system goes into action first (Clem, 2011). The
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innate system includes non-specific white blood cells (i.e.,
macrophages and natural killer cells), which can either destroy the invader or process the pathogen and present its
antigen to aid in the adaptive immune response. Both the
humoral and cell-mediated immune responses are part
of the adaptive immune response. The humoral response
consists of B-cells, which detect the foreign antigen and
then self-mutate to find the antibody that best fits the
antigen. After that is successfully accomplished, the B-cell
that is able to produce the most effective neutralizing
antibodies replicates and becomes either plasma cells,
which secrete antibodies to help fight the current infection, or it creates memory B-cells specific to that antigen,
so that upon future infection the body will have an antibody that targets and destroys the specific disease pathogens. The cell-mediated immune response contains two
types of cells, T-killer and T-helper cells, which are either
activated by major histocompatibility complex I (MHC I)
or major histocompatibility complex II (MHC II). MHC
proteins are expressed on the surface of all bodily cells
to signal that the cells belong in the body. However, when
the cells become infected with a pathogen the MHC will
take the processed antigen and present it on the surface
of the cell, so that the T cells of the cell-mediated immune
system can respond. T-killer cells recognize the antigen
presented by MHC I molecules and subsequently advance
to kill the invading cell. On the other hand, T-helper cells
recognize the antigen presented by MHC II molecules,
and T-helper cells aid in the activation of B cells as well
as T-killer cells. Regardless of their function, either T cell
can replicate and form T-memory cells in preparation of
future infections (Clem, 2011). In all, the job of a vaccine is
to prime the body for a future encounter with a specific
pathogenic agent.
Stages of Vaccine Production
Before any vaccine can be mass produced for public use,
it must go through a series of developmental phases to
assess first and foremost its safety, in addition to the vaccine’s efficacy, required dosage and dose frequency, and
screenings for any harmful side effects (The College of
Physicians of Philadelphia, 2018). Prior to these phases
though, researchers study the specific disease and attempt to identify its immunogenic parts. Once that has
been done, researchers can either isolate the antigenic
portion, or inactivate the virulent part, depending on
what type of vaccine they propose to create.
Following those preliminary steps, the candidate vaccine
can then enter the preclinical phase of study. In this stage,
researchers test the vaccine safety and immunogenicity
on animals (The College of Physicians of Philadelphia,
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2018). Also during this preclinical stage, researchers may
conduct what are known as challenge trials. In these tests,
researchers inject their candidate vaccine into the lab animals or human volunteers, wait an amount of time so
that the vaccine can elicit an immune response and create
memory cells, and then finally, they inject the targeted
virus into the subjects to determine if the vaccine can
do its job. Based on the challenge trial results, researchers will adjust their vaccine development accordingly.
During this phase, there may be a bit of trial and error
in determining a safe starting dose, i.e. how many viral
particles are needed to elicit an immune reaction, and
method of delivery for human subjects of the next phase
(The College of Physicians of Philadelphia, 2018). For the
COVID-19 mRNA vaccine trials conducted by Moderna
and the NIAID, three trial groups have been set up each
with a different dosage. One group is testing the low
dose of 25mcg, a second group is receiving the midrage
amount of 100mcg, and the third group is receiving the
highest dose, 250mcg (National Institute for Allergy and
Infectious Disease [NIAID], 2020).
In order to advance from the preclinical stage to the
clinical phases, the research group must submit an investigational new drug (IND) application to the FDA for approval to further their studies (The College of Physicians
of Philadelphia, 2018). Once the researchers receive
authorization, they can proceed to phase I clinical trials.
At this juncture, researchers experiment with human
subjects once again to test safety and immunogenicity
of the proposed vaccine. This step starts with healthy
adult subjects and if the vaccine is intended for younger
or older age groups, the trials gradually trend towards
the desired group. During this phase, researchers may
conduct human challenge trials as well (The College of
Physicians of Philadelphia, 2018). With regard to COVID19, Moderna has reported that after two doses of their
potential mRNA COVID-19 vaccine, participants in the
low and mid groups have expressed immunity at or above
the level in which someone who was naturally infected
would have.This seems to be a promising result for phase
I trials, especially since it seems that once someone contracts COVID-19 they do not get it again, and so the natural amount of antibodies should be sufficient for vaccine
induced protection (CBS News, 2020).
After successful phase I trials, the vaccine can move on
to phase II clinical trials. Here, researchers study a larger
test group including a control group and the main point
of this phase is to further characterize dosage, frequency
of immunization, and method of delivery (The College of
Physicians of Philadelphia, 2018). In this phase, the clinical
studies will also ascertain whether the vaccine shows any
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efficacy. Safety of the vaccine is monitored as well.
Next, there are phase III clinical trials. This is where
the potential vaccine is determined to be effective by
recruiting hundreds or thousands of volunteers to help
quantitate how effective the vaccine is in a large cohort
(The College of Physicians of Philadelphia, 2018). The
large subject group also allows for the detection of rare
side effects. During this phase, vaccine safety and dosage
are still monitored for necessary corrections. Vaccines
are never 100% effective. Measle vaccine is thought to be
about 85% effective.Therefore, phase III trials must assess
vaccine effectiveness.
Finally, after the vaccine has successfully passed through
all phases of clinical testing, the researchers can submit
a biologics license application to the FDA for licensure
of their candidate vaccine (The College of Physicians of
Philadelphia, 2018). If the FDA approves, and the CDC
subsequently recommends this vaccine for routine administration, the researchers will be able to manufacture
their vaccine and enable mass population immunization.
At this point, researchers can conduct an optional phase
IV clinical trial to further monitor the vaccine’s safety and
efficacy (The College of Physicians of Philadelphia, 2018).
Studies can also be done to learn if the vaccine has potential for any alternate uses (i.e. other than for protection of
the targeted pathogen).
Post licensure, the FDA and CDC continue to monitor
the vaccine (The College of Physicians of Philadelphia,
2018). In 1990, the FDA and CDC established the vaccine adverse event reporting system (VAERS). The VAERS
allows for anyone to report adverse side effects, which
seem to be caused by a particular vaccine.The CDC then
analyzes all of the input data to determine several conclusions. Among those conclusions are whether a new
adverse side effect has indeed been detected, and whether certain health conditions place a patient at a greater
risk of developing an adverse side effect. Also in 1990, the
CDC established the vaccine safety datalink (VSD). This
system provides access to numerous databases listing
which vaccines were given to a particular patient on the
reported date. The VSD conducts vaccine safety studies
based on questions raised in medical literature or reports
from the VAERS. In addition, the VSD monitors the safety
of new vaccines.
Advances in Vaccine Development
In the sixty years since the development of the measles
vaccine, the technologies used have improved as well as
increased. For example, while Enders, Hilleman, and all the
other researchers of that time were experimenting with
either inactivated (dead virus) or live-attenuated vaccines,

researchers of today can work with a greater variety of
vaccine types ranging from pathogen subunit vaccines
to nucleic acid vaccines (NIAID, n.d.). Both forms of the
newer vaccine methods aim at inoculating with only the
antigenic portion of the microbe as opposed to injecting
the whole pathogen, which is what is done with inactivated and attenuated vaccines. In an inactivated vaccine, the
entire pathogen is killed and then subsequently administered to the patient (Clem, 2011).Attenuated vaccines, on
the other hand, leave the pathogen partially alive, and then
upon administration, induce a stronger immune response
than inactivated vaccines. However, because the attenuated vaccine is slightly live, it does present a greater risk to
the immunocompromised community (Clem, 2011). The
challenge in designing inactivated viruses or attenuated
viral particles is that there is no set formula for how to
kill or attenuate the virus. Each virus is different. That is
why it can take months, or even years, to generate an
effective candidate vaccine.
Over the past decade, new innovative technologies
have been instituted to develop effective vaccines. Subunit
vaccines are one example where a mere pathogenic
unit—a protein, or sugars on the microbe’s outer coat—
are administered into the patient to elicit an antibody response, thus allowing a person to attain immunity (NIAID,
n.d.). However, subunits vaccines are often not effective
enough on their own and require an adjuvant to enhance
their immune response (NIAID, n.d.). While historically
composed of only aluminum salts, adjuvants today come
in many more varieties like MF59 (oil in water emulsion
composed of scalene), CpG 1018 (cytosine phosphoguanine, a synthetic form of DNA that mimics bacterial and
viral genetic material), and others (Centers for Disease
Control and Prevention [CDC], n.d.-a). All of these adjuvants serve to aid in the immunogenicity of the vaccine,
hopefully providing a stronger response and longer lasting
protection. The inclusion of adjuvants in vaccine formulation requires researchers to carefully assess where these
added compounds elicit unwanted side effects.
Contrary to the aforementioned vaccines, nucleic acid
vaccines do not inject any physical part of the pathogen
into the body. Rather, these vaccines inject a lab synthesized DNA or mRNA sequence that codes for one or
more antigenic proteins (NIAID, n.d.). Once inside the
body, the nucleic acid is taken up by the virally targeted
cells and instructs those cells to synthesize and secrete
the desired protein. Only then, after the protein is in the
body, will the body generate an immune response and
acquire antibodies to that specific disease (NIAID, n.d.).
With this method of inoculation, the body itself is an integral part in creating the immunogenic portion of the
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vaccine. An mRNA strand alone will do nothing. However,
when acted upon in vivo, the body completes the last step
in the vaccine synthesis, creating the protein to which it
needs to attain immunity.
Nucleic acid vaccines have a quicker production time
than traditional whole-pathogen vaccines (NIAID, n.d.).
This is because a pathogenic specimen does not need to
be grown for the creation of the vaccine (Park, 2020).
Under normal circumstances, the microbe can take a few
months to grow to the desired quantity.Thus, nucleic acid
vaccines may be favored over whole-pathogen vaccines,
especially in situations where time is a consideration.
Additionally, though nucleic acid vaccines can be injected directly into the body, another vaccine delivery mode
has developed over the years. Instead of injecting the
DNA or mRNA directly into the body, options now exist
to use a vector for introduction of the vaccine (NIAID,
n.d.). A vector is a small particle that acts as a vehicle for
vaccine delivery. A viral vector, such as adeno-associated
virus, can incorporate the vaccine’s genetic material by
replacing some of its viral genes with the vaccine’s desired
sequence (Robert-Guroff, 2007). Studies have proven
that viral vector administration is both safe and effective,
though the quantitative values vary amongst the viruses
(Robert-Guroff, 2007). There are also non-viral vectors,
for example, liposomes and lipid nanoparticles (LNP),
which can be used to deliver nucleic acid vaccines as well.
One advantage of non-viral vectors, is that they are less
immunogenic than their viral counterparts. With both
forms of vectors, however, the target site in the body can
be specified with the help of specific receptor molecules.
Like this, researchers can guide and control the vector’s
integration and vaccine delivery within the body.
The Measles Vaccine
In 1954, just a year before the introduction of the inactivated polio vaccine, Thomas Peebles, MD, working
in John Enders’s lab at Boston Children’s Hospital, succeeded in isolating the measles virus from the blood of
13-year-old David Edmonston (The College of Physicians
of Philadelphia, n.d.). After isolating the virus, Enders’s goal
was to formulate a vaccine. It took until 1960 to prove
that the isolated strain could be formulated into an effective attenuated measles vaccine; it just needed additional tweaking to attenuate it further (Hendriks & Blume,
2013). Wanting other researchers to also attempt to
create a measles vaccine, Enders shared the Edmonston
strain. Most researchers of that time were inspired by the
recent success of the polio vaccine, and tried to mimic
that development in their construction of a measles vaccine (Hendriks & Blume, 2013). In countries where Salk’s
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inactivated polio vaccine (IPV) took credit for controlling
the disease, like in Sweden and Netherlands, researchers
worked at creating an effective inactivated measles vaccine. In other countries, such as the U.S. and U.K., where
Sabin’s recently released oral polio vaccine (OPV) was
used to combat polio, researchers preferred to attempt
an attenuated version of the measles vaccine.
Regardless of the method chosen, subsequent patient
trials proved the attenuated measles vaccine to be more
effective than the inactive vaccine (Hendriks & Blume,
2013). Some studies created several groups, each receiving
a different vaccine regimen.While one group received only
inactivated doses, another group received some inactive
doses followed by a live dose, while a third group received
one dose of the attenuated vaccine.Though several studies
tried this method, all pointed to the same results: the inactivated vaccine initiated a lesser immune response and it
was not known how long those antibody titers would last.
The attenuated vaccine however, generated a substantial
response, making it the vaccine of choice for elimination of
measles (Hendriks & Blume, 2013).
It was in 1963 that John Enders and his associates received FDA licensure for their live-attenuated measles
vaccine and mass measles vaccination began (CDC, n.d.-b).
However, the vaccine was not attenuated enough and thus
required coadministration of gamma globulins to prevent
children from developing fever and a rash following inoculation (Hendriks & Blume, 2013). Approximately five years
later, in 1968, Maurice Hilleman, working at Merck labs,
developed Moraten—more attenuated Enders—which
eliminated the need to inject the vaccine along with
gamma globulins (Hendriks & Blume, 2013). Since licensure, Moraten, a descendant of the original Edmonston
strain, has been the only measles vaccine administered in
the U.S. (The College of Physicians of Philadelphia, n.d.).
Even today, when the monovalent vaccine is no longer on
the market, the Edmonston strain is still used to create
the measles component of the MMR vaccine routinely
given to children (CDC, n.d.-c; The College of Physicians
of Philadelphia, n.d.).
Potential COVID-19 Vaccines
The COVID-19 pandemic, rampant now in early 2020, and
possibly beyond, has killed hundreds of thousands worldwide in a matter of months (World Health Organization
[WHO], 2020a). As of June 1, 2020, the WHO reports
that there have been 371,166 deaths globally. Researchers
all over the world are racing to develop a vaccine to combat the virus and stop the ever-rising death toll.
Luckily, there is an extensive history of vaccine development, allowing researchers to base their COVID-19
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vaccine developments on the experiences and accumulated information from the past. More so, unlike the
measles vaccine development, COVID-19 vaccine development has a related precedent. Coronaviruses SARS
(severe acute respiratory syndrome) and MERS (Middle
East respiratory syndrome), while claiming no marketed
vaccine, have documented research and experimentation
on vaccine development. Current researchers are using
these semi-constructed vaccines and adapting them for
further development towards the current strain of coronavirus, SARS-CoV-2. However, regardless of the starting
inspiration, all potential COVID-19 vaccines will have to
go through all phases of vaccine production before being
offered on the market.
As of June 15, 2020, there are scores of COVID-19
vaccine candidates starting the preclinical stage or clinical
studies phase of vaccine development. These attempts
include vaccine designs containing mRNA, DNA plasmid,
protein subunit, non-replicating viral vectors, or inactivated COVID-19 viral particles (WHO, 2020b). Just the
breadth of these alone shows how many more resources and technologies are available now versus the 1960s,
when the measles vaccine was in development.
The more recent vaccine technologies, namely nucleic
acid vaccines, demonstrates how the updated and increased methods are truly playing a role in COVID-19
vaccine development. In this paper, I would like to highlight one specific mRNA candidate vaccine. (An LNPencapsulated mRNA vaccine, co-developed by Moderna
and the NIAID.) As an RNA virus with RNA-dependent
RNA polymerase, SARS-CoV-2 replicates RNA from an
RNA template as opposed to transcribing RNA from
a DNA template (using DNA-dependent RNA polymerase). This can result in high levels of RNA present
within the virus (Wang, et al., 2020). Thus, using RNA
as a method of priming the body towards an RNA-rich
pathogen makes sense in the overall picture of vaccine
development (Wang, et al., 2020).
Also, when developing this RNA vaccine, researchers
opted to use the spike protein as the vaccine’s target
sequence. Though there are other targetable proteins
on SARS-CoV-2, such as the envelope, nucleocapsid, and
membrane proteins, the spike (S) protein is the subunit
of the virus that binds with the body’s ACE2 (angiotensin converting enzyme 2) receptor, and therefore the S
protein comes across as a more effective vaccine target
(Wang, et al., 2020; Zhang, et al., 2020). Figure 1 shows
the location of all four proteins on the virus as well as the
binding of the spike protein to the ACE2 receptor.
After injection of the vaccine which contains the mRNA
sequence for the S protein, a cell in the body should

Figure 1 Proteins and Binding Site of SARS-CoV-2 Source. Zhang, et al., 2020

translate the genetic code into the functional S protein that
can be secreted to allow the immune system to respond.
Figure 2 depicts the process by which this COVID-19
mRNA vaccine ultimately yields memory cells in the body.
As of May 30, 2020, this candidate vaccine has advanced
to phase 2 clinical trials (WHO, 2020b). Though mRNA
vaccines have great theoretical potential, there are currently none on the market. However, this mRNA vaccine may
successfully proceed through all phases of vaccine development, and should that happen, the Moderna/NIAID mRNA
vaccine will be the first of its kind on the market

Figure 2 COVID-19 mRNA Vaccine Response

Conclusion
For the ongoing developments for a COVID-19 vaccine,
it is unknown whether the vaccine’s immunity will be lifelong. Currently, it is unknown if natural immunity is long
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lasting, though whatever that case is, I would hypothesize
that the artificially induced immunity would follow suit. In
my opinion, though vaccine type does play a role in duration of immunity (as illustrated in measles vaccine development), a larger portion depends upon the properties
of the virus itself. Since that is yet to be determined, it
is too soon to draw a conclusion with regards to any
COVID-19 vaccine. Also, because all vaccines are at most
in early phase II clinical trials, one cannot determine
which candidate vaccine will be more effective than the
others. Currently, the mRNA vaccine from Moderna is on
a road to success, though results are still too incipient to
make a final decision.
Finally, although the essence of a vaccine is unchanged—
the goal to elicit an effective immune response still drives
development—advancements in vaccines development
as well as accumulation of scientific knowledge have
broadened our minds when attempting to develop a new
vaccine. We now have more options, some of them with
more precise targeting than ever, and it is the hope that
with our newfound tools, we can go on to create better
vaccines and continue saving lives.
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Kidney Stones
Nephrolithiasis is the process of the aggregation of certain
minerals in the urine due to super saturation, thereby causing the formation of kidney stones. What complicates matters, is, that there is no single cause that can be attributed
to Nephrolithiasis. In fact, as research progresses, an abundance of causative agents are being linked. Outlined below
is a comprehensive summary of the occurrence, recurrence,
treatment and causative factors of kidney stones.
Kidney stones usually form in the renal pelvis and pass
through the urine unnoticed. However, at times these stones
can grow up to several centimeters. These large stones can
cause blockages in different locations in the urinary system
and can be very painful. Stones that do not obstruct passages
cause no symptoms besides hematuria (blood in the urine).
Passing a stone causes renal colic. The pain intensifies as the
stone progresses downward. Pain is felt as the stone passes
through the ureter. When a stone reaches the uretero-vesicular junction it may cause dysuria and urinary frequency.
Unfortunately, colic is felt regardless of body position and
motion. Stone size is a big determinant of treatment option.
Stones smaller than five mm in diameter have a high possibility of passing.Those that are between five to seven mm have
a 50% chance of passage. Stones that are greater than seven
mm almost always require medical intervention (Coe, Evan
and Worcester, 2005).
The prevalence of kidney stones is dependent on many
different factors, including gender. About 5% of American
women will develop a kidney stone at some point in their
life. By contrast, about 12% of American men are likely to
develop a stone. The peak age in men is 30 years old. In
women stones are most common between the ages of 35
and 55 with peaks at both 35 and 55. Previous stone formers
have a 50% chance of forming a second stone within five to
seven years of the first.(Malvinder,2004).
In recent years there has been an increase in the incidence of kidney stones.This has been associated with many
different factors. For example; BMI, race, ethnicity and region
of residence are strongly associated with stone formation.A
seasonal disparity is also seen. Men have high urinary calcium
oxalate saturation during the summer and women during
the early winter. High levels of calcium oxalate in the urine
are prone to solidify into stones. (Malvinder, 2004)
In the majority of cases, stones are passed without
medical intervention. Even so, physicians will still prescribe strong pain killers to combat the typical pain that is
experienced. In addition, anti-nausea medications as well
as antibiotics may also be prescribed. Medicinal treatment
is also an option.Alpha blockers may be prescribed, which
relax the muscles of the ureter, allowing the stone to pass
thereby mitigating the pain. If a stone is too large to pass,

it may require a medical procedure to either break it up
so that it can pass, or to completely remove it. In some
situations, although the stone is small, it still requires
medical intervention to remove it if it has lodged itself
somewhere between the kidney and the urethra; usually
in the ureters (Frassetto & Kohlstadt, 2011).
One method of treatment is using sound waves to break
up stones. This is done through a procedure known as extracorporeal shock wave Lithotripsy (ESWL). ESWL shatters stones into very small pieces by use of shock (sound)
waves that that create powerful vibrations. These stones
can now pass more easily in the urine. This procedure is
done under sedation or light anesthesia. It lasts around 45
minutes to an hour. Possible side effects include bruising on
the back or abdomen and bleeding around the kidney and
other nearby organs (Mayo Clinic, 2020).
Another method involves using a scope to remove
stones. This is often done when the stones are smaller
but have been lodged and can no longer pass on their
own. The physician will pass a ureteroscope equipped
with a camera through the urethra to the ureter. The
stone will then be removed or broken into pieces. This is
done under general anesthesia. Often a stent is placed in
the ureter to relieve some of the swelling.The stent is left
inside the ureter for a few days following the ureteroscopy to allow for further healing (Mayo Clinic, 2020).
When all other therapeutic options have been exhausted, a surgical procedure will be necessary. Smaller stones
that did not respond to the aforementioned treatments
and larger stones require surgery.This procedure is called
percutaneous nephrolithotomy. It is the process of removing the kidney stone using small telescopes and other
tools that are inserted through a small incision in the patient’s back. The patient will be under general anesthesia
at the time of the surgery and will remain hospitalized for
a few days to recover (Mayo Clinic, 2020)
The Composition of Kidney Stones
Kidney stones are composed of different minerals that are
found in urine. Calcium oxalate and Calcium phosphate
comprise the composition of approximately 80% of stones.
19% are composed of struvite and uric acid. The remaining one percent are composed of cystine or ammonium
acid urate. Kidney stones arise from the unwanted phase
change of these substances from the liquid state to the
solid state. The substances listed above exist in the urine
as dissolved salts. However, at times, these salts can become super saturated. When a substance is super saturated no more of this solute can dissolve in solution and it
will consequently precipitate out as a solid, forming hard
granules. Super saturation is approximated by the ratio of
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a substance’s concentration in the urine to its solubility.
At super saturation levels less than one, crystals of a substance will dissolve. But at super saturation levels greater
than one, crystals can grow and form. The composition of
stones correlates with the super saturation values from
the urine produced (Coe, Evan and Worcester, 2005).
Calcium Oxalate Stones:
How/Why do they form?
The vast majority of Calcium Oxalate stone formers do
not suffer from a systemic disease and are therefore described as idiopathic stone formers. In other words, they
form stones spontaneously; the cause is unknown. The
commonality found in many CaOx stone formers are
disorders of calcium metabolism, resulting in abnormal
levels of calcium. In addition, low urine citrate levels have
been shown to permit CaOx stones. This is because urine
citrate binds urine calcium in a soluble calcium citrate
complex which reduces calcium super saturation (Coe,
date unknown). However, when levels are low, calcium
levels rise and ultimately stones may form. Furthermore,
high urine uric acid excretion in men and women (above
750-800mg/d) is associated with idiopathic CaOx stones
as well. These dissolved uric acid salts appear to reduce
the solubility of calcium oxalate thereby promoting the
formation of stones.
Disorders of Calcium metabolism range in severity
and in the scope of their consequences. The most common cause of calcium metabolic irregularities is Primary
Hyperparathyroidism, a systemic disorder in which an
excess of Parathyroid hormone causes increased levels
of calcium in the blood. In a healthy body, the kidneys
lose calcium in the urine every day. In response, calcium receptors on the surface of the parathyroid glands
cause the parathyroid glands to release PTH, a hormone
that increases blood calcium levels. However, because of
abnormalities, there is excess calcium and less reabsorption by the kidney leading to stone formation (Primary
hyperparathyroidism).(Coe, date unknown). High calcium
levels in the urine are also found in people with Idiopathic
Hypercalciuria. Hypercalciuria results in increased intestinal absorption of calcium. High intestinal calcium absorption raises the amount of filtered calcium presented to
the renal tubules in the kidney. It can also result in the
reduction of the reabsorption of the renal tubules. Both
of these mechanisms can increase the urinary calcium
level. In certain instances, the excess calcium may solidify.
Other diseases linked to Hypercalciuria are of genetic
natures. Dent disease is an X-lined hypercalciuric disorder found almost exclusively in males. In affected individuals, kidney problems result from damage to proximal
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tubules. The disorder is due to mutations in the gene
(CLCN5) that codes for the voltage-gated endosomal
chloride channel 5 (Heller & Pak 2002). Another type of
genetic disorder is Barter Syndrome – specifically types
I and II. In this syndrome renal calcifications are found
in the cortex and the medulla. These calcifications come
from problems in transport that reduce the capacity of
the thick ascending limb of the kidney tubules which
consequently reduces salt and calcium reabsorption. This
results in a higher salt and calcium concentration leading
to hypercalciuria (Heller & Pak 2002).
High Oxalate concentrations also lead to the formation
of stones. Hyperoxaluria occurs when there is too much
oxalate in one’s urine. Hyperoxaluria can be caused by
inherited-genetic disorders, because of intestinal disease
or because of a diet of oxalate rich foods (Mayo Clinic,
2019). Primary hyperoxaluria is an autosomal recessive
disorder caused by the overproduction of oxalate. This
overproduction leads to calcium oxalate precipitation in
the kidney and eventually to end stage renal disease (Ther,
2018). Enteric hyperoxaluria is caused by an increase in
absorption of oxalate from foods. Several intestinal diseases including Crohn’s disease and irritable bowel syndrome increase the absorption of oxalate from foods.
This in turn increases the amount of oxalate excreted
from the urine (Mayo Clinic, 2019). There are also many
oxalate rich foods that can contribute to an overabundance of oxalate in the urine. These foods include beans,
beer, beets, berries, chocolate, coffee, cranberries, dark
green vegetables, nuts, oranges, sweet potatoes and tea.
It has been proven that avoiding high oxalate foods can
substantially help lower oxalate levels (Thomson, Husney,
Romito, & Vachharajani, 2019)
Treatment
A new and developing form of treatment for CaOx
stones is using a drug called Stiripentol. Stiripoentol is
an antieplipetic drug used to treat children affected by
Dravet syndrome. It has been shown to inhibit neuronal lactate dehydrogenase 5 enzyme. This isoenzyme is
the last step in hepatic oxalate production and therefore
can potentially reduce hepatic oxalate production and
urine oxalate excretion. A young child affected by type
1 hyperoxaluria received this drug for several weeks, and
her urine oxalate excretion decreased 66% (Dudal…
Letavernier, 2019). Studies are still being conducted to
ascertain the long term affects and the possibly harmful
side effects that are accompanied by this drug.
In addition, a study was performed to see if there was an
association between gut microbiome alterations and renal
calcium oxalate stones. It was found that short chain fatty
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acids may prevent stone formation.The research proposed
that by regulating gut microbiome composition using short
chain fatty acids, it may be possible to prevent kidney stones.
Microbiome analysis was performed on 160 Chinese individuals some with recurring stones, some with one incidence of stone formation, and some non- stone formers.
The results identified that recurrent stone formers and
single time stone formers both exhibited higher fecal microbial diversity than the controls.While the mechanism of
using short chain fatty acids to regulate gut microbiome is
still unknown, the research has shown promising signs that
this may be a cogent method to preventing and treating
kidney stones (Wang…Li, 2019).
Recurrence
While there are many methods of treatment for kidney
stones already in practice and many more in the development stages, recurrence of kidney stones reduces the
effectiveness of many therapeutic methods. Following an
initial stone event, the spontaneous five-year recurrence
rate is 35 to 50 percent. As such it is imperative to institute a treatment plan that will change the whole nature of
the kidney’s function in order to be sure that renal calculi
will not form yet again.
One such method is to alter the pH of the urine.
Recently, the administration of potassium citrate has been
considered as a therapeutic and preventative measure
specifically for calcium oxalate nephrolithiasis. In a study
conducted last year patients who underwent urolithiasis
surgery were divided into subgroups. One subgroup in
each category were given potassium citrate 40 mEq per
day orally. The results were conclusive. The stone recurrence rate for the treatment subgroup was 1.72%, while
it was 25.86% in the control subgroup.The difference was
statistically significant. The treatment works because citrate inhibits the aggregation of calcium oxalate crystals
by increasing the solubility by a mechanism mentioned
above. It also inhibits urinary calcium stone formation due
to change in urine pH. There are many other methods
of prevention as well (Hosseini, Alipour, Omidbakhsh, and
Ashraf, 2019).
Calcium Phosphate Stones:
Why/how do they form?
Calcium phosphate stones are not as common as calcium
oxalate stones. Calcium phosphate stones may be caused
by hyperparathyroidism, renal tubular acidosis, and urinary
tract infections. Calcium Phosphate is present in urinary
stones as either apatite, or brushite. What drives the development of brushite versus apatite stones is unknown.
In patients of calcium phosphate stones, plugs of apatite

fill the lumens of the terminal collecting duct. Epithelial
cells are damaged and destroyed and around affected tubules, the interstitial area is inflamed and scarred. Besides
for being hypercalciuric because of idiopathic hypercalciuria Calcium phosphate stone formers have a distinctive
feature- their urine has a higher pH. This favors calcium
phosphate crystallization by increasing the abundance of
urine mono-hydrogen phosphate, the ion that combines
with calcium. Urine pH rises progressively with increasing
calcium phosphate percentage in stones.The mechanism of
increased urinary pH in Calcium phosphate stone formers
is unknown (Frassetto & Kohlstadt, 2011).
Remarkably, Pregnant women have a double than average chance to form calcium phosphate stones compared
with age-matched nonpregnant women. They are two to
three times more likely to have calcium phosphate stones
over oxalate stones. This can be attributed to the fact
that women have an increased glomerular filtration rate
and have higher urinary calcium during pregnancy. In late
pregnancy, the urine tends to have a higher pH which can
predispose women to calcium phosphate stones. Kidney
stones during pregnancy increase the risk of urinary tract
infections. Also, pregnant women with renal colic have a
50% higher risk of early delivery compared to women who
do not have kidney stones (Frassetto & Kohlstadt, 2011).
Treatment
Thiazide diuretics such as hydrochlorothiazide can help
the kidney absorb more calcium, leaving less of it in the
urine where it can form stones. Thiazide diuretics are a
type of diuretic drug. Diuretic drugs increase urine flow.
They act directly on the kidney and promote urine flow
by inhibiting the sodium/chloride cotransporter located
in the distal convoluted tubule of a nephron. Thiazide decreases sodium reabsorption which increases fluid loss in
urine. Potassium citrate is another medication that can
bind to calcium and help keep calcium phosphate in the
urine from forming stones (Mayo Clinic, 2019).
Brushite stones (calcium phosphate stones) are among
the hardest to break, which, combined with the large size
of the stones, results in poor outcomes with shock wave
lithotripsy (SWL). In an experiment conducted, several
shock waves were needed to break brushite stones. It
was also discovered that pure brushite stones are harder to break than brushite stones that contain a mixed
composition. Shock wave lithotripsy is not the optimal
treatment for brushite stones. However, invasive imaging
is needed to determine a stones composition and so it
remains a challenge in deciding the best treatment plan
(Williams… McAteer, 2012).
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Uric Acid Stones:
Why/how do they form?
Uric acid stones form because of abnormally low-acidic
pH of urine a pH below 5.5. low urinary volume and hyperuricosuria are also associated with the formation of
uric acid stones, (Van Hattum, de Bie, and Somani, 2019).
Low urine pH can be partly ascribed to low ammonia
excretion. Low urinary pH and uric acid stones are common in patients with an assortment of disorders. Patients
with high BMI, gout, diabetes mellitus, and the metabolic
syndrome, may have reduced renal ammonia excretion.
The reduced ammonia excretion may be due to insulin
resistance which is common in these diseases. In addition, urinary pH is inversely proportional to body weight.
As body mass increases, urinary pH falls and becomes
more acidic. Chronic diarrhea also lowers urinary pH and
causes uric acid stones. Uric acid gravel can obstruct
ureters and produce acute anuric renal failure. Uric acid
stones can fill the entire renal collecting system. Uric acid
pebbles and stones are often orange or red, as they have
absorbed uricine, a pigment of bilirubin breakdown. (Van
Hattum, de Bie, and Somani, 2019).

excretion of the dibasic amino acids, including cystine.
Because of the high super saturation of cystine, stones
form (Coe, Evan and Worcester, 2005).
Treatment
Cystine stones can be removed in the same manner as
other kidney stones. They can be removed by nephrolithotomy, a procedure where an instrument is inserted
through the skin and into the kidney to either take the
stone out or break it apart. Ureteroscopy is another
method. It involves sticking a tiny instrument into the
bladder and then up the ureter to remove the stone. A
third method, is Extracorporeal shock wave lithotripsy
(ESWL). This is a procedure that uses shock waves to
break up larger stones into smaller pieces so that they
are passable.This method however, does not work as well
for cystine stones as it does on other types of stones
(Frassetto & Kohlstadt, 2011).

Treatment/Recurrence
Prevention and even dissolution depend on the three
main components of uric acid stone formation; an increase of urinary volume, prevention of hyperuricosuria
and increase in urinary pH. By increasing daily fluid intake
the urinary volume increases thereby decreasing the concentration of uric acid. There are different medications
that can increase the pH of the urine thereby minimizing
the risk of supersaturation and consequently stone recurrences. Medications such as potassium citrate, sodium
citrate and sodium bicarbonate have been proven to increase the pH of urine (Van Hattum, de Bie, and Somani,
2019). Allopurinol is not usually required; however it can
be used if one of the above three medications does not
suffice (Coe, Evan, and Worcester, 2011).

Recurrence
Being that Cystinuria is a lifelong condition, the recurrence
of cystine stones is quite high. To combat this, the patient
must be sure that the super saturation concentration of
cystine is below one. To begin with, patients try to attain
a urine volume of three to five liters a day which can
dissolve the cystine that is excreted. Some also require
a medication to raise the pH of the urine. In addition,
reduction of sodium and protein intake reduces cystine
excretion in the urine. It is for this reason that attention
to diet is an essential part of the treatment process. If
increasing fluid levels and lowering the pH of the urine
by diet does not work, there are medications that can
be used. D-penicillamine, α- mercaptopropionylglycine,
or captopril, all form soluble heterodimers with cysteine
and so they can be used. However, these medications may
have severe side effects such as loss of taste, fever and
proteinuria, and so the former mentioned methods are
more desirable (National Kidney Foundation, 2016).

Cystine Stones:
How/ why do they form?
Cystine stones are the most rare form of kidney stones.
They constitute less than 1% of urinary tract stones.
Cystine stones are often caused by Cystinuria. About 1
in 7000 people worldwide have cystinuria. Most people
with cystinuria get their first stones in their twenties or
thirties, but 30% get them in their teens. According to
some research, 8-10% of kidney stones in children are
cystine stones. Cystinuria is a genetic condition causing
mutations in renal epithelial cell transporters that result
in reduced reabsorption. This leads to an increased urine

The Effect of the Seasons
When attempting to connect seasonal changes with occurrence of kidney stones a huge number of factors must be
taken into account.There have been many studies done on
this topic and the results have been confusing. In one study,
research has shown no difference in urine volume from the
summer to the winter. In another study, during the winter
months when vitamin D intake is limited, urinary calcium
excretion was found to be much higher.This being the case,
it would seem that kidney stones would more likely form
in the winter (Attalla, De, Sarkissian, and Monga, 2018) .
Dietary patterns may fluctuate as well with the changing
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seasons. With a reliance on packaged and processed food
during the winter, urinary sodium may be increased. With
an increase in urinary sodium, urinary calcium will subsequently increase as well. Also, weight fluctuations may
complicate the analysis further.With less opportunities for
physical activity during the winter months, coupled with
the indulgent eating during the holiday season, urinary calcium may be increased. Also, lower levels of vitamin D have
been associated with weight gain (Attalla, De, Sarkissian,
and Monga, 2018) . All these factors point to the winter
months having a high propensity for stone formation.
In contrast to the research above,William Haley, a Mayo
Clinic nephrologist, has found that heat, humidity, and lack
of proper hydration all lead to a higher prevalence of kidney stones in the summer. In the summer there is a greater likelihood of dehydration and thereby the possibility
of a decrease in urine volume. This would consequently
raise the possibility of nephrolithiasis (Sparks, 2015).
Socioeconomic Status
A study was done to ascertain if socioeconomic status
can affect nephrolithiasis. The study used the Distressed
Communities Index (DCI) which takes into account employment status, education level, poverty rate, median
income, and business growth. Diabetes and hypertension were more prevalent in the group of people from
severely distressed communities. Patients from these
communities needed more invasive treatment and 13%
needed staged surgery versus 9% from the non-severely distressed communities. Men from the severely distressed community had a significantly larger stone size;
12.5mm vs 9.7mm. The men also had a higher prevalence
of stones greater than 20 mm. Interestingly, there was no
difference in stone size between the two different groups
of women. Socioeconomic status seems to correlate with
stone size, but appears to have more of an effect in men
than in women(Quarrier, Li, Best, Hedican, Penniston, and
Nakada, 2020)
Obesity
Obesity contributes to the risk of kidney stones more
than dietary factors. Maladaptive changes associated with
obesity are disturbed thermogenesis and dehydration.
This is because body fat is hydrophobic, so the proportion of body water decreases with increasing obesity and
this can lead to dehydration. Also, the decrease in body
surface area compared to body volume complicates heat
exchange and metabolic functions. Obesity is often associated with electrolyte imbalances and altered urine
chemistry.All evidence points to obesity being a great risk
factor for kidney stones.

It would seem logical and apparent that weight loss
would be the solution to the abovementioned complications. However, it is not that simple. Weight loss has to
be done in a healthy and reasonable fashion. A high animal protein diet, quick loss of lean tissue, or insufficient
hydration can actually increase the likelihood of kidney
stone formation. Diets high in acid can increase the risk
of uric acid stones. The patient must make his or her dietary choices in an informed manner taking into account,
his specific propensities to stone formation (Frasseto &
Kohlstadt, 2011)
Serial soda drinkers may be at an increased risk for
kidney stones. An experiment was done with a sample
of males who ingested 200 grams of fructose daily for
two weeks. Research showed that fructose intake greatly
increases the chances of kidney stones. This is because
fructose affects urate metabolism, urinary pH and affects
oxalate. Since fructose is present in so many of the foods
that the average American consumes, it can play a major
role in increasing the risk of forming stones. Moreover,
a randomized trial stated that a 10% reduction in stone
recurrence for those who could reduce their soft drink
intake to less than 24 ounces a week (Johnson, PerezPozo Lillo, 2018)
Occupation-“You are what you do”
Studies have shown that people with certain occupations
have a higher probability of developing kidney stones.
Some forms of work don’t allow for proper fluid intake
leading to a saturated urine concentration. Individuals
who are more active when they work, especially if they
work outdoors, perspire more, leading to more concentrated urine. However, those who have more sedentary
jobs are also in danger. Since they have a higher chance
of metabolic syndrome, they also have a higher risk of
forming stones. Since Astronauts work in environments
without gravity, they assemble calcium from their bones,
leading to greater calcium levels and consequently a higher risk of stone disease (Malieckal & Goldfarb, 2020).
Removal of Kidney Stones- A Wild Ride
In 2016 two physicians came up with a rather unique
method to dislodge a kidney stone after hearing about
this interesting phenomenon from their patients. One
patient reported passing renal calculi after each of 3 consecutive rides on the roller coaster. Many other patients
reported passing renal calculi within hours of leaving the
amusement park, and all of them rode the same rollercoaster during their visit. They used three renal calculi,
based on real life measurements. The renal calculi were
suspended in the urine model and taken for 20 rides
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on the Big Thunder Mountain Railroad roller coaster at
Disney World in Orlando. When the model was sitting in
the front seat of the roller coaster, there was a passage
rate of 4 out of 24. When sitting in the back there was
a passage rate of 23 of 36. Sitting in the rear, different
kidney stone location had different passage rates. An
upper calyceal calculi passage rate of 100%, a middle calyceal passage rate of 55.6% and a lower calyceal passage
rate of 4%. Although the data written above is encouraging, physicians must determine if a roller coaster ride
is the correct form of treatment for their patients, as
size and location may complicate the situation (Mitchell
&Wartinger, 2016).
Corona Virus and the Kidney:
There has been emerging connections between corona virus and kidney failure but why this happens is still
unclear. Many doctors have proposed different theories.
One theory is that the virus directly attacks the kidneys
by its way of infiltration. A study published in March
shows that Corona virus infiltrates the body by binding
to the ACE2 cell receptors. The kidney contains these
ACE2 receptors, and in this way is under direct attack.Yet
another theory states that the kidneys are affected secondary to the virus. Because the lungs are so hard hit, the
body is unable to deliver adequate oxygen to the body.
In turn organs are damaged and functionality is reduced.
The virus also effects the blood, which can lead to clots.
The kidney, being the biggest blood filter in the body is
not susceptible to blood clots within its thousands of
capillaries and vessels of filtration. Also blood clotting has
an effect on the body’s immune system possibly triggering
a cytokine storm in which the body attacks its own cells
and tissues. Furthering the potential damage to the kidneys and other essential organs (Edwards, 2020)
Conclusion
As more research is done on kidney stones it becomes
abundantly clear that even more research is needed.
There are an innumerable amount of factors to take into
account when determining the best course of treatment
for persons with renal calculi. The patient’s occupation,
ethnicity, BMI, family history, and region of residence are
all contributing aspects. Stone composition may be very
varied from case to case. Treatment that was successful
for one may be detrimental for the other. There is no
one-size-fits-all solution. Each case is unique and requires
its own analysis and diagnosis. One thing is universal
though, sufficient hydration is essential for the prevention
of kidney stones.
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Abstract
Fecal microbiota transplantation (FMT) is a method of transferring feces from an individual with a healthy microbiome to a patient
whose healthy gut bacteria is deficient.While this method is not a new one, it is constantly being explored and studied to determine
if it can be an effective way to treat patients with different bowel diseases. The main target of most of these studies are patients
with recurrent Clostridium difficile infections. Many studies were done to determine if the method is safe, and which method is most
effective, as well as who can be a good donor or recipient of the treatment.
Introduction
The large intestine is comprised of the cecum, the colon,
the rectum and the anal canal.The colon is the last step in
the digestive tract before the feces are expelled through
the anus in a bowel movement. It is a tube-like structure
containing the usual four layers; the mucosa, submucosa,
muscularis and serosa. Problems can occur if the mucosa
becomes inflamed or infected. Bacteria colonize the large
intestine and aid in the digestion of proteins and other
food particles to ready them for defecation. Bacteria also
play a role in the homeostasis of the gut (Tortora, 2014).
The colon is packed with bacteria that make up the
human microbiome. These are symbiotic organisms that
perform different functions in the human body. Research
has shown that many are important for metabolism and
epithelial cell growth, doing jobs that are similar to those of
the endocrine system. It seems that the microbial diversity
turns out to be significantly higher in adults than children,
and even more so in that of the elderly. Infants are found
to have an extremely low diversity. (Blaut, et al., 2002)
The many commensal bacteria in the gut influence immune function. There are a few different ways this could
be true. One of these is that the bacteria can promote
the health of the epithelial lining in the intestines. This
strengthens the primary barrier, so that pathogens cannot pass through the lining. In addition, some of these
good bacteria can help produce and secrete an anti-inflammatory response to some inflammatory cytokines.
Other mechanisms include the production of secondary
bile acids, and the competition for nutrients with the
pathogenic bacteria (Zeng et al., 2019).
In people with a healthy gut composition, there are a
different kind of bacteria that contribute to the symbiosis
of the gut.These bacteria serve as an anatomical barrier to
the different pathogens that enter the intestines through
various ways such as with food that is ingested. The four
main phyla that are found are Firmicutes, Bacteroides,
Proteobacteria and Actinobacteria. (Lopetuso et al., 2013).
In a normal bacterial gut composition, there is a symbiosis in which the bacteria work together to perform
different functions. Dysbiosis occurs when there is an
imbalance of the different gut bacteria, often resulting in
disease such as inflammatory bowel diseases (IBD), and
other gastrointestinal disorders. One common disease
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is infectious colitis caused by C. difficile. Others include
gastritis, peptic ulcer, irritable bowel syndrome (IBS) and
even gastric and colon cancer. (Lopetuso et al., 2013).
Methods
Research for this paper included using databases such as
the Touro College Library, PubMed and Google Scholar.
These were used to find peer reviewed articles on studies related to gastrointestinal diseases and FMT as a
treatment.
What is C. Difficile Infection?
As a result of taking antibiotics, many patients are left
with a decrease in gut bacteria diversity, namely of the
commensal Bacteroidetes and Firmicutes variety. At the
same time, there tends to be a proliferation of proteobacteria which include pathogenic organisms such as C.
difficile and shigella (Staley et al., 2016). C. difficile, an opportunistic organism can now cause infection because it
is not outcompeted by good bacteria for nutrients and
other factors that help bacteria thrive. In addition, as
mentioned above, there is a reduction in the bacteria that
normally prevent the proliferation of these pathogens by
different mechanisms. In the majority of cases, C. difficile is treated with the antibiotic vancomycin or other
similar drugs. Often, this course of antibiotic therapy is
ineffective, resulting in recurrent C. difficile infections.
Fecal microbiota transplantation attempts to address the
problem by allowing the feces of the healthy donor to aid
in replenishing the depleted gut bacteria of the patient.
This leads to the patient’s stool bacteria becoming very
similar to that of the healthy donor (Kelly et al., 2015).
Secondary Bile Acid Production by Bacteria
There is evidence that suggests that secondary bile acid
production is a crucial factor in preventing C. difficile infections.There appears to be a difference in the bile acid composition in the colon of patients with C. difficile infections
in comparison to those with a healthy gut composition. A
bile acid analysis study was done on fecal extracts of both
donors and recipients of FMT. The results demonstrated
that the pre-FMT samples contained mainly primary bile
acids and bile acid salts and did not contain any secondary
bile acids. In contrast, the post-FMT samples, as well as the

Is Fecal Transplantation a Safe and Effective Treatment for Gastrointestinal Diseases?

donor samples contained a high abundance of secondary
bile acids, indicating that the bacteria from the healthy
donor had an effect on secondary bile acid production.
These factors seem to indicate that it is indeed the metabolic function of these bacteria that aid in preventing C.
difficile infections (Weingarden et al., 2014).
Primary bile acids are produced in the liver. The main
ones are cholic acid and chenodeoxycholic acid. Before
being secreted into bile, the bile acids are chemically attached to the amino acids taurine and glycine to form bile
salts. These are then secreted into bile and then used for
lipid digestion in the small intestines. While most of these
are reabsorbed, about 5% of them reach the large intestine
where they subsequently become deoxycholic and lithocholic acids which are secondary bile acids. As mentioned
before, post FMT and donor samples contained mainly secondary bile acids and few primary bile acids. Some studies
have inferred that the primary bile acid taurocholic acid
(cholic acid combined with taurine), is actually a requirement for C. difficile growth and proliferation, and is used
in growth media for this organism. It was also noted that
the secondary bile acids lithocholic and ursodeoxycholic
acids (from chenodeoxycholic acids), inhibit the growth of
C. difficile (Weingarden et al., 2014).
In a study done, it became apparent that the Clostridium
scindens, of the firmicutes phylum, is the bacteria that is
likely responsible for preventing infection due to its role
in secondary bile acid production (Staley et al., 2016).
The bile acid experiment was done in conjunction with
the bacterial diversity survey. There was a correlation between the two studies, showing that an increase of secondary bile acids came along with an increase in Bacteroides
and Firmicutes. These experiments indicate that it is likely
these commensal bacteria play a metabolic role in bile acid
production, inhibition of the pathogenic C. difficile, and
overall gut health (Weingarden et al., 2014).
Who is a Good Fecal Donor?
It is not completely clear who makes a good donor for
FMT. It is assumed that it would greatly depend on the
donor’s lifestyle and diet. Though it was noted during one
study that there were good outcomes from one donor
in particular, it was hard to trace exactly what made
that donor so effective. In addition, many FMT trials are
done with multi-donor stools for increased diversity.
This would cause the researchers to be unable to isolate
which donor made it most effective (Quraishi et al, 2017).
There is indication that relatives are beneficial as FMT
donors because they share genetics, and are likely to have a
similar microbiome to the patient. Others say that it is beneficial for a patient to receive FMT from his or her spouse

because they likely have been in contact with similar pathogens and therefore may be protected from harmful effects
of introducing many new bacteria to the gut. Some think
that an unrelated donor is better, because they feel that
someone who is not related would be more honest in answering questions that may rule them out from donating.
There is not enough conclusive evidence to determine if
any of these are indeed true (Kelly et al, 2015).
In gathering the donors, there is a list of exclusion
factors that can rule out those who should not donate
stool. These include those who have been on antibiotics in the past 3 months, have had any history of a
disease that is normally transmitted by stool, or who
are known to have IBD, IBS or other gastrointestinal
complications or conditions. In addition, those who have
had a history of autoimmune diseases, malignant diseases, chronic pain or metabolic syndromes cannot donate
feces. The reason for this is because it is assumed that
people who have these conditions may have an altered
microbiome which might be detrimental to introduce
to a patient who is already compromised (Kelly et al,
2015). In addition, someone who has an autoimmune
disease is likely being treated with immunosuppressants
which suppresses the body’s immune system. If this was
introduced into the recipient, this could be especially
harmful because there is already an infection in the patient that needs to be treated, and they must have an
active immune system. Additionally, it is possible that
certain DNA which causes these conditions would be
present in the stool and it would be very risky to introduce to the patient (Petrov, M. E., 2011). Once they
have fulfilled the above requirements, they are screened
for infections within a month of donating and can then
donate stool (Kelly et al, 2015).
Screening Before Donations
The specific tests done to screen a donor include those
that play a role in metabolic function and the digestive
system in particular. Some of these include a complete
blood count, as well as a c-reactive protein test which
checks for inflammation within the body. In addition,
they are tested for levels of creatinine and liver enzymes.
The stool itself is screened for ova and parasites and C.
difficile in particular, among other intestinal pathogens
(Satokari et al, 2015).
Methods of Preparing Feces for Transplantation
The transferring of feces can be done by different procedures. Those include transplantation with an oral capsule,
colonoscopy or by enema. (Kao et al, 2017). There is also
debate about whether it makes a difference if the feces
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were previously frozen, or if fresh stool is used. Results of
trials show that there is little difference in effectiveness
between these methods. Therefore, it is suggested that
frozen samples be used simply because they are easier to
produce and obtain (Satokari et al, 2015).
In addition to what was mentioned above, using frozen
stool allows for universal donors. That means that when
a potential donor is screened and found to be a good
candidate, his feces can be used for multiple patients. This
would also allow clinics to store the frozen feces and use
them as needed (Satokari et al, 2015).
Fresh Stool for FMT
When using fresh stool for FMT, the stool must be used
within a 6-hour window of time, from defecation to transplantation. With this method, approximately 30 grams of
stool is mixed with 150 ml of tap water and then administered to the patient within 15 minutes of preparation.
This method is very limiting, and not as readily available
as frozen stool (Satokari et al, 2015).
Preparing Fecal Slurry for Colonoscopy with
Frozen Stool
There are slight variations in methods of preparing frozen
stool for FMT. The following is one of them:
Fresh stool is collected and stored in units of 80-100 g.To
each collection, 200 ml of .9% saline is added. The resulting mixture is filtered through a stomacher bag, designed
to keep samples uncontaminated, yielding 180 ml of fecal
slurry. Mixing the slurry with 20 ml of 100% glycerol allows it to be frozen at -70 degrees Celsius for 2 months,
until needed. For use, the slurry is defrosted overnight at
4 degrees Celsius and then reconstituted with 160 ml of
.9% saline. (Kao et al, 2017)
In using fresh or frozen stool, one method of administering it is through a biopsy channel, a piece of flexible
tubing in the cecum (Satokari et al, 2015).
Preparing Feces for Capsule Manufacturing
Forty ml of 100% glycerol is added to 200 ml of prepared
fecal slurry and centrifuged for 20 minutes at room temperature and 400 G (gravitational force). After decanting
the supernatant, the sample is then centrifuged at 4-8 degrees Celsius and 10,000 G by high speed centrifuge. The
remainder of the sample is mixed to yield about 12 ml of
sample containing 10^13 microbes by estimation. This is
then pipetted into size No. 1 gelatin capsules which are
then encapsulated twice by size 0 and then 00, yielding
40 capsules. These capsules are then flash frozen at -55
degrees Celsius on dry ice to preserve them. Just like the
fecal slurry, the capsules can remain stored at -70 degrees
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Celsius for 2 months.To administer FMT, the patient swallows approximately 40 capsules within a short period of
time (Kao et al, 2017).
Synthetic FMT
Vos W.M writes that synthetic FMT is likely a good alternative to the common use of donor stool. Synthetic FMT
is a lab produced combination of the needed strains of
bacteria, without the actual stool of the donor. The reason
for this is because by the time the donor stool reaches the
patient, many of the organisms are no longer viable. In addition, stool contains other wastes, mucus and pathogens.
Vos suggests that administering synthetic microbiota which
was cultured to get the right composition of bacteria is not
only more effective, but less likely to have adverse effects
as well. Synthetic FMT would not contain all the parts of
the stool that are unnecessary as well as detrimental to the
patient. In addition, it would allow for greater viability and
microbial diversity as well as being able to be manufactured
and reproduced (Vos, 2013).
Effectiveness in Treating C. difficile Infections
In order to determine effectiveness, a DNA sequencing
test is performed to determine which bacteria were colonized in the gut of the patient post FMT treatment. In
studies that were done, the patients who were treated
with heterologous stool samples- that of a donor showed
a greater diversity in stool microbiology than those who
were treated with autologous samples- their own, i.e.
the placebo group. In the heterologous stool samples,
there was a significantly higher presence of Bacteroidetes
and firmicutes, indicating that these are the phyla that
should be present in healthy stool. In contrast, those who
were treated by placebo did not contain an abundance
of these bacteria. Instead, they presented with more of
the Clostridium XIVa clade and Holdemania bacteria
that were thought to take part in causing the C. difficile
infection. Results from this study seem to imply that a
complete engraftment- proliferation of all the bacteria, is
not necessary so long as the needed bacteria are present.
(Staley, et all ,2016)
In a systematic review by Cammarota, Laniro, and
Gasbarrini, A. indicates an 87% success rate when comparing the data of numerous studies.The rates of diarrhea
resolution varied depending on the site of the fecal transplantation. The data indicated a rate of 81% in the stomach, 86% in the duodenum-jejunum, 93% in the cecum-ascending colon, and 84% in the distal colon. (Cammarota,
et al, 2014)
A randomized trial was performed on 46 patients with
3 recurring episodes of C. difficile. All of these patients
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were treated with vancomycin without success. During
the study, all the patients were treated by colonoscopy.
Some of the patients were treated with donor stool,
while others were treated with their own autologous
stool. Those treated with autologous stool were checked
to determine if the donor stool was indeed more effective, or similar to the placebo effect. Of the 22 who were
treated with donor stool, 20 had a full recovery from C.
difficile, accounting for a 90.9% recovery rate. In contrast,
of the 24 who were treated with their own stool, only 15
recovered, which is a 62.5% recovery rate. The patients
who contracted another C. difficile infection following
FMT with autologous stool were subsequently treated
with donor stool, with success.The outcome of this study
seems to indicate that FMT is a safe, effective way to treat
recurrent C. difficile infections (Kelley et al, 2016)
A study was done to determine whether transplantation by colonoscopy or by oral capsule was more efficient.
The outcome of the study seems to indicate that neither
one is preferable and both were effective. The factors to
consider were those that an oral capsule is both less invasive and cheaper to administer. (Kao et al, 2017)
FMT for Ulcerative Colitis
Ulcerative colitis is a condition in which the mucosal
layer of the colon is inflamed. Patients with this condition present with bloody stool, anemia and abdominal
pain (Costello et al, 2019). A trial was done in 3 hospitals,
treating 85 patients to see if FMT could work to cure ulcerative colitis in addition to the known effects of treating
C. difficile infections. In this trial, patients were treated
with stool from multiple donors to increase the biodiversity. There was also a placebo group. In both groups color
and odor was added so that the patients would not know
if they were receiving the real transplant. The original infusion was administered by colonoscopy, directly into the
terminal ileum and caecum. The patients were monitored
periodically for 8 weeks (Paramsothy et al., 2017).
Though there was not a significant majority, 27% of
people who received donor FMT saw a relief of symptoms, while only 8% of placebo patients saw these effects.
After the 8 weeks however, the numbers on both sides
increased. It was observed that a particular bacterium of
the Fusobacterium variety was present in those who did
not have a remission of symptoms after FMT. It is important to note that majority of the patients in the placebo
group had milder symptoms to begin with. The outcome
of the study indicated that FMT may be a good alternative to usual steroidal therapies used for ulcerative colitis,
though more research would need to be done to determine if that is indeed the case (Paramsothy et al., 2017).

A study was done to determine if anaerobically prepared stool would be as effective as aerobically prepared
FMT for ulcerative colitis. The purpose of the trial was to
determine if the organisms in the stool would be more
viable if they were prepared anaerobically. This study was
done after the study mentioned above by Paramsothy.
Based on data that was collected from the above study,
researchers were hopeful that FMT could be very effective in ulcerative colitis patients. This study was a variation of the first one. The outcome of the study indicated
that 32% of those who received donor FMT saw an initial
relief of symptoms. Nine percent of those who received
autologous stool saw an initial relief of symptoms as well.
(Costello et al, 2019). This data seems to be very similar
to that of the aerobically prepared FMT. More trials would
be needed to determine if anaerobically prepared stool is
actually more effective. This study adds to the research
that FMT is helpful in some cases for ulcerative colitis.
FMT for IBD
IBD is a general term for different inflammatory bowel diseases. Included in these are ulcerative colitis and Crohn’s
disease. As mentioned above, these diseases cause chronic inflammation of the bowel. Either of these conditions
can cause colorectal cancer, and other medical problems
in the individual. There is evidence that suggests that it is
the microbiome gut composition that plays a role in these
diseases. After seeing great success in treating recurrent
C. difficile with FMT, researchers are hopeful that it can
work as a therapeutic treatment for other conditions as
well (Quraishi et al., 2017).
According to studies, it seems that IBD can be an abnormal reaction to having microbiota in the gut. Patients
with this condition possess genes that view these enteric
bacteria as pathogens, even those that are considered
symbiotic in a healthy person. Evidence to support this
study included testing on germ-free animal models that
were predisposed to IBD. In addition, there were studies done in which the fecal stream was diverted. In both
of these studies, it appeared that not having any bacteria
present in the gut led to having no inflammatory symptoms. The activation of innate and adaptive immunity by
bacteria that is normally nonpathogenic can lead to an
inflammation in the gut in the absence of pathogenic bacteria (Quraishi et al., 2017).
It is noted by Quraishi et al., that though it seems that
any presence of bacteria induces IBD in those that are predisposed, there are studies done that suggest that there
is indeed a difference in microbial diversity in those with
IBD in comparison to those with a healthy gut (Quraishi et
al, 2017.) The composition is characterized by an increase
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in bacteria which include Enterobacteriaceae, Pasteurella,
Veillonella, and Fusobacteria, and also contains less Firmicutes,
Bacteroidetes, and Clostridia (Gevers et al., 2014). It is also
noted that there is an increase of Proteobacteria in those
with IBD. Using FMT with IBD has been met with very limited success in the past. There has been more evidence of
success with ulcerative colitis patients, than in those with
Crohn’s disease (Quraishi et al, 2017).
FMT for Hepatic Myelopathy
Hepatic myelopathy is a neurological complication that
comes from severe liver disease. Usually, it can only be
treated by a liver transplant.There was a case study done,
however, that indicated that FMT may indeed be a solution to this illness. The study was done on one 45-yearold woman in china. She was admitted to the hospital
numerous times, and underwent various procedures. The
reasons for these included different complications such as
splenomegaly, vomiting blood and other internal bleeding.
The last visit was due to a weakness and stiffening in her
legs. Interestingly, after being treated with 3 courses of
FMT, she reported a relief of symptoms. There is no conclusive evidence that this can work in all cases. However,
due to the known correlation between gut symbiosis and
neurological health, the researchers say that FMT may be
a good therapeutic alternative to a liver transplant as it is
more available and less invasive (Sun et al, 2019).
Adverse Effects of FMT
In a randomized trial done, it was noted that there were
no serious adverse effects following fecal microbiota
transplantation. The study did not include anyone who
was immunocompromised, or above age 75. Following
FMT the patients were monitored periodically for 6
months, and none exhibited any serious symptoms in relation to FMT (Kelley et al, 2016).
Kao et al reports that two patients died following FMT,
though it was not likely due to the procedure. Both had
significant cardio-pulmonary disorders and both were elderly (Kao et al, 2017).
While FMT has seems to have many beneficial uses,
as with any therapy, there are downsides as well. Dr.
Schwartz, Gluck and Koon say that a reason for this may
be because though fecal donors go through extensive
screening, it is possible that they were carrying diseases
that they were unaware of. They could have been asymptomatic and not have been tested for that specific pathogen. There were two cases noted of norovirus in Virginia
Mason Medical Center in Seattle. Norovirus is a common
contagious virus that causes gastroenteritis in many people. In those cases, the donors were asymptomatic and it
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was unknown whether the virus was transmitted through
the feces as there was a window of time between the
collection of the feces and the actual transplantation. The
most significant effect of these cases was that both patients presented with a relapse of C. difficile infections.
It was speculated that it is possible that the norovirus
altered the bacterial community present in healthy stool
resulting in an ineffective FMT (Brandt, L. J., 2013).
In an FMT trial on ulcerative colitis patients, a significant
amount reported adverse effects. Approximately 78% of
the donor stool recipients and 83% of the placebo recipients reported gastrointestinal upset.The complaints were
self-limiting, resolving on their own and having no longterm effects. In addition, 2 patients who received donor
stool, and 1 who received autologous stool as a placebo
presented with serious adverse effects (Paramsothy et al,
2017). The study did not mention what they were.
Quraishi et al. note that FMT should not be administered to those who have Crohn’s disease with deep
patch ulceration in the gut. The reason for this is because
it is likely that the bacteria may translocate. That is, the
bacteria may cross the organ barrier and enter into the
bloodstream where it does not belong. Administering
FMT in those patients could cause many harmful effects. It
is different however for ulcerative colitis because in that
condition the inflammation is contained to the epithelium
and risk of bacterial translocation is not high (Quraishi et
al., 2017).
In a letter written to the editor of The American
Journal of Gastroenterology, Dr. Brandt presents his observations that there are effects of C. difficile that are not
yet known. He noted however that it is reasonable to assume that down the line there would be adverse effects.
Those may include short term affects like allergic reactions or transmitted infections. He speculates that it is
likely that FMT patients may suffer long term effects such
as conditions that result from an altering the recipient’s
microbiome to be similar to that of the donor (Brandt, L.
J., 2013). It is interesting to note, however, that this was
written in 2013, and articles written in later years did not
report these predictions.
Why Not Oral Probiotics?
People think that probiotics are helpful for the gut microbiome. The reason for this assumption is that if some
bacteria are considered good, an increase in those bacteria should be considered helpful to a person’s overall
wellbeing. Research has shown, however, that this may
not necessarily be the case. It was noticed that certain
cancer patients were not responding to immunotherapy
and that majority of those patients were taking probiotic
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supplements. There is evidence that taking a probiotic
supplement reduces the biodiversity in the gut. Though it
does cause an increase in certain essential bacteria, those
bacteria in large quantities may be harmful to other systems. For example, an increase in Bacteroides is said to
increase metabolism, but seems to be detrimental to the
immune system (Hardy, L., 2019).
There is also research that indicates that taking probiotics after a course of antibiotics actually slowed the
body’s response in replenishing the gut. In this study, three
groups of patients were given antibiotics. One group was
not subsequently treated, another was given probiotics,
and the third was given autologous FMT with stool collected before they were given antibiotics. Evidence from
this study indicated that those who were given probiotic
supplements took significantly longer to recover than the
others.This study also seems to show that FMT is indeed
a good way to replenish the gut bacteria after treatment
with antibiotics (Hardy, L., 2019).
Conclusion
In conclusion, there is hope that FMT can effectively treat
dysbiosis of the gut. This is especially true for the case
of a recurrent Clostridium difficile infection, where the
majority of cases were cured with few or no adverse
effects noted.There are studies that imply that other gastrointestinal diseases could be treated effectively as well.
It was also noted that there is little difference in outcome
of treatment when different methods of transplantation
are used. Other than for recurrent C. difficile infections
for which FMT has been deemed effective, more research
should be done to determine if it is effective for the other
mentioned diseases. Overall, FMT is a promising and innovative therapy for gastrointestinal problems.
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Abstract
Nicotine dependence as a result of smoking is a chronically relapsing disorder with detrimental effects. However, fortunately for
smokers, an armamentarium of smoking cessation aids is available in the forms of nicotine replacement therapy (NRT), non-nicotinic drugs (namely varenicline and bupropion), and the novel nicotine vaccines, each with their own mode of action to moderate
nicotine addiction. This paper analyzes the mechanism of action associated with nicotine addiction and the various methods of
combat, or at the very least, attenuation of the addiction.
Introduction
role, if any, in causing smoking-induced diseases, the addicThough incognito, nicotine addiction has been proven to
tion to nicotine, which leads to sustained smoking use, is
be the true killer in the seemingly innocent activity of
the proximate cause of these diseases (Onor et al., 2017).
smoking, for it reinforces the desire to smoke. To preNicotine (C10H14N2) is a plant alkaloid found in the
vent the myriad adverse effects of smoking, smokers
tobacco plant (Onor et al., 2017) that consists of a pyrineed to work very hard to break nicotine addiction
dine and pyrrolidine ring, each one possessing a tertiary
through smoking cessation. Nonetheless, many smokers
amine (Escobar-Chávez et al., 2011). The pKa of the pyrfind themselves dealing with many ups and downs in the
idine nitrogen is 3.04 and the pKa of the pyrrolidine niquitting process. It comes as no surprise that nicotine
trogen is 7.84 under standard conditions. Based on these
addiction is therefore identified as a “chronic condition”
characteristics, nicotine’s distribution exists among three
by The US Clinical Practice Guideline, as many smokers
forms, depending on the pH of the solution. An increase
need to make several attempts before they
successfully wean themselves off completely
(Fagerström & Hughes, 2008). Smoking is the
second most expensive chronic health condition in the United States, with an estimated
economic cost of 300 billion dollars per year
(Jordan & Xi, 2018).Yet, stopping smoking can
reverse the biological and economical damage caused by smoking (Benowitz, 2010).
Understandably, 70% of smokers admit that Figure 1.The various forms of nicotine based on pH (Centers for Disease Control and
they would like to quit. Every year, about 40% Prevention, 2010).
quit for at least a day. However, due to the extreme difin acidity of solution increases the fraction of protonated
ficulty to abstain, about 45 million Americans currently
molecules; conversely, a more basic environment increassmoke tobacco. Moreover, the 80% who attempt to quit
es the fraction of the unprotonated, or free base, form
on their own return to smoking within a month. Each
(Figure 1).Although all forms of nicotine are highly soluble
year, only 3% of smokers quit successfully and remain abin water and can easily dissolve in lung fluids and blood,
stinent one year later, highlighting the critical need for
the unprotonated nicotine smoke particles are volatile,
effective long-term smoking treatments (Benowitz, 2010).
whereas the protonated form is not. Conventionally, a
sample of particulate matter from cigarette smoke is not
Methods
acidic enough to cause the protonated form to dominate.
This comprehensive review is based on critical analyThus, a higher percentage of unprotonated nicotine can
ses of literature obtained using various databases availrapidly cross biological lipid membranes and be deposited
able through The Touro College Library online, such
in the respiratory tract (Centers for Disease Control and
as PubMed and ProQuest. The National Center for
Prevention, 2010). Nicotine begins to reach the brain ten
Biotechnology (NCBI) website was also useful in
seconds after inhalation and its concentration continues
provi di ng additional source material.
to increase gradually (Dani et al, 2011).
Blood concentrations of nicotine rise rapidly and peak
Nicotine Addiction
at the completion of smoking. The rapid absorption of
Ci garett e smoki ng i s a major cause of death, cardionicotine is attributed to the broad surface area of the
vascular disease, and pulmonary disease. It also presalveoli and small airways. This rapid rise allows the smokents the risk for various infections, osteoporosis, reproer to titrate and manipulate the level of nicotine during
ductive disorders, adverse postoperative events, delayed
smoking, which makes smoking the most reinforcing and
wound healing, duodenal and gastric ulcers, and diabetes
dependence-producing form of nicotine administration
(Benowitz, 2010). Although nicotine itself plays a minor
(Benowitz et al., 2009).
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Essentially, pharmacologic feedback, learned factors, genetics, and environmental factors (including tobacco product design and marketing, stress, smoking cues, or peers
who smoke) contribute to nicotine addiction. Other factors include sex, age, mental illness, and substance abuse.
Although each of these features contributes, the one that
will be discussed with percipience is the pharmacological
interplay with nicotine addiction (Benowitz et al., 2009).
The pharmacological basis for nicotine use is enhancement of mood and augmentation of mental and physical
functions. Inhalation of smoke from a cigarette allows
nicotine from the smoke particles to diffuse through the
lungs, where it is rapidly absorbed into the pulmonary
venous circulation. From there, it moves quickly to the
left ventricle of the heart and to the systemic arterial circulation and brain. Based on human autopsy samples from
smokers, the liver, kidney, spleen, and lung have the highest
affinity for nicotine (Benowitz et al., 2009). Subsequently,
the nicotine enters arterial circulation to be moved from
the lungs to the brain with high affinity, where it binds to
nicotinic acetylcholine receptors (nAchRs), ligand-gated
ion channels that normally bind a neurotransmitter acetylcholine (Benowitz, 2010).
NAchRs are pentameric structures consisting of a combination of five different subunits, including nine α subunits (α2 through α10) and three β subunits (β2 through
β4), resulting in at least 12 unique nAchR subtypes that
have been identified thus far. The α4β2 receptor, though,
is the prime mediator of nicotine dependence. As seen
in positron emission tomography studies in humans,
smoking a full nicotine cigarette nearly saturated α4β2
receptor occupancy. In fact, when disruption of the β2
subunit gene was tested in mice, the behavioral effects of
nicotine were eliminated. Similarly, the α4 subunit is an
important determinant of sensitivity to nicotine. This was
confirmed when a mutation affecting a single nucleotide
in the pore-forming region of the receptor gene in mice
made it hypersensitive to the effects of nicotine. These
observations strongly implicate α4β2 nAchRs in nicotine
addiction and illustrate the α4β2 receptor as a potentially
attractive medicinal target for treatment of the addiction
(Jordan & Xi, 2018).
The smoker craves nicotine to propagate dopamine
overflow in the pleasure-seeking areas of the brain. The
α4β2 are located on the dopamine (DA) cells of the mesolimbic system. The system is comprised of projections
from DA neurons in the ventral tegmental area (VTA)
to the nucleus accumbens (NAc), the part of the brain
responsible for reward, pleasure, laughter, aggression, and
fear, and the prefrontal cortex. Nicotine binding to α4β2
receptors on VTA DA cells increases neuronal excitability
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and neurotransmitter release, opening the ligand-gated
ion channel, and allowing Ca2+ and Na+ to cascade intracellularly, which stimulates DA release to NAc (Figure 2).
This is the underlying effect of nicotine’s reward cascade,
as dopamine serves as a pleasure signal and mood modulator and is critical for reinforcing nicotinic effects (Jordan
& Xi, 2018).
When studied under laboratory conditions, nicotine
elicits classic addictive responses (Dani et al, 2011). In
order to reap the rewarding feeling associated with nicotine and avoid withdrawal symptoms, smokers must maintain a certain nicotine level. Repetitive exposure to nicotine leads to neuroadaptation and tolerance to nicotine’s

Figure 2. Schematic diagram of the mesolimbic DA projection
pathway in the human brain. Nicotine activates a4b2 nAChRs
located on DA neurons located in the VTA, as illustrated (Xi, 2010).

effects, and accumulation of nicotine in the body leads to
a more substantial withdrawal reaction if cessation is attempted. Common withdrawal symptoms include anxiety,
difficulty concentrating, and irritability, all of which can
last for days, weeks, or longer (Onor et al., 2017).
As neuroadaptation occurs, the number of binding
sites on the nicotinic cholinergic receptors in the brain
increases.This causes desensitization, wherein a ligand-induced closure and unresponsiveness of the receptor
occurs due to the profusion of ligand infiltration. Thus,
the feelings of craving and withdrawal are exacerbated
during periods of abstinence due to the mitigated levels of dopamine and other neurotransmitters. However,
during a smoking period, binding to the α4β2 cholinergic
receptors alleviates the need for nicotine. To circumvent
withdrawal symptoms, smokers will sustain sufficient levels of plasma nicotine (Benowitz, 2010).
It comes as no surprise that nicotine withdrawal is
extremely taxing on the smoker. Such repercussions are
powerful incentives to take up smoking again (Benowitz,
2010). Fortunately for smokers, there is an expansive market of nicotine treatments that promote smoking cessation, some of them in the form of nicotine replacement
therapy (NRT), non-nicotinic drugs such as bupropion and
varenicline, and finally, the emergence of nicotine vaccines.

Effective Treatments for Nicotine Addiction

Nicotine Replacement Therapy (NRT)
Nicotine’s rapid rate of absorption and entry to the brain
are key factors responsible for the high abuse potential.
Unlike cigarettes, nicotine replacement therapy (NRT)
products such as gums, inhalers, and transdermal patches can help relieve the physical withdrawal symptoms
by providing gradual increments of nicotine without the
damaging chemicals found in cigarette smoke (Jordan &
Xi, 2018). The gradual distribution of nicotine results in
low abuse liability of NRTs. Although NRT doesn’t completely eliminate withdrawal symptoms since it does not
provide rapid and high levels of nicotine, NRT may provide a coping mechanism, making cigarettes less enticing
to smoke (Molyneux, 2004) and increasing the rate of
quitting by 50 to 70% (Stead et al., 2012). NRTs are well
tolerated and have minimal adverse effects, but are most
effective when used in conjunction with intense behavioral support (Molyneux, 2004).
In 1984, transmucosally delivered nicotine polacrilex, or
nicotine gum, was introduced as the first effective NRT to
serve as a smoking cessation aid, as approved by the US
Food and Drug Administration (FDA). It is not chewed like
ordinary confectionary gum, as it must be intermittently
chewed and held in the mouth for over 30 minutes to
achieve optimal release of nicotine. The absolute dose of
nicotine absorbed systemically is much less than the nicotine content of the gum, in part because considerable nicotine is swallowed with first-pass metabolism (Benowitz et
al., 2009), where it gets metabolized in a specific location
other than the location of interest, reducing the concentration that enters systemic circulation (Herman &Santos,
2019). The dosage is slowly decreased until it is no longer
required (Wadgave & Nagesh, 2016).
To satisfy the behavioral hand-to-mouth ritual of smoking, the nicotine oral inhaler was introduced to the NRT
market. Contrary to its label, the inhaler is mainly delivered
to the oral cavity, esophagus, and stomach, and negligibly to
the lungs. Because absorption is mainly through the oral
mucosa, a slow absorption rate of nicotine is achieved, akin
to that of nicotine gum (Wadgave & Nagesh, 2016).
In a parallel fashion, nicotine patches deliver nicotine
at a relatively steady rate when applied to and readily
absorbed through the skin. In fact, the patch is the form
that delivers nicotine at the slowest rate when compared
to the other forms of NRT. A chief advantage of nicotine patches is the simplicity of user compliance, since
the patch can be placed on the skin in the morning and
worn for the duration of the day.The patches are available
in a range of doses, allowing users to gradually decrease
their nicotine intake over the span of several weeks or
longer to ensure a proper adjustment to lower nicotine

levels until they can attain a nicotine-free state. The rate
of nicotine release is controlled by the permeability of
the skin, rate of diffusion through a polymer matrix, and
rate of passage through membranes in the various patches on the market. In all cases, there is an initial lag time of
1 hour before nicotine enters the bloodstream, followed
by continued systemic absorption once the patch is removed, the latter due to the vestiges of nicotine in the
skin (Benowitz et al., 2009). Current evidence supports
the safety of long-term use of nicotine patches for nicotine treatment (Wadgave & Nagesh, 2016).
Non-Nicotinic Drugs
Bupropion (Wellbutrin)
The first non-nicotine drug to treat nicotine addiction
was introduced in 1997. Bupropion (amfebutamone),
marketed as Wellbutrin and Zyban among others (Fava,
et al., 2005), an amphetamine-based drug, is a reuptake
inhibitor of dopamine into neuronal synaptic vesicles
and a blocker of nicotine’s activation of several neuronal nAChRs. Bupropion undergoes metabolic transformation to an active metabolite, 4-hydroxybuproprion,
through hepatic cytochrome CYP2B6, (Foley et al., 2006).
Bupropion’s structure is akin to nicotine, rendering it a
compatible competitor (Figure 3). Originally developed
as an antidepressant, a systematic review of 44 clinical
trials found that sole therapy with bupropion significantly
increased long-term (≥6 months) smoking abstinence, affirming its efficacy as an anti-smoking agent (Onor et al.,
2017). It should be noted that the antismoking effect does
not seem to correlate with its antidepressant effect, as
bupropion is equally as effective for smoking cessation for
individuals with and without depression (Roddy, 2004).

Figure 3.The chemical structures of bupropion (left) and nicotine
(right) (National Center for Biotechnology Information).
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When nicotine infiltrates the blood and crosses the
blood brain barrier, there is a release of dopamine into
the synaptic cleft of neurons in the dopaminergic pathways. After nicotine levels subside, dopamine reuptake
into the axon terminal vesicles occurs. Bupropion is
thought to inhibit this dopamine reuptake. In vivo studies
have also shown that bupropion antagonizes the effects
of nicotine at the postsynaptic acetylcholine nicotinic receptor (Wilkes, 2008). During withdrawal, bupropion may
attenuate symptoms by mimicking the effects of nicotine
on dopamine (Warner & Shoaib, 2005). These effects may
explain how bupropion inhibits the reinforcing effects
of nicotine, though it is still unclear whether bupropion
offers any long-term relapse prevention following termination of treatment. Nonetheless, both pragmatic and observational trials of bupropion have shown that approximately 1 in 5 smokers will successfully remain abstinent
for at least a year post-treatment (Wilkes, 2008).
Varenicline (CHANTIX)
Cytisine is a naturally occurring insecticide found in the
leaves and seeds of Cytisus laburnum (golden rain tree).
During World War II, soldiers smoked leaves of this tree
in lieu of tobacco. Both varenicline and cytisine target
the α4β2 receptor, where varenicline was developed to
improve binding to the receptor to enhance efficacy of
smoking cessation. However, the cytisine structure did
not lead to a viable drug candidate. In due course, a series
of efforts based on analgesic bicyclic benzazepines, one of
which was unveiled as a potent α4β2 nAchR antagonist,
served as a novel template that led to the development
of varenicline, branded as CHANTIX. FDA approval was
based on randomized clinical trials conducted in 3659
subjects in the United States. The subjects, all of whom
were chronic smokers, averaged 43 years of age and reported smoking an average of 21 cigarettes per day for
the previous 25 years. The primary outcome measured
abstinence from smoking, which came in at a 44% rate,
a significant improvement over bupropion (30%) and
placebo (18%). Secondary outcomes, such as the urge to
smoke and withdrawal symptoms, were likewise improved
in varenicline-treated subjects over placebo (Jordan & Xi,
2018). In 2006, varenicline received FDA approval, and it
was highly touted as an aid to quit smoking (Fagerström
& Hughes, 2008).
Like bupropion, varenicline has a somewhat parallel configuration to its nicotine competitor in order to
operate as an appropriate replacement. In fact, in vitro
binding assays indicate that varenicline’s affinity for the
α4β2 receptor (Ki = .15 nM) is higher than that of nicotine (Ki = 1.6 nM) and cytisine (Ki = 0.23 nM) (Jordan
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& Xi, 2018). Varenicline has the following chemical name:
7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3- h]
[3]benzazepine, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
(Figure 4). Varenicline has a molecular weight of 361.35
Daltons and is highly soluble in water (Pfizer Labs, 2016).
With varenicline, dopamine is still released, but less so
than with nicotine. Since the α4β2 had been identified to
have the highest sensitivity to nicotine, it had become a
potential target for the smoking cessation drug.Varenicline
was developed to have a high affinity for the α4β2 neuronal nicotinic acetylcholine receptors in the mesolimbic
dopamine system and stimulate receptor-mediated activity,
but at a significantly lower level than nicotine. Varenicline’s
highly selective nature ensures that it will bind more po-

Figure 4.The chemical structures of nicotine (left), cytisine (middle),
and varenicline (right) (Xi, 2010).

tently to α4β2 receptors than to other common nicotinic
or non-nicotinic receptors (Pfizer Labs, 2016).
As a result of being a partial agonist, varenicline displays
both agonist and antagonist effects. Partial agonists have
been reviewed thoroughly as a method of attenuating
nicotine addiction. Partial agonists bind to nAchRs but
do not elicit the maximum response of a full agonist, and
instead depend on receptor occupancy by other ligands.
For instance, in the presence of a full agonist like nicotine,
a partial agonist would behave as an antagonist by occupying the receptor site, thereby minimizing nicotine’s effects
at the receptor. However, in the absence of nicotine, a
partial agonist would behave as an agonist by mitigating
nicotine withdrawal symptoms through triggering a degree of dopamine release (Jordan & Xi, 2018).
Given that continuous abstinence rates across studies
remain low (18-30% with varenicline; 4-10% with placebo), novel and more effective treatments may be required.
However, since FDA approval in 2006, incoming reports
have been continuing to demonstrate varenicline’s efficacy for smoking cessation over the alternatives. For
example, in a randomized trial involving 376 participants
over the span of 52 weeks, varenicline resulted in higher
abstinence rates from smoking (55.9%) when compared
to transdermal NRT (43.2%), highlighting varenicline’s
progress (Jordan & Xi, 2018).
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Nicotine Vaccines
With the advent of the novel nicotine vaccines, smokers
have an alternative course of action through which they
can quit smoking. Currently undergoing clinical trials, the
goal of the vaccine is to generate antibodies that sequester
nicotine in the blood and hinder the pharmacological effects by preventing access into the brain. Thus, the vaccine
brims with potential for treatment of nicotine addiction
and relapse prevention (Goniewicz & Delijewski, 2013).
Based on the assumption that a rapid increase in brain
nicotine levels induces feelings of reward, preventing nicotine from entering the brain is an intriguing idea with
precedent in other, similar treatments. Using antibodies
to bind a drug and thus disabling it from crossing the
blood-brain barrier was first tested in the realm of heroin
addiction and extended to nicotine and cocaine addiction
(Raupach et al., 2012).
Since nicotine is too small to elicit a response from the
immune system, nicotine is not immunogenic. In order
to elicit an immune response, nicotine or a structurally
similar hapten needs to be paired with a larger carrier
protein, thus producing a conjugate vaccine (Goniewicz
& Delijewski, 2013). Vaccination administers an immunogenic substrate that activates T and B cells, leading to
the formation of specific antibodies within the individual,
imprinting the response in immunological memory. By
virtue of this mechanism, this approach has been shown
to yield longer lasting protection (Raupach et al., 2012).
When nicotine enters the body, the vaccine causes
it to bind to the nicotine-specific antibodies, forming a
complex too large to cross the blood-brain barrier. Thus,
there is no nicotine-induced cerebral stimulation for
the smoker and the impression received by the smoker
is comparable to smoking a cigarette without nicotine
(Escobar-Chávez et al., 2011).
The success of this immunological strategy hinges on immunogenicity of the vaccine, affinity of antibodies, and specificity of antibodies (Raupach et al., 2012). Immunogenicity
refers to the antibody serum concentration. A vaccine
must elicit and maintain a high antibody serum concentration throughout the period of interest in order to be
maximally effective (Escobar-Chávez et al., 2011).
The primary measure of antibody affinity to the target
drug can be measured by the binding equilibrium constant, Ka. The Ka is defined by Ka = [NicAb]/[Nic][Ab].
[NicAb] represents the plasma volume concentration of
bound nicotine-antibody complexes, and [Nic] and [Ab]
denote the volume concentrations of unbound drug and
unbound antibody, respectively. Hence, in order to calculate the percentage of bound nicotine, data regarding
the amount of antibody present in circulation must be

obtained beforehand. The Ka should be high enough to
bind to nicotine and low enough to allow for unbound
nicotine release and elimination (Goniewicz & Delijewski,
2013). However, extremely high affinity may be disadvantageous, as saturation of all antibodies compromises efficacy for subsequent nicotine doses (Fahim et al., 2011).
Interestingly, the interaction of antibodies with nicotine is reversible and each antibody binds to and releases nicotine many times, much like a juggler catches and
releases multiple sticks many times. Thus, it is observed
that the binding capacity of the antibodies for nicotine is
far in excess than the expected stoichiometric calculation
(Escobar-Chávez et al., 2011).
Specificity refers to the extent to which the elicited
antibodies bind to nicotine in preference to other molecules (Raupach et al., 2012). Greater specificity reduces
competition from other molecules, thus improving safety and minimizing the likelihood of adverse side effects
(Escobar-Chávez et al., 2011). This has practical applications for the design of conjugate vaccines. For example,
one recent study showed that using longer rather than
shorter linkers, amino acid sequences used to separate
multiple domains in a protein (Reddy Chichili et al., 2013),
increases antibody selectivity to nicotine. Additionally,
linker position influences specificity. Linkers that are distant from the prime sites of metabolism (i.e. attached to
the 6- rather than 5- position of the pyridine ring) help
enhance antibody selectivity (Raupach et al., 2012).
In order to maintain an ideal serum antibody concentration, repeated administration of the nicotine-conjugate
system in the form of the vaccine is required. The first
vaccination administered causes a primary immune response, comparable to when the organism had its initial
encounter with an infectious antigen. Each subsequent
administration acts as a “planned infection,” which uses
memory about the antigens during the production of antibodies. Therefore, a faster and more effective response
to the subsequent vaccinations is anticipated (Goniewicz
& Delijewski, 2013).
Due to the prolonged effect that nicotine vaccines provide, they have an advantage over the existing pharmacotherapies (Shen et al., 2012, as cited
in Goniewicz & Delijewski, 2013) and are a critical
addition to the pharmacological smoking cessation
aids. The relapse rate is minimal since only bimonthly booster shots are required to achieve a high level
of antibodies. Thus, patient adherence to the necessary protocol can significantly improve. Nevertheless,
early clinical trials have casted some doubts in that
many patients may not elicit a sufficient antibody response. To circumvent this issue, novel carriers and/
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or adjuvants with immunogenic properties can be
introduced to stimulate a more potent immune response (Cerny et al., 2009, as cited in Goniewicz &
Delijewski, 2013).
For those who attain high levels of antibodies, vaccination has been shown to be effective in achieving and
maintaining abstinence (Goniewicz & Delijewski, 2013).
Vaccines against nicotine are at an advanced stage of
clinical trials but have not yet been approved for treatment of individuals (Escobar-Chávez et al., 2011). Future
strategies for enhanced specificity that the vaccine can
provide in conjunction with a high affinity to nicotine
and increased antibody level offer an effective avenue for
smoking-cessation (Goniewicz & Delijewski, 2013).
Discussion and Conclusion:
After reviewing the various smoking cessation techniques,
it seems that a combination of a few would be the most
viable option. The smoker can implement preliminary arrangements with the use of NRT. NRT may be useful for
those who want to attenuate the smoking habit but do
not want to put a halt to it completely, known as quitting
“cold turkey.” The choice of NRT can be guided by the
patient’s preference, though it may be wise to have a firstline agent in conjunction with NRT; however, healthcare
professionals must learn the benefits and potential detriments of different types of NRT before guiding patients in
its potential use (Wadgave & Nagesh, 2016).
Smokers who find that they are unsuccessful with NRT
can choose an alternative method. Although nicotine vaccines have an advantage over existing pharmacotherapies
in that they have a prolonged effect and require substantially less cooperation from patients with bimonthly
booster shots, data from clinical trials suggest that many
patients may not produce sufficient antibody response
(Goniewicz & Delijewski, 2013), suggesting that it may
not be the most pragmatic approach.
Since nicotine addiction is primarily responsible in
impeding smoking cessation and long-term abstinence,
it seems that the most prudent option would be a modality that targets the activity at the α4β2 receptor, the
prime mediator of nicotine dependence. Where bupropion therapy aims to alleviate the withdrawal symptoms
experienced during the transition state to a steady state
of neurotransmitter activity, as does NRT, varenicline was
developed to selectively target nicotine activity at the
receptor that leads to the addiction, a seemingly more
robust approach. Though varenicline presents a surfeit
of undesirable side effects, some in the forms of nausea, abnormal dreams, taste perversion, and headaches
(Burke et al., 2016), these effects may prove manageable
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and worthwhile under a cost-benefit analysis. The strong
rationale for targeting the α4β2 receptor with a partial agonist, coupled with promising findings from clinical studies, reinforce varenicline’s efficacy and safety as
a reliable smoking cessation aid. Upregulation of these
receptors and adaptation lead to the compulsive use of
nicotine to maintain homeostasis, both of which render
the α4β2 receptor an effective candidate for pharmacologic intervention. However, patients and providers
should determine whether to use varenicline only after
an assessment of the potential risks and benefits. The
efficacy of varenicline can be improved in combination
with NRT and bupropion, especially for smokers who are
more heavily dependent on nicotine (Burke et al., 2016).
Greater understanding of the exact mechanisms of these
drugs, particularly bupropion, could lead to the development of drugs that are more effective in promoting
smoking abstinence (Warner & Shoaib, 2005).
All things considered, nota bene that relapse is often
prominent in a patient’s attempt to quit smoking. The average patient will quit four or five times before reaching
complete cessation, an important point to convey to patients to prevent disillusionment and hopelessness during
recovery (Woody et al., 2008).
Essentially, the adverse health effects associated with
cigarette smoking are numerous and continual efforts to
reduce the prevalence of smoking are imperative (Onor
et al., 2017). Nevertheless, due to futile attempts to quit,
many smokers feel demoralized and incapable of taking
action towards quitting. However, there are options
available to the smoker. Whether in the form of NRT,
non-nicotinic drugs (namely varenicline and bupropion),
or the novel nicotine vaccines, nicotine addiction can be
mitigated to aid the journey towards recovery.
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Abstract
This paper covers several pathogenic theories of Parkinson’s disease (PD); the physiology and biological pathways involved. This
includes a mitochondrial DNA (mtDNA) route, a nuclear DNA route, and other hypotheses about idiopathic PD. The subsequent
discussion of PD symptoms utilizes a neurological perspective, analyzing the neuroanatomical systems involved, and how they
are treated. This includes medications and surgical techniques that are employed in an effort to manage symptomatology and
increase health-related quality of life.
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Introduction
Neurodegenerative diseases are characterized by progressive and selective loss of anatomically or physiologically related neuron systems. The clinical syndromes associated with particular neuroanatomical patterns of cell
loss and dysfunction are typically categorized by whether
they initially affect cognition, movement coordination,
sensation, vision, or autonomic control. Typical examples
of such neurodegenerative diseases include Alzheimer’s
disease, Huntington’s and Parkinson’s disease (Lezi and
Swedlow, 2012). Cholinergic neurons are implicated in
Alzheimer’s, and a degeneration of neurons in the dopaminergic system is responsible for Parkinson’s disease.
Parkinson’s disease (PD) is the second most common
neurodegenerative disease, afflicting 1-3% of the 65+ age
group. It is characterized by accumulation of abnormal
protein (Lewy bodies) in the dopaminergic neurons of
the substantia nigra pars compacta (SNc) and their
subsequent degeneration. These are abnormal circular
structures with a dense protein core and a halo of radiating fibers. They consist of aggregations of misfolded
α-synuclein along with neurofilaments and other proteins. This neuron loss leads to a difficulty controlling
movement. The motor symptoms include bradykinesia,
postural instability, muscle rigidity, and tremors. Some
of the non-motor symptoms (NMS) include depression,
insomnia, anxiety, apathy, psychosis, incomplete bowel
emptying, impulse control disorders, and dementia.
The disease involves progressive degeneration which,
as of now, cannot be stopped or slowed. There are effective medications that can be used to compensate for dopaminergic neuron loss, such as L-dopa, and other types
of dopamine (DA) agonists. These work by increasing the
potency of the surviving neurons and synapses, but only
temporarily. Eventually, the disease will wipe out these
pathways entirely. Furthermore, the disease spreads to
other regions of the brain and causes other symptoms.
For example, when neurodegeneration spreads to cholinergic neuronal pathways, the patient will start to show
signs of dementia. For now, treatment options are limited

to symptom management. This paper discusses some of
those treatment options, but first it is important to consider the PD pathogenesis and symptom origin. Then, this
paper will delve into the innovations available for those
suffering from PD, and explain how they work.
Mitochondrial Pathogenesis of PD
Mitochondria are the site of bioenergetics and biosynthesis in the cell. Hans Krebs, for whom the tricarboxylic
acid (TCA) cycle is named, said of his discovery “in some
micro-organisms the cycle primarily supplies intermediates rather than energy, whilst in the animal and most
other organisms it supplies both energy and intermediates”. The energy supplied by the TCA cycle is in the
form of NADH and FADH2, whose electrons are then
fed into the electron transport chain (ETC) to pump protons into the inner membrane space of the mitochondrion creating a pH gradient. This gradient is then used to
power the conversion of ADP into ATP. A high ATP/ADP
ratio is required to catalyze the chemical reactions that
comprise many of the metabolic operations of the cell.
Additionally, many of the building blocks that a cell
needs to form its assortment of macromolecules are
made using the intermediates of glycolysis and the citric acid cycle. For example, about half of the 20 amino
acids found in human protein can be synthesized in vivo
through the modification of Krebs Cycle intermediates
(Reece et al., 2011). Also fatty acids are synthesized from
acetyl CoA, which is produced by the conversion of pyruvate within the mitochondria. It is important to note
that when the mitochondria are employed in an anabolic
capacity (the building of larger molecules and utilization
of TCA intermediates) they are no longer producing ATP
but consuming this molecule.
There is some evidence implicating mutations in mitochondrial DNA (mtDNA) or nuclear genes coding for
mitochondrial protein in the pathogenesis of PD. Several
research teams working in 1989 reported a reduction of
activity of Complex 1 of the ETC in the substantia nigra
in patients with idiopathic PD (Lezi and Swedlow, 2012).
This study was based on reports of healthy individuals developing Parkinson’s like symptoms after consuming the
compound 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP). It was determined that the active metabolite
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of MPTP is taken up by the cell via the dopamine transporters, allowing them to cluster and wreak havoc in dopaminergic neurons. This particular metabolite inhibits
Complex 1 of the electron transport chain, which was
assumed to have led to the exhibition of Parkinson’s
symptomatology.
The suggested hypothesis is that mutations within
genes coding for mitochondrial DNA or in mtDNA itself, specifically Complex 1 genes, can be implicated in PD
pathogenesis. Complex 1 contains 46 protein subunits,
seven of which are encoded by mtDNA. A mutation
causing a decrease in Complex 1 activity would lead to
a drop in ATP production and increased oxidative stress
and cellular deterioration from the accumulation of free
radicals (Lezi and Swedlow, 2012).
It is unclear why dopaminergic neurons of the substantia nigra would be uniquely susceptible. However, what
is clear is that the failure of these nigral dopaminergic
systems are responsible for the symptoms of PD. Based
on the research done on mitochondrial involvement in
dopaminergic deterioration in PD or induced PD symptoms, there is sufficient justification to investigate treatment options targeting the mitochondria, which work to
encourage proper functionality and cellular respiration
(Lezi and Swedlow, 2012).
α-synuclein and PD
Researchers have discovered that a mutation on chromosome 4 will produce PD (Polymeropoulos, et al., 1996),
the gene that codes for α-synuclein. This protein can be
found in the axon terminals and is involved in synaptic
transmission in dopaminergic neurons. A mutation in this
gene can result in a mistranslated and subsequently misfolded α-synuclein that is toxic to the cell. These proteins
group together in large aggregates called Lewy bodies
which devastate normal cell function.
The majority of PD cases are sporadic. They occur
without any family history or hereditary basis for the disorder. Some researchers suggest that an unknown toxin
in the environment, faulty metabolism, or infection may
be the culprit in these cases. There are two insecticides
that are known to cause PD, and presumably there may
be more. These toxins might interfere with mitochondrial signaling which, when impaired, could cause these
aggregations of α-synuclein to resist degradation and persist in the cytoplasm of nigral neuron systems.
Symptoms and Their Physiology
The loss of the brain’s most important dopamine suppliers, the neurons of the SNc, leads to a variety of
symptoms. Resultant motor symptoms include tremors,
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muscle rigidity, bradykinesia, and postural imbalance the symptoms that normally come to mind when people think of Parkinson’s disease. These symptoms arise
directly from neuron loss in the motor regulation centers of the brain (Carlson & Birkett, 2017). Additionally,
many other neural pathways are affected by damage to
the substantia nigra, such as the areas where these dopaminergic neurons project, namely, the basal ganglia and
the nucleus accumbens. The basal ganglia are involved in
controlling movement, but they also project to the frontal
lobes of the brain and play a role in thinking and executive functions. The nucleus accumbens has been linked
to behavioral regulation, Thus, dopamine irregularities in
this region can lead to changes in personality (Carlson &
Birkett, 2017).
The causes for some of the non-motor symptoms are
pretty clear, while others are more complicated and debatable. Some symptoms arise directly from a decrease in
dopamine (DA) production in the substantia nigra. Other
symptoms are a result of the DA agonist prescribed to
the patient. This might be due to the dramatic fluctuations of DA in the brain owing to the medication schedule. Still other symptoms might be due to an increased
potency in certain dopaminergic systems that have not
been impacted by the disease. When the patient takes
L-dopa, these functioning dopaminergic neurons release
too much DA. This DA flood triggers a deficit in executive functions, according to the Dopamine Overdose
Hypothesis (Dirnberger & Jahanshahi, 2013).
Other symptoms result from unrelated pathways that
happen to be proximal to damaged areas of the brain.
Lewy bodies are often present in the dopaminergic neurons of those with PD. Many of these misfolded proteins
that cause neurodegeneration can be transferred from
cell to cell (Lee, et al., 2011). This perhaps explains how
the serotonergic, noradrenergic, and cholinergic systems
become impacted in later stages of PD.
Treatments
Since there is no cure for PD, the standard treatment is
symptom management, by way of DA agonists. The most
common one in use is L-dopa, a neurotransmitter (NT)
precursor which dopaminergic neurons can convert to
dopamine. This maximizes its potency through increasing the amount of NT present in the synaptic cleft with
each firing of the surviving neurons. When other systems
are involved in degeneration, such as the serotonergic,
noradrenergic, and cholinergic systems, agonists for each
of those NTs can be used to alleviate symptoms. Some
symptoms arise from too much dopamine in the healthier
dopamine pathways, or fluctuations of dopamine based
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on medication schedule (Dirnberger & Jahanshahi, 2013).
These symptoms can be treated by using different DA
agonists at different times and by changing doses. The
reason for the variety of dopamine agonists is to reduce
fluctuations and mitigate some symptoms that may arise
from any one particular DA agonist.
Another possible medication is Deprenyl, which was
initially discovered to be effective after the outbreak of
PD among users of the drug MPTP. The idea behind it
was to inhibit the activity of the monoamine oxidase-B
enzyme and hopefully block the toxins from attacking and
damaging the neurons. Although the drug does alleviate
symptoms, it does not reverse, stop, or slow the progression of disease (Williams, 2010).
One surgical technique involved the grafting of nigral
neurons taken from aborted fetuses, to replace the ones
lost to PD. This was shown to work particularly well in
patients who responded well to L-dopa earlier in the disease. Presumably, these patients had enough healthy neurons in the basal ganglia to process and secrete dopamine,
whether intrinsic or from grafted tissue. Unfortunately,
many of these patients later developed debilitating dyskinesias and the surgery is no longer recommended
(Olanow, et al., 2003).
Upon closer inspection, it seemed as though the fetal
tissue had been successful in making the proper connections with the basal ganglia. However, with time, the
aggregate α-synuclein deposits made their way from damaged host cells to transplanted healthy cells (Kordower, et
al., 2011). Any misfolded proteins responsible for neurodegeneration can be transferred from cell to a cell close
by (Lee, et al., 2011). It seems that adding healthy cells to
the basal ganglia will not work unless a way is found to
prevent the α-synuclein from aggregating in the first place
and spreading to neighboring cells.

to L-dopa. Neurosurgeons can get similar results by
destroying the subthalamic nucleus (STN) (Guridi, J &
Obeso, 2001), which has an excitatory effect on GPi.
Another option that is growing in popularity due to refined surgical techniques is deep brain stimulation (DBS).
Here, instead of destroying GPi and STN, microelectrodes
are placed in these regions for the patient to stimulate as
needed. This technique is as effective as brain lesions in
suppressing tremors but with fewer risks (Esselink, et al.,
2009). DBS might also be effective against depression and
cognitive impairment in PD.

GPi and STN Related Therapies
The main output of the basal ganglia is from the internal
division of the globus pallidus (GPi) and it is inhibitory.
Researchers found that whenever there is a decrease of
activity to the putamen and the caudate nucleus (which
is a byproduct of SNc neuron death due to PD) there is
an increase in inhibitory signaling from GPi to the motor
cortex. It was suggested that destroying this area might
help mitigate some of the motor symptoms. This strategy worked well and was a pretty good option but the
surgery was quite risky. The optic tract is located quite
proximal to the GPi and some patients were blinded by
the surgery. Due to advancements in imaging and surgical
techniques, this option has become safer, and can be recommended for younger patients who no longer respond
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